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Introduction
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1 IntroduCtIon
Cardiovascular disease is a very common condition, especially among elderly 
[1, 2]. Cardiovascular risk prediction via the Framingham risk score is the 
most commonly used risk prediction [3]. However, the Framingham risk score 
has only been validated until the age of 75 and the power of the classical risk 
factors have been shown to decline with advancing age [4, 5].
A strong predictor of cardiovascular disease in older populations is arterial 
stiffness. Arterial stiffness is involved in the pathogenesis of cardiovascular 
disease, with pulse wave velocity being the major marker for cardiovascular 
risk [6-10]. Over the years, arterial stiffness have been shown to be an im-
portant pre-clinical stage of cardiovascular disease of interest for research, 
mainly based on preventive strategies. Arterial stiffness is associated with 
many lifestyle factors and disorders, among others smoking [11], vitamin D 
deficiency [12], physical functioning [13], renal failure [14], diabetes [15, 
16] and constructive obstructive pulmonary disease (COPD) [17].
Arterial stiffness is a condition, which is caused by a disturbance in the 
interaction between stable and dynamic changes of the vessel wall [18]. 
These changes can be influenced by both hemodynamic forces, as well as by 
other external factors such as hormones. Also ageing itself leads to changes 
in the vascular tree that contribute to the arterial stiffening process [18]. 
The stability of the vascular wall depends on two proteins: collagen and 
elastin. When misbalance occurs due to for example inflammatory stimuli or 
hypertension, collagen is overproduced, which in turn leads to less elastin 
in the vascular wall, with vascular stiffness as a consequence [19]. Collagen 
and elastin are regulated by catabolic matrix metalloproteases (MMPs). Both 
vascular cells and inflammatory cells like macrophages produce MMPs. The 
balance between MMP-inhibitors and MMP-producers is important in control-
ling the remodeling of the vascular wall [20]. Another important pathway 
of the arterial stiffening process is through advanced glycation endproducts 
(AGEs) [21]. AGEs form irreversible cross-links in collagen. This collagen 
derived from AGEs is stiffer, not easy to break down and it therefore leads 
to an accumulation of this type of collagen with vascular stiffness as a 
consequence [22]. AGEs are also able to affect the endothelial function by 
stimulating stress and inflammatory responses, increasing radical oxidant 
formation, pro-inflammatory cytokines and vascular adhesion molecules 
[23]. This subsequently may lead to vascular stiffness via MMP signaling [24] 
or to endothelial dysfunction because the smooth muscle tone will increase, 
12
flow-mediated dilation will decrease and atherosclerotic plaque formation 
will be enhanced [25, 26]. Next to these structural changes, endothelial cells 
and vascular smooth muscle cells also have a role in vascular stiffening. 
Vascular smooth muscle cells react on mechanostimuli, a.o. because of cell 
stretch [18]. Endothelial cells can suffer from disturbances in the nitric oxide 
expressions, which has also been associated with vascular stiffness [27, 28]. 
Arterial stiffness results in increased pulse pressure, which is the difference 
between the systolic and the diastolic pressure. This has its influence on the 
heart, in particular because the ventricle load increases. A stiffer arterial 
tree needs higher systolic pressures in order to have the same amount of 
net stroke volume. A stiff vascular wall thereby lowers the efficacy of the 
ejection fraction [29] and the perfusion of the coronary arteries [30]. In 
turn, the systolic hypertension caused by arterial stiffness, leads to a higher 
vascular tone, which further increases the amount of arterial stiffness by 
a disturbance in the collagen-elastin ratio and by stretching the vascular 
smooth muscle cells. 
Arterial stiffness can be measured in several ways. The most commonly used 
method is assessing the pulse wave velocity (PWV) [31]. During each heart 
beat, a pulse wave travels from the heart down the arterial wall in advance of 
blood flow. The more rigid the wall of the artery, the faster the wave moves. 
The PWV is the time it takes for the pulse wave to travel from the heart to 
the branching point, often the iliacal bifurcation. When the wave hits the 
major branching points, these waves are reflected back so that they reverse 
direction and travel back to the point of origin. Normally, the reflected wave 
returns after the aortic valve is closed (Figure 1.1) [6]. This amplifies dia-
stolic blood pressure and facilitates blood flow through the coronary arteries. 
Another measure of arterial stiffness is the augmentation index (AIx). The 
augmentation pressure is the contribution of the reflection wave to systolic 
arterial pressure. When the compliance of the arteries is reduced, the reflec-
tion wave will return earlier, so before the aortic valve has closed, causing a 
rise in systolic pressure. The augmentation index is the augmentation pres-
sure divided by the pulse pressure and is therefore a indirect measurement 
of arterial stiffness (Figure 1.2) [6]. Also, the compliance and distensibility 
of an artery can be measured directly. The carotid distensibility is often 
used, because this artery is easy to approach by ultrasonography. With the 
distensibility of the carotid artery we measure the difference of expansion 
of the artery between the diastolic and the systolic phase. This is one of the 
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parameters of arterial stiffening: the stiffer the vessels, the less expansion 
there will be [32, 33]. 
Another important cardiovascular risk indicator in elderly, next to arterial stiff-
ness, is the amino-acid homocysteine. Elevated levels of homocysteine form 
an independent predictor for cardiovascular disease [34, 35], in particular in 
the oldest old [36]. In this age group, hyperhomocysteinemia has even been 
shown a better predictor for cardiovascular mortality than the traditional risk 
factors used in the Framingham risk score [36]. However, the underlying 
mechanism is not completely clear, especially since homocysteine-lowering 
intervention trials failed to demonstrate beneficial effects on cardiovascular 
devices. The Complior Systemw (Colson, Les Lilas, France)
employs dedicated mechanotransducers directly applied on
the skin.44 The transit time is determined by means of a cor-
relation algorithm between each simultaneous recorded
wave. The operator is able to visualize the shape of the
recorded arterial waves and to validate them. Three main
arterial sites can be evaluated, mainly the aortic trunk
(carotid-femoral) and the upper (carotid-brachial) and
lower (femoral-dorsalis pedis) limbs. This system was used
inmost of the epidemiological studies demonstrating the pre-
dictive value of PWV for CV events (Table 4).
Pressure waves can also be recorded sequentially from
different sites, and transit time calculated using registration
with a simultaneously recorded ECG. In the SphygmoCorw
system (ArtCor, Sydney, Australia), a single high-fidelity
applanation tonometer (Millarw) to obtain a proximal (i.e.
carotid artery) and distal pulse (i.e. radial or femoral)
recorded sequentially a short time apart and calculates
PWV from the transit time between the two arterial sites,
determined in relation to the R-wave of th ECG. The time
between the ECG and the proximal pulse is subtracted
from the time between ECG and distal pulse to obtain the
pulse transit time. The initial part of the pressure waveform
is used as a reference point. It is also possible to che k
offline the variability of measurement over a range of
pulses, according to each algorithm. Since the measure-
ments are made a short time apart, the change in the isovo-
lumic period of the LV or heart rate variability has little or no
effect on measured pulse transit times.
Japanese researchers advocated the use of brachial-ankle
pulse-wave velocity (baPWV) and showed the aortic PWV
was the primary independent correlate of baPWV, followed
by leg PWV.47 Previous remarks concerning the calculation
of the path length apply here. In small cohorts of either
elderly community-dwelling people48 or coronary heart
disease patients,49 baPWV was an independent predictor
for CV deaths and events.
Methods using mechanotransducers or high-fidelity appla-
nation tonometers are well accepted for carotid-femoral
PWV measurement.
Methods based on Doppler probes and other methods
The distension waves obtained from the high-definition
echotracking devices (discussed subsequently) can be used
to calculate PWV. As described earlier for the SphygmoCor
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Figure 1 Measurement of carotid-femoral PWV with the foot to foot
method.
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Figure 1.1. Measurement of carotid-femoral PWV. 
From: Laurent et al. Eur Heart J 2006; 27: 2588-2605
Arterial pressure waveform should be analysed at the
central level, i.e. the ascending aorta, since it represents
the true load imposed to the LV and central large artery
walls. Aortic pressure waveform can be estimated eith
from the radial artery waveform, using a transfer func-
tion,77–79 or from the common carotid waveform. On both
arteries, the pressure wavefor can be recorded non-
invasively with a pencil-type probe incorporating a high-
fidelity Millar st ain gauge tr nsducer (SPT-301, Millar
Ins ruments). The ost widely us d approach is to perform
r dial artery tonometry and then apply a transfer function
(Sphygmocor, AtCor, Sydney Australia) to cal ulate the
aortic pressure waveform from the radial waveform.77–82
Indeed, in contrast to the car tid artery, the radial artery
is well supported by bony tissue, making optimal applana-
tion easier to achieve.
Individual and generalized inverse transfer functions are
applied to reconstruct the aortic waveform from radial
tonometry.77–79 The estimation of central aortic pressures
is accepted as more accurate than the estimation of AIx (dis-
cussed subsequently).76,83–85 In addition, brachial artery
pressures are used as surrogates of radial artery pressures
for the calibration of central pressures, and this may intro-
duce some errors.64
Despite these limitations, radial tonometry is popular,
since it is simple to perform and well tolerated. Carotid
tonometry requires a higher degree of technical expertise,
but a transfer function is not necessary, since the arterial
sites are very close and waveforms are similar.77
There are two major issues in quantification of reflected
waves on central pressure waveforms. First, it is necessary
to assess the timing and the proportion of the reflected
wave, i.e. the time necessary for the pressure wave to
reach the reflection site (which is a theoretical site rather
than an actual site, as the reflected wave is a composite
of many reflected ‘wavelets’) and return. The inflection
point is the point in time which coincides with the peak of
the flow wave in the artery. The proportion of reflected
pressure wave is assessed through the AIx. As it is calculated
as the ratio between the augmentation pressure (pressure
above the inflection point) and pulse pressure, it is dimen-
sionless and usually expressed in percentage, but it does
not depend on the absolute pressure. Although the use of
a radial-to-aortic transfer function for the measurement of
central systolic blood pressure has been well estab-
lished,78,79 the accuracy of this approach for the determi-
nation of aortic AIx has been disputed.28,83–85 Indeed, the
measurement of AIx is dependent on higher frequency
signals than blood pressure measurement and the transfer
function appears to be less accurate and to show greater
between-subject variability at high frequencies.78,79,83
The second issue, more challenging,83,84 is the estimation
of absolute values of central pressures, including pulse
pressure, augmentation pressure, or systolic blood pressure.
Although the AIx is a relative measurement and can be
calculated without calibration, central pulse pressure,
augmentation pressure, and systolic blood pressure are
absolute values and require calibration. Direct measure-
ments obtained at the site of the common carotid artery
using applanation tonometry can be calibrated according
to the methods suggested by Kelly and Fitchett63 and Van
Bortel et al.,7,31,64 with adaptation (Figure 4). Calibration
of the artery tonometer pressure wave is based on the
observation that mean BP is constant throughout the large
artery tree and that diastolic BP does not change substan-
tially.8 In practice, BP is measured at the reference artery,
in general, the brachial artery, with a validated BP device
and PP is calculated as SBP minus DBP. Applanation tonome-
try is performed at carotid artery. From these data, the
absolute value of PP at the target artery can be calculated.
An alternative is to compute mean BP on the carotid
pressure wave from the area of the wave in the correspond-
ing heart period. Carotid mean BP is then set equal to
brachial mean BP. Carotid PP is then computed from the
diastolic BP and the position of mean BP on the carotid
pressure wave. Carotid SBP is obtained by adding PP to
DBP (Figure 4).7,45,61,63,86
A transfer function may be useful when applanation tono-
metry cannot be applied at the site of the carotid artery, for
instance, in obese subjects or in patients with major athero-
sclerotic plaques or calcified arteries, in whom this method
may not be free from any risk. However, the use of a transfer
function should be limited to the upper limb, where elastic
properties remain relatively constant with age and disease,
as previously discussed. It would allow assessing carotid
artery and ascending aorta systolic BP and PP from radial
artery PP.31,80
Central AIx and central pulse pressure have shown inde-
pendent predictive values for all-cause mortality in ESRD
patients,87,88 and CV events in patients undergoing percuta-
neous coronary intervention (PCI)89 and in the hypertensive
patients of the CAFE´ study.90
Box 4: Position statement: Central pulse-wave analysis.
Pulse-wave analysis should be optimally obtained at the
central level, i.e. at the site of the carotid artery or
the ascending aorta, and either directly recorded or com-
puted from the radial artery waveform using a transfer
function. Pulse wave should be analyzed through three
major parameters: central pulse pressure, central systo-
lic pressure, and the AIx.
Pulse-wave analysis at peripheral sites
Other techniques were derived from peripheral waveform
shape analysis. The determination of the amplitude ratios
of the second derivative of the pulse pressure waveform,
obtained by finger photoplethysmography (Fukuda Electric
Figure 3 Carotid pressure waveform is recorded by applanation tonometry.
The height of the late systolic peak (P1) above the infl ction (P2) defines the
augmentation pressure, and the ratio of augmentation pressure to PP defines
the AIx (in percent).
Arterial stiffness: methods and applications 2595
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Figure 1.2 Augmentation Index.
The height of the late systolic peak (P1) above the inflection (P2) defines the augmentation 
pressure, and the ratio of augmentation pressure to pulse pressure defines the AIx (in %). 
From: Laurent et al. Eur Heart J 2006; 27: 2588-2605. 
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outcomes [37]. Therefore, it has been proposed that homocysteine may act 
as a biomarker, rather than a risk factor [38]. The question remains what 
the controversy can be between the prospective studies and the intervention 
studies. There is a discrepancy between studies which clearly demonstrate 
that homocysteine is a risk indicator and the randomized controlled trials, 
who failed to demonstrate a benefi t of B-vitamin supplementation, while this 
would be expected based on pathophysiological grounds – the one carbon 
metabolism (Figure 1.3). There are several potential explanations. First 
of all, many trials were performed in folic-acid fortifi ed and middle-aged 
populations. Next, the administration of B-vitamins did not always lead to 
the anticipated lowering of homocysteine. Also, the duration of the stud-
ies was relatively short, based on the pathophysiology of atherosclerotic 
disease. However, an alternative hypothesis is that the lack of effect may 
be explained by the fact that B-vitamin supplementation has dual, opposing 
effects. It has been hypothesized that B-vitamins on the one hand lower 
homocysteine, but on the other hand at the same time lead to increased 
infl ammation status [38]. 
However, it is also possible that arterial stiffness is the actual link between ho-
mocysteine level and adverse cardiovascular events. Because arterial stiffness 
Methionine
Homocysteine
Tetrahydrofolate
5-methyl-THF
5,10-methylene-THF
SAM
SAH
Cystathionine
Cysteine
MMA-CoA
Suc-CoA
MMA
FA
B2
B12
B6
B6 B12
Methionine-
synthase
MTHFR
Cystathionine-
β-synthase
Cystathionine-
y-lyase
methylmalonyl-
CoA mutase
Methionine-cycle
Folate-cycle
Figure 1.3. The one-carbon metabolism.
Vitamins, metabolites and enzymes which are involved in the one carbon metabolism. Ab-
breviations: THF: tetrahydrofolate; SAM: S-adenosylmethionine; SAH: S-adenosylhomocys-
teine; MTHFR: methylenetetrahydrofolate reductase; MMA: methylmalonic acid; MMA-CoA: 
methylmalonyl-CoA; Suc-CoA: succinyl-CoA; FA: folic acid; B12: vitamin B12; B2: vitamin 
B2; B6: vitamin B6. 
From: van Dijk et al. Nutr Metab Cardiovasc Dis 2014, Jan; 31. 
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is a condition that is not easily or rapidly reversible, an association between 
homocysteine levels and arterial stiffness may explain the lack of benefi cial 
effects of homocysteine-lowering therapy. There is already some evidence 
that homocysteine is indeed associated with arterial stiffness, however these 
association studies are equivocal, and were often done in younger populations 
with relatively low homocysteine levels [39-42]. Pathophysiologically, homo-
cysteine leads to an increased thrombogenecity, increased oxidative stress 
and to an overactivation of infl ammatory pathways (Figure 1.4). 
Because hyperhomocysteinemia is a very common condition among elderly, 
with a prevalence of 25-50% in European countries [43], and because hy-
perhomocysteinemia has been shown to be a strong cardiovascular risk 
predictor in this age group, we aimed to investigate the association between 
homocysteine and arterial stiffness within older individuals participating in 
Liver
↑↑ Hcy↑↑ plasma Hcy
↓↓↓ Plasma 5-MTHF
↑ factors II, V, X, XII
↓ Protein C, anti-thrombin III
↑↑ thrombosisCirculation
Vascular 5-MTHF ↑ Hcy
↑ Other O2-sources 
(NADPH oxidase)
↑ O2-
↓ NO
↑ ONOO-
Redox-sensitive
transcription pathwaysAtherogenic effect
↑ ONOO-
↓ BH4
BH2
↑ Uncoupled eNOS
↓ Coupled eNOS
THF
Hcy
Met
↓ ADMA
↑ NO↑ eNOSEC
VSMC
Figure 1.4. Pathophysiological effects of hyperhomocysteinemia. 
This fi gure demonstrates the liver, the blood vessel, the endothelial cell and the vascular 
smooth muscle cell, which are all likely to be involved in the pathophysiological mechanism 
of homocysteine. First, high homocysteine levels in the liver increases the synthesis of pro-
atherogenic factors and decreases the biosynthesis of anti-thrombotic factors, resulting into 
a net trombotic effect. Second, in the vascular endothelium, 5-MTHF increase intracellular 
homocysteine (Hcy) and a rise in O2 radicals. Also, 5-MTHF directly increase peroxynitrite 
(ONOO), leading to less oxidation of hydrobiopterin (BH), and therefore decreases endothelial 
nitric oxide synthase coupling (eNOS). Third, endogenous 5-MTHF is synthesized by methyl-
tetrahydrofolate reductase (MTHFR). 5-MTHF is converted back to THF in parallel to the con-
version of Hcy to methionine (Met) by methionine synthase (MS), which uses vitamin B12 as 
a co-factor. Due to high plasma Hcy levels, the conversion of methionine back to Hcy is less. 
Therefore the methylation of L-arginine (L-arg) to asymmetrical dimethylarginine (ADMA) is 
decreased, leading to an enhancement of eNOS. In the end, this all results in an reduction of 
vascular redox and endothelial function. 
From: C. Antoniades et al. Eur Heart J 2009; 30: 6-15.
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the B-PROOF trial [44]. The B-PROOF (B-vitamins for the PRevention Of 
Osteoporotic Fractures) trial is a large, multi-center placebo-controlled, 
double-blind, randomized controlled trial conducted in the Netherlands. 
Participants were included after the age of 65 and when they had mildly 
elevated homocysteine levels (12-50 µmol/L). Exclusion criteria were renal 
insufficiency (creatinine level >150 µmol/L) and the presence of a malig-
nancy. The intervention included 500 µg vitamin B12 and 400 µg folic acid for 
a period of 2 years. Both the intervention and the placebo group received 15 
µg (600 IE) vitamin D3. In total, 2919 participants were included. The main 
outcome of this trial was osteoporotic fracture incidence. Also many second-
ary outcomes have been defined, such as cardiovascular disease incidence, 
arterial stiffness measures, cognitive functioning and physical performance 
[44].
The aim of this thesis is, because this large trial forms a unique opportunity, 
to not only investigate the association between homocysteine level and arte-
rial stiffness, but also the effect of B-vitamin supplementation on arterial 
stiffness and other cardiovascular outcomes in an older population. 
At first, we will focus on the methods for measuring arterial stiffness in 
our elderly population in Chapter 2. Furthermore, it would be of interest to 
explore other cardiovascular risk prediction markers in the elderly, especially 
in the pre-clinical phase as arterial stiffness represents. In Chapter 3 we ex-
plore the association between arterial stiffness and vitamin D, osteoporosis 
and physical function. In Chapter 4 the association between homocysteine 
and arterial stiffness are explored and we address the question whether B-
vitamin supplementation has an influence on cardiovascular disease, arterial 
stiffness and endothelial function. 
The results of this thesis will therefore be helpful in order to better under-
stand the underlying mechanisms of arterial stiffness as being an important 
cardiovascular predictor in the elderly. 
17
 C
h
ap
te
r 
1
 |
 I
nt
ro
du
ct
io
n
referenCes
 1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease 
and stroke statistics--2007 update: a report from the American Heart Associa-
tion Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 
115:e69-171.
 2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease 
and stroke statistics--2008 update: a report from the American Heart Associa-
tion Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 
117:e25-146.
 3. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk 
profiles. Am Heart J 1991; 121:293-298.
 4. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr 
Cardiol 2002; 11:101-107.
 5. Kannel WB, D’Agostino RB. The Importance of Cardiovascular Risk Factors in the 
Elderly. Am J Geriatr Cardiol 1995; 4:10-23.
 6. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et 
al. Expert consensus document on arterial stiffness: methodological issues and 
clinical applications. Eur Heart J 2006; 27:2588-2605.
 7. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, 
Schalekamp MA et al. Arterial stiffness and risk of coronary heart disease and 
stroke: the Rotterdam Study. Circulation 2006; 113:657-663.
 8. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave veloc-
ity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler 
Thromb Vasc Biol 2001; 21:2046-2050.
 9. Safar ME, Henry O, Meaume S. Aortic pulse wave velocity: an independent 
marker of cardiovascular risk. Am J Geriatr Cardiol 2002; 11:295-298.
 10. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent 
S. Aortic stiffness is an independent predictor of primary coronary events in 
hypertensive patients: a longitudinal study. Hypertension 2002; 39:10-15.
 11. Yu-Jie W, Hui-Liang L, Bing L, Lu Z, Zhi-Geng J. Impact of smoking and smoking 
cessation on arterial stiffness in healthy participants. Angiology 2013; 64:273-
280.
 12. Giallauria F, Milaneschi Y, Tanaka T, Maggio M, Canepa M, Elango P et al. Arterial 
stiffness and vitamin D levels: the Baltimore longitudinal study of aging. J Clin 
Endocrinol Metab 2012; 97:3717-3723.
 13. Gando Y, Yamamoto K, Murakami H, Ohmori Y, Kawakami R, Sanada K et al. 
Longer time spent in light physical activity is associated with reduced arterial 
stiffness in older adults. Hypertension 2010; 56:540-546.
 14. Liu IT, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Mild chronic kidney disease 
associated with greater risk of arterial stiffness in elderly adults. J Am Geriatr 
Soc 2013; 61:1758-1762.
 15. Agnoletti D, Lieber A, Zhang Y, Protogerou AD, Borghi C, Blacher J, Safar ME. 
Central hemodynamic modifications in diabetes mellitus. Atherosclerosis 2013; 
230:315-321.
18
 16. Mansour AS, Yannoutsos A, Majahalme N, Agnoletti D, Safar ME, Ouerdane S, 
Blacher J. Aortic stiffness and cardiovascular risk in type 2 diabetes. J Hypertens 
2013; 31:1584-1592.
 17. Vivodtzev I, Tamisier R, Baguet JP, Borel JC, Levy P, Pepin JL. Arterial stiffness 
in COPD. Chest 2014; 145:861-875.
 18. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy 
of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25:932-943.
 19. Johnson CP, Baugh R, Wilson CA, Burns J. Age related changes in the tunica 
media of the vertebral artery: implications for the assessment of vessels injured 
by trauma. J Clin Pathol 2001; 54:139-145.
 20. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and ath-
erogenesis: the good, the bad, and the ugly. Circ Res 2002; 90:251-262.
 21. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing 
Dev 2001; 122:735-755.
 22. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ et al. Effect of 
collagen turnover on the accumulation of advanced glycation end products. J 
Biol Chem 2000; 275:39027-39031.
 23. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of 
endothelial nitric oxide synthase expression by albumin-derived advanced gly-
cosylation end products. Circ Res 2000; 86:E50-4.
 24. Kuzuya M, Asai T, Kanda S, Maeda K, Cheng XW, Iguchi A. Glycation cross-links 
inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells 
cultured on collagen lattice. Diabetologia 2001; 44:433-436.
 25. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM. Receptor for 
advanced glycation endproducts (RAGE) and vascular inflammation: insights 
into the pathogenesis of macrovascular complications in diabetes. Curr Athero-
scler Rep 2002; 4:228-237.
 26. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endprod-
ucts: a multiligand receptor magnifying cell stress in diverse pathologic settings. 
Adv Drug Deliv Rev 2002; 54:1615-1625.
 27. Matz RL, Schott C, Stoclet JC, Andriantsitohaina R. Age-related endothelial 
dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing 
factor and cyclooxygenase products. Physiol Res 2000; 49:11-18.
 28. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. En-
dogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. J 
Cardiol 1999; 33:105-106.
 29. Kelly RP, Tunin R, Kass DA. Effect of reduced aortic compliance on cardiac ef-
ficiency and contractile function of in situ canine left ventricle. Circ Res 1992; 
71:490-502.
 30. Saeki A, Recchia F, Kass DA. systolic flow augmentation in hearts ejecting into 
a model of stiff aging vasculature. Influence on myocardial perfusion-demand 
balance. Circ Res 1995; 76:132-141.
 31. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De 
Backer T et al. Expert consensus document on the measurement of aortic stiff-
ness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 
2012; 30:445-448.
19
 C
h
ap
te
r 
1
 |
 I
nt
ro
du
ct
io
n
 32. Hoeks AP, Willekes C, Boutouyrie P, Brands PJ, Willigers JM, Reneman RS. Auto-
mated detection of local artery wall thickness based on M-line signal processing. 
Ultrasound Med Biol 1997; 23:1017-1023.
 33. Brands PJ, Hoeks AP, Ledoux LA, Reneman RS. A radio frequency domain com-
plex cross-correlation model to estimate blood flow velocity and tissue motion 
by means of ultrasound. Ultrasound Med Biol 1997; 23:911-920.
 34. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart 
disease and stroke: a meta-analysis. JAMA 2002; 288:2015-2022.
 35. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl 
J Med 2005; 352:1685-1695.
 36. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le 
Cessie S, Gussekloo J. Use of Framingham risk score and new biomarkers to 
predict cardiovascular mortality in older people: population based observational 
cohort study. BMJ 2009; 338:a3083.
 37. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE et al. Effects of 
lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, 
and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 
485 individuals. Arch Intern Med 2010; 170:1622-1631.
 38. Smulders YM, Blom HJ. The homocysteine controversy. J Inherit Metab Dis 
2011; 34:93-99.
 39. Kampus P, Kals J, Ristimae T, Muda P, Ulst K, Zilmer K et al. Augmentation index 
and carotid intima-media thickness are differently related to age, C-reactive 
protein and oxidized low-density lipoprotein. J Hypertens 2007; 25:819-825.
 40. Levy D, Hwang SJ, Kayalar A, Benjamin EJ, Vasan RS, Parise H et al. Associa-
tions of plasma natriuretic peptide, adrenomedullin, and homocysteine levels 
with alterations in arterial stiffness: the Framingham Heart Study. Circulation 
2007; 115:3079-3085.
 41. Mayer O, Filipovsky J, Dolejsova M, Cifkova R, Simon J, Bolek L. Mild hyperho-
mocysteinaemia is associated with increased aortic stiffness in general popula-
tion. J Hum Hypertens 2006; 20:267-271.
 42. Nakhai-Pour HR, Grobbee DE, Bots ML, Muller M, van der Schouw YT. Circulating 
homocysteine and large arterial stiffness and thickness in a population-based 
sample of middle-aged and elderly men. J Hum Hypertens 2007; 21:942-948.
 43. de Bree A, van der Put NM, Mennen LI, Verschuren WM, Blom HJ, Galan P et 
al. Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and 
hypertension in European populations. Eur J Clin Nutr 2005; 59:480-488.
 44. van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, van der Velde N, 
Swart KM, Enneman AW et al. Rationale and design of the B-PROOF study, a 
randomized controlled trial on the effect of supplemental intake of vitamin B12 
and folic acid on fracture incidence. BMC Geriatr 2011; 11:80-2318-11-80.
20
Chapter 2
Measurement of 
arterial stiffness

2.1
Oscillometry and applanation 
tonometry measurements in 
older individuals with elevated 
levels of arterial stiffness
Suzanne C. van Dijk, 
Anke W. Enneman, 
Karin M.A. Swart, 
Natasja M. van Schoor, 
André G. Uitterlinden, 
Yvo M. Smulders, 
Anton H. van den Meiracker, 
Nathalie van der Velde, 
Francesco U.S. Mattace Raso
Blood Pressure Monitoring 2013
24
2.1.1 AbstrACt
Objective 
Indices of arterial stiffness and aortic pressure are usually assessed by ap-
planation tonometry. The more recently introduced oscillometric device is 
simpler to use. Several studies have investigated the agreement between 
these two devices, but not in populations with elevated levels of arterial 
stiffness. Therefore, we evaluated the agreement in an elderly population 
with high risk of arterial stiffness.
Patients and methods 
We included a subgroup of the B-PROOF study (n= 344, mean age 73 years, 
60% men), whose aortic pulse wave velocity (aPWV), aortic augmentation 
index (AIx), aortic pulse pressure (PP), and aortic systolic blood pressure 
(SBP) were assessed both with applanation tonometry (SphygmoCor) and 
with oscillometry (Arteriograph). We investigated agreement between the 
two devices using Pearson correlations and Bland–Altman analysis. We car-
ried out a stratified analysis in participants with more pronounced arterial 
stiffness (SphygmoCor aPWV > 12 m/s).
Results 
The oscillometric method produced higher values of AIx, aortic PP, and aortic 
SBP (P <0.01) than applanation tonometry. aPWV values were lower (P < 
0.01) and were not correlated (r= – 0.06, P = 0.92), whereas AIx measure-
ments (r= 0.35 P <0.01), aortic PP (r =0.57 P < 0.01), and aortic SBP 
(r= 0.68 P < 0.01) measurements were correlated. Bland–Altman analysis 
showed insufficient agreement between the two devices, especially in those 
with elevated levels of arterial stiffness (aPWV > 12 m/s).
Conclusion 
Particularly in the elderly with elevated levels of arterial stiffness, measure-
ments of aPWV obtained with oscillometry and applanation tonometry show 
poor agreement. Also, AIx, aortic SBP, and aortic PP show clearly less than 
optimal agreement.
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Arterial stiffness has become a well-established marker for cardiovascular risk 
[1], and is measured routinely by pulse wave analysis, from which one can 
derive both pulse wave velocity (PWV) and augmentation index (AIx). The 
European Society of Hypertension and the European Society of Cardiology have 
even recommended pulse wave analysis for cardiovascular risk assessment [2]. 
Applanation tonometry is commonly used for pulse wave analysis to assess 
PWV and AIx. It uses the carotid–femoral transit time to provide an indirect 
measurement of the central artery system [3]. A disadvantage of applana-
tion tonometry is that the accuracy of the measurements depends on the 
examiner’s experience. Therefore, a computerized device that uses an oscil-
lometric method to determine PWV and AIx has been developed. This method 
uses the changes in pulsatile pressure in the brachial artery as an indirect 
measurement for the pressure oscillations in the central artery system.
Several studies have recently compared these types of devices, but these 
studies were carried out only in younger adults and hypertensive patients, 
with relatively low PWV values [4–7]. Furthermore, the results of these 
studies were conflicting. None of the comparisons were performed in older 
individuals or individuals with elevated levels of arterial stiffness. Because it 
is still unclear whether the oscillometric method is comparable with applana-
tion tonometry within a general elderly and arterial stiffness population, we 
compared the PWV and AIx and aortic systolic blood pressure (SBP) and 
aortic pulse pressure (PP) measurements obtained with applanation tonom-
etry and oscillometry in an elderly population.
2.1.3 Methods
Study population
This study was carried out within the framework of the B-vitamins for the 
Prevention Of Osteoporotic Fractures (B-PROOF) study. A detailed description 
of this randomized-controlled trial has been reported elsewhere [8]. Briefly, 
B-PROOF is a multicenter, randomized, placebocontrolled, double-blind trial 
investigating the effect of vitamin B supplementation on osteoporotic frac-
tures in older patients. 
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B-PROOF has 2919 participants from the area in and around three Dutch 
cities: Rotterdam, Amsterdam, and Wageningen. The main inclusion crite-
ria were age 65 years and older and a mildly elevated homocysteine level 
(12–50 μmol/l). Follow-up has been completed recently.
Clinical characteristics
During the baseline measurements, all participants filled in a questionnaire 
on their medical history, use of medication, use of nutritional supplements, 
current habits of coffee and alcohol intake, and smoking habits. Their height 
and weight were measured, and BMI was calculated as weight divided by 
height2 (expressed as kg/m2).
Cardiovascular disease was defined as a positive medical history for 
myocardial infarction, angina pectoris, heart failure, valvular disorders, ar-
rhythmia, and aneurysms. The presence of hypertension, diabetes mellitus, 
hypercholesterolemia, and renal disease was also registered.
Vascular function tests
At the Erasmus Medical Center (Rotterdam) and the VU Medical Center 
(Amsterdam), a subsample of participants was invited to undergo vascular 
function tests (n=560). Participants with cardiac arrhythmia were excluded 
from these additional measurements. During the measurements, partici-
pants were placed in supine position on a flat examination couch in a quiet 
laboratory room for at least 5–10 min before the measurements, and the 
participants were not allowed to speak during the measurements. Use of 
alcohol or coffee during 12 h before the measurements was prohibited.
Applanation tonometry
Peripheral blood pressure used for applanation tonometry was measured 
once using a semiautomatic oscillometric device (Datascope Accurator Plus 
Device; Datascope Corp., Mahwah, New Jersey, USA) [9] after at least 5min 
of supine rest. All blood pressure measurements were performed on the right 
arm. Arterial tonometry was obtained once from the right radial, carotid, 
and femoral artery using the SphygmoCor device (SphygmoCor version 7.1; 
AtCor Medical, Sydney, New South Wales, Australia). With use of the radial 
arterial wave form, an estimate of the corresponding central aortic pulse 
wave was calculated using a validated generalized transfer function incorpo-
rated into the device. Using the integrated software, the central augmented 
pressure was calculated as the difference between the early and late systolic 
peaks of the estimated central pressure wave form. Central aortic AIx was 
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calculated as the augmented pressure expressed as a percentage of the PP. 
PWV was measured simultaneously with three-channel ECG recording and 
recording of the right carotid and femoral artery pulse waveforms, and was 
calculated as the delay between the femoral pulse wave and the carotid pulse 
wave, divided by the transit distance. Transit distances were assessed by 
body-surface measurement from the carotid artery to the femoral artery [3].
Oscillometric analysis
The participant was lying in a supine position for at least 10 min before the 
oscillometric measurement of the Arteriograph (Arteriograph; TensioMed, 
Budapest, Hungary) was obtained. The oscillometric measurement was 
performed once, directly after the SphygmoCor measurements, only at the 
Erasmus Medical Center. The conditions of the room and participant were 
similar. The blood pressure cuff was applied to the right upper arm and was 
inflated to a pressure of 35mmHg above the SBP on the brachial artery. The 
pressure in the underlying occluded artery is transmitted through the cuff 
to the pressure sensor. The first systolic peak corresponds to the ejection of 
the left ventricle, whereas the second peak is assumed to be the reflection of 
the first pressure wave from the periphery. The difference in time between 
the first and the second wave is the return time. The distance traveled is 
twice the distance between the aortic arch and the iliac bifurcation, and is 
measured with a tape measure as the distance between the sternal notch 
and the pubic symphysis. PWV was recorded as continuous data [10].
Statistical analysis
The comparison between applanation tonometry and oscillometry was tested 
by the Pearson correlation coefficient, Bland–Altman [11], and linear regres-
sion analysis. Only linear regression analysis had the possibility to account 
for possible confounders. We used a multivariate model that included all 
variables that caused a change in the point estimate of more than 10% or 
were considered clinically relevant. The covariates age and sex were con-
sidered as potential confounders. We also carried out a stratified analysis 
in a population with elevated levels of arterial stiffness, defined as an aortic 
pulse wave velocity (aPWV) measured with SphygmoCor more than 12 m/s, 
and we compared this with a population with less arterial stiffness (aPWV 
SphygmoCor ≤ 12 m/s). Another stratified analysis was carried out between 
populations aged 73 years or less and more than 73 years (mean age 73 
years). Statistical analysis was carried out using SPSS 20.0 statistical soft-
28
ware package (SPPS Inc., Chicago, Illinois, USA). P-values of less than 0.05 
were considered statistically significant.
2.1.4 results
In total, 344 participants had evaluable applanation tonometry and oscil-
lometric measurements; 203 were men and 141 were women. Their mean 
age was 72.5±5.5 years, mean BMI was 26.5±3.4 kg/m2, and mean brachial 
blood pressure levels were 134.9/77.2mmHg measured using a semiauto-
matic datascope (Table 1).
Table 1. Participant characteristics, total population (n = 344)
Variable Mean ± SD
Age (years and range) 72.5 ± 5.5 [65-95)
Sex (n, %)
 Male 203 (59.0%) 
Brachial blood pressure (mmHg)a
 SBP 134.9 ± 16.9 
 DBP 77.2 ± 9.5 
Plasma homocysteine (μmol/L) 14.3 [12.9 – 16.3]
MDRD (ml/min per 1.73m2) 90.4 ± 34.0
BMI (kg/m2) 26.5 ± 3.4
Medical history of
 Hypertension 131 (38.1%) 
 Diabetes mellitus 38 (11.0%) 
 Hypercholesterolemia 88 (26.7%) 
 Cardiac disease 74 (21.5%) 
 TIA / Stroke 26 (7.6%) 
Smoking status
 Nonsmoker 126 (36.6%) 
 Former smoker 190 (55.2%) 
 Current smoker 28 (8.1%) 
Values are presented as number and percentage or as mean ± SD, except for homocysteine 
[median (IQR)].
Abbreviations: DBP, diastolic blood pressure; MDRD, modification of diet in renal disease; SBP, 
systolic blood pressure; TIA, transient ischemic attack.
aMeasured with a semiautomatic oscillometric device.
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Peripheral blood pressure measurements obtained with a semiautomatic 
oscillometric device, used for applanation tonometry, were significantly cor-
related with the peripheral blood pressure measurements of the oscillometric 
method (SBP: r=0.76, P<0.01; diastolic blood pressure: r=0.65, P<0.01). 
The mean bias between the two blood pressure measurements is 5.6±12.7 
mmHg, with 95% limits of agreement ranging from –19.2 to 30.4 mmHg. 
The peripheral SBP explains 4% of the variation in the PWV level and 80% in 
the variation with aortic SBP with applanation tonometry. With oscillometry, 
the peripheral SBP explains 11% of the PWV level and 89% of the aortic SBP 
level.
AIx ranged from 0 to 57% and aPWV measurements from 2.3 to 48.0 m/s 
with applanation tonometry. With oscillometry, AIx ranged from 1.8 to 74.4% 
and aPWV from 6.3 to 17.7 m/s. AIx and aPWV differed significantly between 
the two devices: oscillometry yielded higher values of the AIx (P<0.01) but 
lower values of aPWV (P<0.01) than applanation tonometry. When data were 
stratified on the basis of aPWV levels of more than 12 m/s, aPWV values only 
differed in participants with increased arterial stiffness (Table 2). 
With applanation tonometry, aortic SBP ranged from 77 to 224 mmHg and 
the aortic PP from 21 to 144 mmHg, whereas with oscillometry, aortic SBP 
ranged from 98 to 198 mmHg and aortic PP from 29 to 102 mmHg; aortic 
Table 2. Vascular characteristics (n = 344)
Sphygmocor Arteriograph p-value
PWV ≤ 12 m/s
AIx (%) 24.9 ± 10.2 37.4 ± 14.8 < 0.01
aPWV (m/s) 10.1 ± 2.0 9.9 ± 2.3 0.46
Aortic SBP (mmHg) 123.6 ± 16.7 133.0 ± 19.5 < 0.01
Aortic PP (mmhg) 46.2 ± 13.0 51.8 ± 13.5 < 0.01
PWV > 12 m/s
AIx (%) 26.7 ± 9.8 37.8 ± 14.9 < 0.01
aPWV (m/s) 16.1 ± 4.1 10.3 ± 2.0 < 0.01
Aortic SBP (mmHg) 130.2 ± 18.9 145.5 ± 22.0 < 0.01
Aortic PP (mmhg) 51.2 ± 15.4 59.7 ± 16.3 < 0.01
Values are presented as mean±SD.
Abbreviations: AIx, augmentation index; aPWV, aortic pulse wave velocity; PP, pulse pres-
sure; SBP, systolic blood pressure.
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SBP and aortic PP were higher with the oscillometric method than with the 
respective values of applanation tonometry (P<0.01) (Table 2).
The AIx measurements between applanation tonometry and oscillometry 
were correlated, but rather weakly (r=0.35, P<0.01). The mean bias with 
Bland–Altman analysis was –12.6±14.8%, with 95% limits of agreement 
ranging from –41.6 to 16.4% (Figure 2.1.1a). aPWV assessed by applana-
tion tonometry and oscillometry did not correlate at all (r= –0.06, P=0.92), 
and the level of agreement assessed by Bland–Altman analysis showed a 
Discussion
In participants with normal arterial stiffness (PWV<12
m/s), we found a moderate agreement between applana-
tion tonometry and oscillometry. However, the lack of
agreement was considerable when there were elevated
levels of arterial stiffness. The other arterial stiffness
measurements AIx, aortic SBP, and aortic PP also differed
between the devices.
Since oscillometry became available, several studies have
compared this method with applanation tonometry [4–7].
A population-based research found a complex pattern of
agreement in the peripheral and central AIx. Because the
values of the AIx depend on age and diastolic blood
pressure, agreement differed within subcategories [12].
In hypertensive populations (mean PWV 8–10m/s), the
devices did not agree sufficiently in their arterial stiffness
measurements [5,6]. In patients with severe renal disease
(mean PWV 11m/s), arterial stiffness measurements with
the oscillometric device did not correspond to those
of the tonometric measurements [13]. However, none of
these studies were carried out in the elderly with
Fig. 1
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Scatter plots of the total population. Scatter plots of the (a) augmentation index (AIx) values measured with the Arteriograph versus the AIx values
measured with the SphygmoCor, (b) the pulse wave velocity (PWV) values measured with the Arteriograph versus the PWV values measured with the
SphygmoCor, (c) the aortic systolic blood pressure (SBP) values measured with the Arteriograph versus the aortic SBP values measured with
the SphygmoCor, (d) the aortic pulse pressure (PP) values measured with the Arteriograph versus the aortic PP values measured with the SphygmoCor.
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Figure 2.1.1. 
Scatter plots of the (a) augmentation index (AIx) values measured with the Arteriograph ver-
sus the AIx values measured with the SphygmoCor, (b) the pulse wave velocity (PWV) values 
measured with the wArteriograph versus the PWV values measured with the SphygmoCor, (c) 
the aortic systolic blood pressure (SBP) values measured with the Arteriograph versus the 
aortic SBP values measured with the SphygmoCor, (d) the aortic pulse pressure (PP) values 
measured with the Arteriograph versus the aortic PP values easured with the SphygmoCor.
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mean bias of 4.2±4.9 m/s, with 95% limits of agreement varying from –5.3 
to 13.7m/s (Figure 2.1.1b).
The oscillometric and applanation tonometric aortic SBP measurements 
correlated moderately (r=0.68, P<0.01). Bland–Altman analysis showed a 
mean bias of -13.5±15.3 mmHg, with the 95% limits of agreement ranging 
from –43.5 to 16.5 mmHg (Figure 2.1.1c). For aortic PP, the correlation 
coefficient was moderate (r=0.57, P<0.01). The level of agreement had a 
mean bias of –8.8±15.2 mmHg, with 95% limit of agreement ranging from 
–38.6 to 20.9 mmHg (Figure 2.1.1d).
elevated levels of arterial stiffness, whereas accurate
arterial stiffness measurements are particularly important
in such a population, as this is important for enhanced
cardiovascular risk prediction.
Both devices have been validated by comparison with
invasive measurements of arterial stiffness [14–16]. Appla-
nation tonometry is currently used as the standard for
noninvasive arterial stiffness measurements and although
oscillometry has also been validated invasively, in agree-
ment with the studies mentioned above, our study found
that also in an older population applanation tonometry and
oscillometric measurements do not have comparable
arterial stiffness measures. Therefore, some authors are
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Figure 2.1.2.
Bland–Altman plots of (a) augmentation index, (b) pulse wave velocity, (c) aortic systolic 
blood pressure, and (d) aortic pulse pressure within the total population.
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A stratified Bland–Altman analysis of aPWV applanation tonometry measure-
ments more than 12 m/s (n=219) showed a mean bias of 6.1±4.5 m/s, with 
95% limits of agreement ranging from –2.7 to 14.9 m/s (Figure 2.1.2). A 
mean bias of 0.29±2.8 m/s was found in a stratified analysis of aPWV ap-
planation tonometry measurements 12 m/s or less (n=125), with 95% limits 
of agreement ranging from –5.3 to 5.9 m/s (Figure 2.1.2).
A stratified analysis of aPWV measurements between the age categories 
73 years or less and more than 73 years showed no differences between 
the level of agreement. aPWV values in participants aged 73 years or less 
showed a mean bias of 3.1±4.5 m/s, with 95% limits of agreement ranging 
from –5.7 to 11.8 m/s, and for aPWV values of participants aged more than 
73 years, a mean bias of 5.9±5.0 m/s was found, with 95% limits of agree-
ment ranging from –3.8 to 15.7 m/s (data not shown).
2.1.5 dIsCussIon
In participants with normal arterial stiffness (PWV ≤ 12 m/s), we found 
a moderate agreement between applanation tonometry and oscillometry. 
However, the lack of agreement was considerable when there were elevated 
levels of arterial stiffness. The other arterial stiffness measurements AIx, 
aortic SBP, and aortic PP also differed between the devices.
Since oscillometry became available, several studies have compared this 
method with applanation tonometry [4–7]. A population-based research 
found a complex pattern of agreement in the peripheral and central AIx. 
Because the values of the AIx depend on age and diastolic blood pressure, 
agreement differed within subcategories [12]. In hypertensive populations 
(mean PWV 8–10 m/s), the devices did not agree sufficiently in their arterial 
stiffness measurements [5,6]. In patients with severe renal disease (mean 
PWV 11 m/s), arterial stiffness measurements with the oscillometric device 
did not correspond to those of the tonometric measurements [13]. However, 
none of these studies were carried out in the elderly with elevated levels 
of arterial stiffness, whereas accurate arterial stiffness measurements are 
particularly important in such a population, as this is important for enhanced 
cardiovascular risk prediction.
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Both devices have been validated by comparison with invasive measure-
ments of arterial stiffness [14–16]. Applanation tonometry is currently 
used as the standard for noninvasive arterial stiffness measurements and 
although oscillometry has also been validated invasively, in agreement with 
the studies mentioned above, our study found that also in an older popula-
tion applanation tonometry and oscillometric measurements do not have 
comparable arterial stiffness measures. Therefore, some authors are skepti-
cal about the data that oscillometry yields. To understand the difference in 
agreement, which appears to depend on the amount of arterial stiffness, 
determinants of aPWV values are important. We have found that age is not a 
determinant of aPWV levels measured with oscillometry, and also not when 
there are elevated levels of arterial stiffness. As a stratified analysis per age 
category did show a larger lack of agreement in the oldest age category, this 
fits with our hypothesis that increased arterial stiffness is not that accurately 
measured with oscillometry as with applanation tonometry. Furthermore, 
AIx is a significant determinant of aPWV levels measured with oscillometry, 
independent of the amount of arterial stiffness. As AIx is an arterial stiffness 
measurement, which also represents peripheral resistance [17], this could 
also be a clue that the oscillometric measurement is more sensitive to local 
brachial stiffness, as has been debated previously [10,18]. The conditions of 
measuring with a cuff result in the pulse wave traveling back and forth in the 
brachial artery, where it reflects distally on the occluded cuff and proximally 
on the reflection of the aortic junction. However, other authors suggest that 
the brachial artery does have higher PWV levels, but that these levels would 
be much less affected by age-related stiffness than the aorta and that this 
artery is often not involved in atherosclerotic changes.
Nevertheless, the above-mentioned results may be an explanation why 
the measurements obtained with the oscillometric method do agree more 
with applanation tonometry in a non-arterial stiffness population and that 
no agreement has been shown in a population with more prominent arte-
rial stiffness. Yet, it is still unclear whether oscillometry and applanation 
tonometry measure similar vascular properties.
To the best of our knowledge, this study is the first to compare measure-
ments of arterial stiffness obtained with both oscillometry and applanation 
tonometry in an elderly population with elevated levels of arterial stiffness. 
As arterial stiffness is an important cardiovascular risk predictor in older 
populations in whom arterial stiffness is more prominently present, accurate 
measurements of arterial stiffness are important. Despite aPWV being the 
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most robust marker for arterial stiffness, aPWV measurements have the 
largest lack of agreement. Because the technology of applanation tonometry 
is more complicated, the oscillometric method was developed for its ease of 
arterial stiffness assessment. Despite this easy-to-use technology, with our 
results, it may be questioned whether the lack of agreement of aPWV levels 
is too large for the oscillometric method to be used for clinical applications 
in an elderly population with elevated levels of arterial stiffness as this is an 
important marker for cardiovascular risk assessment.
Several limitations of this research should be mentioned. One is the selected 
group of participants. Our study was carried out in older individuals partici-
pating in the B-PROOF study, all of whom had increased homocysteine levels. 
As hyperhomocysteinemia is associated with arterial stiffness [19], our 
participants are more prone to have elevated arterial stiffness, as the mean 
value of aPWV of 14 m/s indicates. However, as we aimed to investigate 
the accuracy of measurements with oscillometry, especially in a population 
with elevated levels of arterial stiffness, our study population could also 
be considered as a strength. Our stratified analysis of elderly with more 
pronounced arterial stiffness endorses this importance. A second limitation 
of our study is that the analysis we used for comparison did not allow us 
to adjust for different transit distances used by applanation tonometry and 
oscillometry and it was more difficult to compare the methods. Applanation 
tonometry uses the carotid–femoral distance, and the oscillometric method 
uses the distance from the sternal notch to the pubic symphysis. Another 
limitation is that different blood pressure methods were used for the calcula-
tion of vascular function with the two devices. Peripheral blood pressure 
levels are needed for calculation of AIx and PWV. Applanation tonometry 
uses a separate automatic oscillometric device to measure peripheral blood 
pressure, and the oscillometric method measures peripheral blood pressure 
itself. This difference might have influenced the results. Nevertheless, the 
mechanisms of measuring blood pressure are similar. However, although 
the blood pressure measurements were obtained with different devices and 
not simultaneously, we found a statistically significant correlation between 
these measurements and for both devices the peripheral SBP explains the 
variability in PWV levels to the same extent. Furthermore, measurements 
with both devices were performed only once. Repeated measurements would 
have yielded a more accurate analysis comparing the devices. The fact that 
the known determinants of PWV values as mean arterial pressure and heart 
rate are not explaining much of the variance of the PWV levels in our popula-
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tion is also worth mentioning. Therefore, one may question whether there is 
an accurate way of measuring arterial stiffness in such an older population 
at all. Also, we need to mention that it is possible that the oscillometric 
method will be appropriate for cardiovascular risk prediction, despite the 
fact that measurements are not in agreement with those of the applanation 
tonometry method. Because of our cross-sectional design, we cannot draw 
any conclusions on the predictive value of this device. However, in renal 
disease patients, oscillometry could not predict cardiovascular mortality 
[13]. It still needs to be established whether oscillometry has clinical value 
in cardiovascular risk assessment in the elderly and other patients with high 
risk of arterial stiffness.
In conclusion, in our study, we found that in elderly individuals with elevated 
levels of arterial stiffness, measurements with the oscillometric method do 
not agree with those of applanation tonometry. These findings should be 
taken into account when using the oscillometric device for cardiovascular 
risk assessment.
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3.1.1 AbstrACt
Background 
Whereas evidence exists about the benefits of intensive exercise on car-
diovascular outcomes in older adults, data are lacking regarding long-term 
effects of physical fitness and physical activity on cardiovascular health. 
Therefore, we aimed to investigate the longitudinal association of physical 
fitness, physical activity and muscle strength with arterial stiffness measures. 
Design: Longitudinal with 2-yr follow-up. 
Setting / Participants: A subgroup of the B-PROOF study (n=497, mean 
age 72.1 ± 5.4). 
Measurements
The primary outcome was arterial stiffness after 2 years of follow-up as esti-
mated by pulse wave velocity (PWV) measured with applanation tonometry. 
Furthermore, augmentation index and aortic pulse pressure were assessed. 
Physical activity was estimated using a validated questionnaire regarding 
daily activities. Physical fitness was measured with a physical performance 
score, resulting from a walking, chair-stand and balance test. Muscle strength 
was assessed with hand-grip strength using a handheld dynamometer. 
Results
Our population was aged 72 ± 5.4 years and 57% was male. The median 
performance score was 9.0 [IQR 8.0-11.0], the mean physical activity was 
744.4 (SD 539.4) kcal/day and the mean hand-grip strength was 33.1 (SD 
10.2) kg. AIx differed between the baseline and follow-up measurement 
(26.2% (SD 10.1) vs. 28.1% (SD 9.9); p < 0.01), whereas PWV and aortic 
PP did not. In multivariable linear regression analysis, physical performance, 
physical activity and hand-grip strength at baseline were not associated with 
the amount of arterial stiffness after two years of follow-up. 
Discussion
Physical fitness, activity and muscle strength were not associated with ar-
terial stiffness. Possibly only intensive activity will modify arterial stiffness 
within an older population, especially since this is also the case in younger 
individuals.
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Physical fitness and exercise have been shown to reduce the risk of cardio-
vascular disease to a relatively large extent in young and middle-aged popu-
lations [1, 2]. A potential important pathophysiological pathway consists of 
an exercise-induced reduction of the inflammatory status. Research showed 
that short-term regular exercise reduces the atherogenic activity of blood 
mononuclear cells, with a decrease in the production of atherogenic cyto-
kines and an increase in atheroprotective cytokines [3]. However evidence 
of the long-term benefit of physical fitness on cardiovascular outcomes in 
elderly is ambiguous as compared to younger populations [4]. 
Arterial stiffness is an interesting phenotype to target in this perspective, 
because it is a pre-clinical state of cardiovascular disease. Arterial stiffness is 
an abnormality of the vasculature, that has been shown to be an pre-clinical 
phase for cardiovascular disease at older age [6]. A variety of studies already 
showed that indeed short-term aerobic exercise (~12 weeks) improved arte-
rial function in older persons [7-10]. It has however been hypothesized that 
the pathophysiology of vascular adaptation to exercise differs between short 
and long-term exercise [11]. Whereas short-term adaptations of the arteries 
are likely due to changes in the vascular smooth muscle tone or changes in 
the vascular endothelium vasodilator tone, long-term adaptations are more 
likely to be represented by changes in the elastin-collagen composition, 
both may lead to less arterial stiffness. However, because arterial stiffness 
is an abnormality that is not easily or rapidly reversible, it is plausible that 
exercise will be no longer beneficial when arteries have already stiffened as 
is often the case in older individuals. 
Despite the promising results of short-term exercise in older adults, data 
are lacking regarding long-term effects of physical fitness and activity. Since 
the B-PROOF study included a general elderly population in which data are 
available regarding physical fitness and physical activity, we aim to investi-
gate the association between these physical parameters and arterial stiffness 
longitudinally. 
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3.1.3 Methods
Study population
The present study was conducted as a longitudinal analysis within the 
framework of the B-PROOF (B-vitamins for the Prevention Of Osteoporotic 
Fractures) study. A detailed description of this randomized controlled trial 
has been reported elsewhere [12]. In short, B-PROOF is a multi-center, ran-
domized, placebo-controlled, double-blind trial including 2919 participants 
from three areas in the Netherlands. The main outcome is osteoporotic 
fractures. Secondary outcomes include a.o. physical function measures and 
cardiovascular outcomes [12]. The intervention comprises 500 μg vitamin 
B12 and 400 μ folic acid. Both the intervention and the placebo group re-
ceived 15 μg vitamin D. Main inclusion criteria were age 65 years and older, 
and an elevated homocysteine level (12 – 50 μmol/l). Main exclusion criteria 
were renal insufficiency (creatinine level > 150 μmol/l) and presence of a 
malignancy (past 5 years). All participants gave written informed consent 
before the start of the study. The Wageningen Medical Ethics Committee 
approved the study protocol, and the Medical Ethics committees of Rotter-
dam and Amsterdam gave approval for local feasibility. The B-PROOF study 
has been registered with the Netherlands Trial Register (www.trialregister.
nl) under identifier NTR 1333 since June 1, 2008 and with ClinicalTrials.
gov under identifier NCT00696514 since June 9, 2008. In the current study 
participants were included in whom both physical parameters and arterial 
stiffness parameters were available. 
Physical performance, activity and hand grip strength
Physical Performance
Physical fitness was measured with the physical performance score, which 
was assessed using three different tests: the walking test, i.e. the time 
needed to walk 3 meters, turn around and walk back as quickly as possible; 
the chair stands test, e.g. the time needed to rise from and sit down in a 
chair for five times without the use of arms, as quickly as possible; and the 
tandem stand, i.e. the ability to stand with one foot in front of the other for 
10 seconds. Quartiles of the time needed to perform the walking test and 
chair stands were calculated [13]. The categories for walking were: score 0 
(unable or able to hold < 4 s), score 1 (≥9 s), score 2 (7–8 s), score 3 (6 s) 
and score 4 (≤5 s); the categories for the chair stands were: score 0 (un-
able), score 1 (≥15 s), score 2 (12–14 s), score 3 (10–11 s) and score 4 (≤9 
s). The tandem stand score was categorized as follows: score 0 (unable), 
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score 2 (able to hold position for 4–9 s), and score 4 (able to hold position 
for at least 10 s). A total physical performance score (range 0–12, with a 
score of 12 representing optimal physical performance) was calculated by 
summing up the scores of the three different tests. The physical performance 
test has been shown to be reliable and valid instrument to measure physical 
performance: A lower total score has been associated with an increased 
fall- and fracture risk, frailty and lower cognitive functioning [13-16].
Hand Grip strength
Muscle strength was assessed with hand-grip strength (kg), which was mea-
sured using a strain-gauged dynamometer (Takei, TKK 5401, Takei Scientific 
Instruments Co. Ltd., Japan, inter observer CV = 5%). Participants were 
asked to perform two maximum hand-grip trials with each hand in standing 
position with their arms along their body. Maximal hand-grip strength was 
defined as the average of the highest score of the left and right hand.
Physical Activity
Total physical activity (min/day) was measured with the validated LASA 
Physical Activity Questionnaire (LAPAQ) [17]. The activities in this question-
naire included walking, cycling, gardening, participation in sports and light 
and heavy household activities. Frequencies and duration of each activity 
during the last two weeks were assessed. Physical activity was subsequently 
calculated in kcal/day.
Arterial stiffness parameters
At the Erasmus MC (Rotterdam) and VU University Medical Center (Amster-
dam), a subsample of participants of the B-PROOF study underwent vascular 
measurements (n = 567). Participants with cardiac arrhythmia were excluded 
from these additional measurements. During the measurements, partici-
pants were situated in supine position on a flat examination couch in a quiet 
laboratory room for at least 5-10 minutes prior to the measurements, and 
the participants were not allowed to speak during the measurements. Use of 
alcohol or coffee during 12 hours before the measurements was prohibited. 
Blood pressure measurement
Peripheral blood pressure at the time of vascular function tests was mea-
sured once with a semi-automatic oscillometric device (DatascopeAccurator 
Plus device, Datascope Corp. New Jersey, USA) after at least five minutes 
of supine rest. All blood pressure measurements were conducted at the 
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right arm and measured in mmHg. The mean arterial pressure (MAP) was 
measured and the pulse pressure was calculated as the systolic minus the 
diastolic blood pressure. 
Applanation tonometry
Arterial tonometry was obtained from the right radial, right carotid and right 
femoral artery using the Sphygmocor device (Sphygmocor version 7.1, AtCor 
Medical, Sydney, Australia). An estimate of the corresponding central aortic 
pulse wave was calculated, using a validated generalized transfer function 
incorporated in the device. With the integral software, the central augmented 
pressure was calculated as the difference between the early and late systolic 
peaks of the estimated central pressure wave form. Central aortic augmenta-
tion index (AIx) was calculated as the augmented pressure expressed as a 
percentage of the pulse pressure (intra CV = 3%, inter CV = 5%). Aortic 
pulse wave velocity (PWV) was measured with three channel ECG recording 
and simultaneously recording of the right carotid artery pulse wave form and 
subsequently the femoral artery pulse waveform. The PWV was calculated 
as the delay between the femoral pulse wave and the carotid pulse wave, 
divided by the transit distance (intra CV = 5 %, inter CV = 8%). Transit dis-
tance was assessed with body surface measurement from the carotid artery 
to the femoral artery [18].
Covariates
Alcohol intake, smoking habits and presence of cardiovascular risk factors: 
hypertension, hypercholesterolemia and diabetes mellitus were determined 
using a structured questionnaire. Questions regarding cardiovascular disease 
history, including angina pectoris, myocardial infarction, transient ischemic 
attack and/or stroke were included in this questionnaire. 
Body mass index (BMI) was calculated as weight divided by squared height 
and expressed as kg/m2.
Serum creatinine was measured with the enzymatic colorimetric Roche 
CREA plus assay (CV=2%). The estimated Glomerular Filtration Rate (eGFR) 
was defined as the Modification of Diet in Renal Disease (MDRD) which was 
calculated in ml/min/1.73m2 with the formula: 186 * (serum creatinine 
(μmol/l) / 88.4) – 1.154 * age (years) – 0.203 * 0.742 (for females) [19].
Serum CRP was measured with electrochemiluminescence immunoassay 
on a Roche Modular E170 (Roche, Almere, The Netherlands). 
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The associations between physical fitness, physical activity and muscle 
strength and arterial stiffness parameters were tested longitudinally. For 
these analyses, baseline measurements of the physical parameters were 
used and follow-up measures of arterial stiffness. 
The distributions of all variables of interest were examined with histograms 
and Kolmogorov-Smirnov tests. If a variable was not normally distributed, a 
categorized variable was created. The linearity of associations of the predic-
tion of arterial stiffness measures with physical performance, activity and 
hand grip strength was tested with curve estimation modeling. When linear 
relations had the best fit, Pearson correlation coefficients were calculated 
and multivariable linear regression analysis was done. If the relations were 
non-linear, cubic spline models were created with R version 3.0.0 [20].
Covariates which were considered as potential confounders were baseline 
measures of arterial stiffness parameters, age, gender, study center, treat-
ment allocation of the participant in the BPROOF study, MAP, heart rate, 
smoking status, alcohol use, eGFR and BMI.
Furthermore, we tested whether gender or age modified the association 
between physical performance, activity, hand-grip strength and measures 
of arterial stiffness. If the interaction-term gender * physical performance, 
activity or hand-grip strength was significant (p < 0.1), a stratified analysis 
was done. This also accounted for the interaction terms with age. 
In order to further explore the pathophysiological hypothesis that in par-
ticipants with increased arterial stiffness, the association between physical 
parameters and arterial stiffness is different, we tested if this modified the 
association between physical performance, activity or hand-grip strength. If 
the interaction-term was significant (p < 0.1), a stratified the linear regres-
sion analysis was done for participants with and without increased arterial 
stiffness at baseline. 
Statistical analyses were performed using the statistical software package 
of SPSS version 20.0 (SPSS Inc, Chicago, Illinois, USA). The α-level was set 
at 0.05.
3.1.4 results 
In total, our population consisted of 497 participants for whom both arterial 
stiffness measurements and physical variables were available. The mean age 
of our population was 72 (SD 5.4) years and 57% was male. The characteris-
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tics of the study population are depicted in Table 1 and Table 2. The median 
performance score was 9.0 [IQR 8.0-11.0], the mean physical activity was 
744.4 (SD 539.4) kcal/day and the mean hand-grip strength was 33.1 (SD 
10.2) kg. 
AIx differed between the baseline and follow-up measurement ( p < 0.01), 
whereas PWV and aortic PP did not (Table 2).
Table 1. Population characteristics at baseline (n = 497)
Variable Mean ± SD
Age (years and range)  72.1 ± 5.4
Sex (n, %)
 Male  283 (57%)
BMI (kg/m2) 27.0 ± 3.7
Treatment allocation B-PROOF trial (n, %)
 Intervention with B-vitamins
 Placebo
260 (52.3%)
237 (47.7%)
Smoking behavior
 Never 
 Former
 Current
183 (36.8%)
272 (54.7%)
42 (8.5%)
Alcohol consumption (n, %)
 Light
 Moderate
 Excessive
 Very excessive
319 (64.2%)
152 (30.6%)
21 (4.2%)
5 (1.0%)
SBP (mmHg) 137.1 ± 17.8
DBP (mmHg) 77.2 ± 9.4
Hypertension (n, %) 194 (39.4%)
Diabetes mellitus (n, %) 53 (10.7%)
Hypercholesterolemia (n, %) 138 (27.8%)
eGFR (ml/min per 1.73m2) 91.8 ± 34.9
Plasma homocysteine (μmol/L) 14.2 [12.9 – 16.3]
CRP (mg/L) 1.0 [1.0 – 3.0]
Performance score (0-12) 9.0 [8.0 – 11.0]
Physical activity (kcal/day) 744.4 ± 539.4
Hand-grip strength (kg) 33.1 ± 10.2
Data are presented as mean ± SD, unless for categorical variables and variables with a non-
normal distribution. Categorical variables are presented as number of cases and the percent-
age of cases and variables which were not normally distributed are presented as medians with 
IQR. Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein. 
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In the multivariable linear regression analysis, neither physical performance, 
nor physical activity, nor hand-grip strength were associated with the amount 
of arterial stiffness after a follow-up period of 2 years (Table 3). Gender as 
well as age did not modify these models. 
To test the hypothesis of arterial stiffness being irreversible, a stratified 
analysis was done comparing participants with and without increased arterial 
stiffness (PWV ≥ 12 m/s) at baseline. In both groups, physical performance, 
activity and hand-grip strength were not able to predict the amount of arte-
rial stiffness after 2 years.
3.1.5 dIsCussIon
In our study, physical performance, physical activity and hand-grip strength 
were not associated with arterial stiffness after a follow-up period of 2 years. 
Stratification for the presence of elevated arterial stiffness at baseline did not 
modify these results.
Table 2. Descriptives of the vascular parameters at both baseline and follow-up
n Baseline Follow-up p-value difference 
baseline – follow-up
PWV (m/s) 448 14.1 ± 4.3 14.2 ± 4.4 0.67
AIx (%) 483 26.2 ± 10.1 28.1± 9.9 < 0.01
Aortic PP (mmHg) 487 49.8 ± 15.0 48.6 ± 14.0 0.08
Data are presented as mean ± SD. Abbreviations: PWV: pulse wave velocity; AIx: augmenta-
tion index; PP: pulse pressure. P-values were based on the students’ t-test. 
Table 3. Multivariate linear regression analysis of the association between physical pa-
rameters at baseline and arterial stiffness after 2yrs of follow-up
PP PA HGS
PWV (m/s) -0.04
[-0.20 ; 0.11]
-2.92·10-5
[-0.01 ; 0.01]
-0.03
[-0.10 ; 0.04]
AIx (%) 0.23
[-0.11 ; 0.57]
-3.13·10-4
[-0.01 ; 0.01]
0.08
[-0.06 ; 0.21]
Aortic PP (mmHg) 0.05
[-0.32 ; 0.43]
-8.61·10-4
[-0.01 ; 0.01]
-0.11
[-0.26 ; 0.05]
Data are presented as estimated beta with 95% confidence interval (CI) and were adjusted 
for baseline measure of arterial stiffness parameter, age, gender, treatment allocation, study 
center, MAP, heart rate, smoking status, alcohol use, eGFR, BMI. Abbreviations: PWV: pulse 
wave velocity; AIx: augmentation index; PP: pulse pressure; PP: physical performance score, 
PA: physical activity measured with LAPAQ; HGS: hand-grip strength. 
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To the best of our knowledge, our study is the first to address the longitudinal 
relation between physical fitness, physical activity and muscle strength on 
vascular parameters among elderly individuals. Although many other studies 
have been done, these were mainly trials investigating the effect of exercise 
on vascular function, in general follow-up time was relatively short, with 
a mean duration of approximately 12 weeks [6-9]. In our study, we did 
not observe an association between physical fitness, physical activity and 
hand-grip strength with arterial stiffness longitudinally during a long-term 
follow-up of 2 years. 
The lack of an association may be explained in several ways. First, there may 
be a difference between short-term and long-term adaptations of the arter-
ies. On short-term, aerobic exercise has been shown to change endothelial 
function and inflammation, mediating the improvement of the arterial stiff-
ness process [10]. It has also been shown that structural adaptations of the 
artery are possible, based on elastin and collagen changes, which are less 
likely to occur after a short period of time, but rather occur on the long-term 
[10]. Nevertheless, we did also not observe an association between physical 
parameters and arterial stiffness over a period of 2 years. Our finding might 
indicate that these structural changes are not present in older individuals. 
Potentially this has to do with the limited reversibility of the arterial stiffen-
ing process. If the latter holds true, the predictive value of the physical 
parameters would differ between participants with and without elevated 
arterial stiffness at baseline. Nevertheless, stratification did not show differ-
ent results between both groups. Also in the participants without elevated 
arterial stiffness, physical fitness, physical activity and muscle strength were 
not associated with the amount of arterial stiffness after 2 years. Therefore 
we may conclude, that these mechanisms are probably of less importance in 
the arterial ageing process. Nevertheless, it is possible that in older persons 
only very intense physical exercise will lead to the adaptations mentioned 
above, as these vascular changes occur more within younger individuals 
during intensive activities.
Besides, we did not observed an association between hand-grip strength and 
arterial stiffness after a period of 2-years. Hand-grip strength is possibly only 
a reliable way for measuring muscle resistance in trained individuals, and not 
in an untrained older population. Especially since hand-grip strength is more 
often used as a marker of frailty in this age group and not as a measure of 
muscle strength [20, 21].
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There are several limitations that need mentioning. First, our population 
consists of hyperhomocysteinemic elderly [11], which makes our findings 
not generalizable to the overall population. Nevertheless, almost 50% of 
all European elderly has increased homocysteine levels [22], making this 
condition very common. Furthermore, for the vascular measurements, par-
ticipants were invited to come to the hospital for undergoing the tests and 
it cannot be ruled out that the more frail participants would be restrained 
for this appointment. Because our participants were slightly more active, 
had higher performance score and higher hand-grip strength compared 
to the total population, this is certainly a possibility. Third, all participants 
participated in a trial and all received low dose vitamin D during the study 
and were allocated in a B-vitamin treatment group or placebo [11]. Although 
the B-vitamin treatment did not influence the arterial stiffness parameters 
[23], a potential effect of vitamin D supplementation on arterial stiffness 
levels, in particular for AIx, cannot be excluded. However, a trial with vitamin 
D supplementation in postmenopausal women did not show beneficial ef-
fects on arterial stiffness [24]. Fourthly, physical activity was assessed with 
the LAPAQ, a self-report questionnaire. It is possible this self-report is not 
completely representative for the true activity load, especially for lighter 
activities [25]. Nevertheless, this questionnaire has been validated in an 
older population, showing to be valid and reliable for measuring physical 
activity [16], and we calculated the activity in kcal/day, therefore adding 
more value to heavier activities. Regarding the physical performance score, 
this score has been validated in a more frail population [12] compared to our 
relatively healthy study population. These instruments of measuring physical 
activity and fitness may therefore not be able to detect subtle differences 
among fitter elderly. 
Conclusion
Physical fitness, physical activity and muscle strength were not associated 
with preclinical cardiovascular disease in the older B-PROOF population. 
Potentially only very intensive activity will be able to modify arterial stiffness 
rather than daily activity. Furthermore, with regard to the limited reversibil-
ity of arterial stiffness, the influence of physical activity would be minimal in 
older individuals. Nevertheless, more research is warranted to elucidate the 
long-term effects of daily and intensive physical activity on arterial stiffness 
in an elderly population, preferably by using an intervention trial. Only in 
this way knowledge regarding the long-term effects of physical activity on 
the prevention of cardiovascular disease in older persons can be obtained.
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3.2.1 AbstrACt
Introduction
Several studies have observed positive associations between bone disease 
and cardiovascular disease. A potential common pathway is hyperhomocys-
teinemia. However, up to now, data are lacking regarding hyperhomocys-
teinemic populations. Therefore we examined, both cross-sectionally and 
longitudinally, whether there is an association between bone parameters and 
arterial stiffness in a hyperhomocysteinemic population, and investigated the 
potential common role of homocysteine level on these associations. 
Methods
Data of the B-PROOF study were used (n = 519). At both baseline and 2-year 
follow-up we determined bone measures: incident fractures and history of 
fractures, bone-mineral density (BMD) and quantitative ultrasound (QUS) 
measurement; arterial stiffness parameters were measured at baseline: 
pulse wave velocity (PWV), augmentation index (AIx) and aortic pulse pres-
sure (PP) levels with applanation tonometry. Linear regression analysis was 
used to examine these associations and we tested for potential interaction 
of homocysteine level.
Results 
Mean age was 72.3 years and 44.3% was female. Both cross-sectionally and 
longitudinally there was no association between arterial stiffness measures 
and BMD or QUS measurements, nor with incident fractures (n = 16) within 
the 2-3 years of follow-up. Homocysteine level did not modify the associa-
tions and neither did adjustment for homocysteine change the results.
Conclusion
Arterial stiffness was not associated with bone parameters and fractures, 
and homocysteine neither acted as a pleiotropic factor nor as a mediator. 
The potential association between bone and arterial stiffness is therefore not 
likely to be driven by hyperhomocysteinemia.
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3.2.2 IntroduCtIon
Both cardiovascular disease and osteoporosis are common conditions in the 
older population. Research has demonstrated that diseases of vasculature 
and bone share several similar determinants, like for example advancing 
age, smoking and diabetes mellitus [1-5]. Recently, it has been shown that 
prevalence of cardiovascular disease is associated with new occurrence of hip 
fractures [6]. Furthermore, in several studies osteoporosis and bone mineral 
density have been shown to predict cardiovascular mortality, cardiovascular 
morbidity and atherosclerosis [7-10]. However, there are also a few studies 
that did not observe an association between BMD and cardiovascular mortal-
ity [11, 12]. Therefore, the question rises whether the relation between 
bone diseases and cardiovascular disease is causal, or may be driven by a 
common pathway. 
One of the hypothesized common pathways is hyperhomocysteinemia [13-
16]. Hyperhomocysteinemia is associated with both osteoporosis and with 
cardiovascular disease via dysregulation of the RANK-ligand/RANK axis and 
via inflammation [17-19]. Particularly in elderly, hyperhomocysteinaemia is 
associated with osteoporosis and hip fractures [16, 20]. Hyperhomocyste-
inaemia is also an important risk predictor for cardiovascular disease in this 
age group [21], predominantly via arterial stiffness, a preclinical cardiovas-
cular condition [22, 23].
Up to now there are no reports addressing the association between bone 
and cardiovascular parameters in elderly or hyperhomocysteinemic popula-
tions. Nevertheless, different associations might be expected between bone 
and vascular parameters in individuals having a relatively low versus high 
homocysteine level. As mentioned above, high levels of homocysteine are 
associated with lower BMD levels, increased fracture risk and elevated arte-
rial stiffness, and therefore, we expected a stronger relationship at higher 
homocysteine levels as compared to lower homocysteine levels. The first 
aim of this study was therefore to investigate whether arterial stiffness is 
associated with bone parameters and fractures in older persons with mildly 
elevated homocysteine levels (the B-PROOF study). Our second aim was to 
better explore the potential role of homocysteine in the etiology of osteopo-
rosis and cardiovascular disease (Figure 3.2.1).
58
3.2.3 Methods
Study population
The present study was conducted within the framework of the B-PROOF 
(B-vitamins for the PRevention Of Osteoporotic Fractures) study. A detailed 
description of this randomized controlled trial has been reported elsewhere 
[24]. In short, B-PROOF is a multi-center, randomized, placebo controlled, 
double-blind trial including 2919 participants from three areas in the Neth-
erlands. Main inclusion criteria were age 65 years and older, and an elevated 
homocysteine level (12 – 50 μmol/l). Main exclusion criteria were renal 
insufficiency (creatinine level > 150 μmol/l) and presence of a malignancy. 
All participants gave written informed consent before the start of the study. 
The Wageningen Medical Ethics Committee approved the study protocol, and 
the Medical Ethics committees of Rotterdam and Amsterdam gave approval 
for local feasibility. The present study was conducted in a randomly invited 
subsample of 519 participants in whom both vascular parameters and bone 
measures were available. 
Laboratory measurements
Venous blood samples were obtained in the morning, when participants 
were in a fasted state, or had taken a restricted breakfast [24]. For total 
homocysteine analysis, a plasma EDTA tube was stored on ice immediately 
after blood drawing [24], and samples were processed within 4 hours in 
order to prevent a temperature- and time-dependent increase in plasma 
homocysteine [25]. Plasma homocysteine was measured using the Architect 
Homocysteine
Figuur 3.2.1.
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i2000 RS analyzer (VU University Medical Center, intra assay CV=2%, inter 
assay CV=4%) and LC-MS/MS (Erasmus intra assay CV=5.5%, inter assay 
CV=1.3%). Outcomes of the centers did not differ significantly at cross-
calibration. Serum creatinine was measured with the enzymatic colorimetric 
Roche CREA plus assay (CV=2%). The Modification of Diet in Renal Disease 
(MDRD) was calculated in ml/min/1.73m2 with the formula: 186 * (serum 
creatinine (μmol/l) / 88.4)– 1.154 * age (years)– 0.203 * 0.742 (for females) [26]. 
Arterial stiffness 
At the Erasmus MC (Rotterdam) and VU University Medical Center (Amster-
dam), a subsample of participants underwent vascular measurements at the 
same day of BMD measurement. Participants with cardiac arrhythmia were 
excluded from these additional measurements. During the measurements, 
participants were situated in supine position on a flat examination couch in a 
quiet laboratory room for at least 5-10 minutes prior to the measurements, 
and the participants were not allowed to speak during the measurements. 
Use of alcohol or coffee during 12 hours before the measurements was pro-
hibited. 
Blood pressure measurement
Peripheral blood pressure at the time of vascular function tests was mea-
sured once with a semi-automatic oscillometric device (Datascope Accurator 
Plus device, Datascope Corp. New Jersey, USA) after at least five minutes 
of supine rest. All blood pressure measurements were conducted at the 
right arm and were measured in mmHg. The mean arterial pressure was 
measured and the pulse pressure was calculated as the systolic minus the 
diastolic blood pressure. 
Applanation tonometry
Arterial tonometry was obtained from the right radial, right carotid and right 
femoral artery using the Sphygmocor device (Sphygmocor version 7.1, AtCor 
Medical, Sydney, Australia). An estimate of the corresponding central aortic 
pulse wave was calculated, using a validated generalized transfer function 
incorporated in the device. With the integral software, the central augmented 
pressure was calculated as the difference between the early and late systolic 
peaks of the estimated central pressure waveform. Central aortic augmenta-
tion index (AIx) was calculated as the augmented pressure expressed as a 
percentage of the pulse pressure (intra CV = 3%, inter CV = 5%). Aortic 
pulse wave velocity (aPWV) was measured with three channel ECG recording 
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and simultaneously recording of the right carotid artery pulse wave form and 
subsequently the femoral artery pulse waveform. The aPWV was calculated 
as the delay between the femoral pulse wave and the carotid pulse wave, 
divided by the transit distance (intra CV = 5 %, inter CV = 8%). Transit dis-
tance was assessed with body surface measurement from the carotid artery 
to the femoral artery [27].
Bone parameters (outcome variables)
Fractures
Fracture history was assessed at baseline using a structured questionnaire. 
During the 2-3 year follow-up, participants reported incident fractures on 
a study calendar every three months. Finally, at the end of follow-up par-
ticipants were asked for the occurrence of fractures during the study period 
to confirm the data collected during follow-up. All reported fractures were 
verified with the participants’ general practitioner or hospital. 
Bone mineral density
At Erasmus MC (Rotterdam) and VU Medical Center (Amsterdam), participants 
were invited for bone mineral density (BMD) measurement. Dual-energy X-
ray assessment (DEXA) was used to measure femoral neck and lumbar spine 
BMD (g/cm2) under standard protocols within four weeks of the individual’s 
start in the intervention. For all measurements, the Hologic QDR 4500 Delphi 
device (VUmc, (Hologic, USA)) or the GE Lunar Prodigy device (Erasmus MC, 
(GE Healthcare, USA)) were used. The two devices were cross-calibrated by 
measuring a European spine phantom (ESP) five times on both machines and 
all results were adjusted accordingly.
Bone quality – Quantitative ultrasound of the calcaneus
During the blood-drawing visit, a random subgroup of participants was 
invited to undergo Quantitative ultrasound (QUS) measurements of the 
calcaneus. These measurements were performed using a Hologic Sahara 
bone densitometer (Hologic, USA) (Erasmus MC, VUmc, WUR) or a CUBA 
Clinical system (VUmc). Subjects were excluded from QUS measurements 
if edema in the foot/ankle was visibly present, since this is known to affect 
the measurement [28]. Broadband ultrasound attenuation (BUA, dB/MHz) 
and speed of sound (SOS, m/s) were measured in duplicate in both the right 
and the left calcaneus. For each individual, averages of these four measure-
ments were calculated. Measurements were excluded when violation of the 
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expected linear frequency-attenuation relation occurred, since this indicates 
invalid results.
Covariates
Height was measured in duplicate to the nearest 0.1 cm while standing erect 
and wearing no shoes, using a stadiometer [24]. Weight was measured with 
the participant wearing light garments without shoes and empty pockets to 
the nearest 0.5 kg using a calibrated weighing device (SECA 761) [24]. Body 
Mass Index (BMI) was calculated as weight divided by squared height and 
expressed as kg/m2. 
Alcohol intake and smoking habits were determined using a questionnaire 
[24]. Questions regarding cardiovascular disease risk factors including hy-
pertension, hypercholesterolemia and diabetes mellitus were also included 
[24]. 
Statistical analysis
The distributions of all variables of interest were examined with histograms. 
The linearity of associations between arterial stiffness parameters and bone 
parameters was tested with curve estimation modeling. Because linear as-
sociations had the best fit, Pearson correlation coefficients were calculated 
and multivariable linear regression analysis was used. Potential confounders 
were age, gender, study center, smoking status, alcohol use, eGFR, BMI, 
diabetes, hypertension and hypercholesterolemia. These parameters were 
added to the final model when they were considered to be clinically relevant 
or contributed to a > 10% change of the point estimate. 
We tested the association of arterial stiffness with bone parameters both 
cross-sectionally at baseline and longitudinally after 2 years of follow up. 
Arterial stiffness measures at baseline were used as independent variables 
and bone parameters, including fractures (at baseline and after 2 years of 
follow-up; fractures 2-3 years of follow-up), were the outcome variables. 
Regarding the longitudinal analysis, we considered it justified to include all 
B-PROOF participants who were also included in the cross-sectional analy-
ses (the participants who received placebo as well as the participants who 
received the B-vitamin treatment), because the intervention with vitamin 
B12 and folic acid overall did not significantly prevent fractures and did not 
change the levels of BMD, BUA or arterial stiffness [29, 30], however in 
order to adjust for any potential residual confounding we did adjust for group 
assignment. 
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Within the cross-sectional multivariable linear regression analysis we 
tested whether adjustement for homocysteine affected the possible associa-
tion between measures of arterial stiffness and bone parameters. Also for 
the longitudinal analysis we adjusted for homocysteine level. 
Potential effect modification of homocysteine
We cross-sectionally tested whether plasma homocysteine modified the as-
sociation between measures of arterial stiffness and bone parameters. If the 
interaction term homocysteine * PWV or another arterial stiffness measure 
was significant (p < 0.1), a stratified analysis was done. Strata were created 
based on homocysteine level < 18 µmol/L and homocysteine level ≥ 18 
µmol/l. 
We also tested whether the change in homocysteine level during the two 
years of follow-up modified the longitudinal analysis. If the interaction term 
homocysteine-change * PWV (or AIx/aortic PP) was significant (p < 0.1) a 
stratified analysis was done with participants with an increase in homocyste-
ine level after 2yr follow-up, no change in homocysteine during 2 yrs and a 
decrease in homocysteine level after 2yr follow-up. 
Statistical analyses were performed using the statistical software package 
of SPSS version 20.0 (SPSS Inc, Chicago, Illinois, USA). The α-level was set 
at 0.05. 
3.2.4 results
Characteristics of the population are described in Table 1. The mean age 
was 72.3 years and 44.3% was female. The median number of fractures 
occurred in history was 0.0 [IQR 0-1], total number ranging from 0 to 7. One 
hundred ninety-nine participants had at least 1 fracture in history. 
Within the cross-sectional analysis at baseline, PWV correlated negatively 
with FN-BMD (r = -0.09, p = 0.04), but not with LS-BMD, BUA or SOS. AIx 
correlated negatively with FN-BMD, LS-BMD, BUA and SOS levels (r=-0.24 
p < 0.01; r=-0.21 p<0.01; r=-0.17 p<0.01; r=-0.12 p=0.04 respectively). 
Aortic PP correlated with FN-BMD (r=-0.16 p<0.01), but not with LS-BMD, 
BUA or SOS. The number of sustained fractures in history did not correlate 
with either of the vascular parameters.
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Within the cross-sectional multivariable linear regression analysis, adjusted 
for age, gender and study center, none of the arterial stiffness measures 
were associated with the number of sustained fractures in history, FN-BMD, 
LS-BMD, BUA or SOS (Table 3). In particular the adjustment for age altered 
the associations to non-significant. Also in the longitudinal linear regression 
Table 1. Population characteristics
n Mean ± SD 
Age (years and range) 519 72.3 ± 5.4
Gender (n, %)
 Female
519 230 (44,3%)
Homocysteine (μmol/L) 519 14.1 [12.9 – 16.4]
Number of sustained fractures 
in history
519 0.6 ± 1.1
[range 0-7]
Cardiovascular risk factors
Smoking behavior (n, %)
 Never
 Former
 Current
519
186 (35.8%)
286 (55,1%)
47 (9,1%)
Alcohol use (n, %)
 Light
 Moderate
 Excessive
 Very excessive
519
330 (63,6%)
159 (30,6%)
24 (4,6%)
6 (1,2%)
eGFR (ml/min per 1.73m2) 519 90.5 ± 35.0
BMI (kg/m2) 519 27.0 ± 3.7
Brachial blood pressure 
(mmHg)
 SBP
 DBP
519
137.6 ± 17.9
77.3 ± 9.5
Hypertension (n, %) 519 210 (40,5%)
Diabetes mellitus (n, %) 519 57 (11,0%)
Hypercholesterolemia (n, %) 519 142 (27.4%)
Vascular parameters
PWV (m/s) 479 14.2 ± 4.3
AIx (%) 509 26.3 ± 10.1
Aortic PP (mmHg) 510 50.0 ± 15.0
Data are presented as mean ± SD or as number (%) when categorical variables. Homocyste-
ine is presented as median [IQR]. 
Abbreviations: eGFR: estimated glomerular filtration rate; BMI: body mass index; SBP: sys-
tolic blood pressure; DBP: diastolic blood pressure; PWV: pulse wave velocity; AIx: augmen-
tation index; PP: pulse pressure. 
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analysis, we did not observe an association between the vascular parameters 
and bone parameters after a period of 2 years (Table 4). During the 2-year 
follow-up period, 16 participants suffered at least one fracture. We did not 
find an association between the vascular parameters and incident fractures 
(data not shown). 
Additional adjustment for homocysteine (baseline level in the cross-sectional 
analysis and homocysteine change in the longitudinal analysis) did not sig-
nificantly change the associations between arterial stiffness measures and 
bone parameters (Table 3 and 4). 
Potential effect modification of homocysteine
In order to investigate the effect of homocysteine level on the association 
between bone and vascular parameters, we tested the interaction effect of 
homocysteine. The homocysteine * aortic PP interaction was significant in 
the association with FN-BMD (p = 0.02). However, in a stratified analysis for 
Hcy < 18 µmol/l and Hcy ≥ 18 µmol/l we did not observe any association be-
tween aortic PP and FN-BMD (data not shown). Regarding sustained fracture 
history, we observed a significant homocysteine * aortic PP interaction (p = 
0.09) and a significant homocysteine * AIx interaction (p = 0.02) (data not 
shown). In the stratified analysis for Hcy < 18 µmol/l and Hcy ≥ 18 µmol/l, 
we observed a significant association between the number of sustained 
fractures in history and aortic PP in the group with homocysteine levels ≥ 18 
µmol/l (beta -0.04 95%CI [-0.07 ; -0.01]). In other words, in the group with 
high homocysteine levels, lower number of fractures was associated with 
higher levels of aortic PP. 
In the longitudinal analysis, the homocysteine change – aortic PP interaction 
was again significant (p = 0.01) for FN-BMD (at follow-up), but not for the 
Table 2. Bone characteristics at baseline and 2-yr follow-up
Baseline Follow-up p-value 
FN-BMD (g/cm2) 0.87 ± 0.16 0.86 ± 0.16 < 0.01
LS-BMD (g/cm2) 1.15 ± 0.24 1.16 ± 0.24 < 0.01
BUA (dB/mHz) 72.9 ± 16.3 72.5 ± 17.2 < 0.01
SOS (m/s) 1541.2 ± 29.4 1544.7 ± 32.8 0.47
Data are presented as mean ± SD. Abbreviations: FN-BMD: femoral-neck bone mineral den-
sity; LS-BMD: lumbal-spine bone mineral density; BUA: bone ultrasound attenuation; SOS: 
speed of sound. 
64 65
 C
h
ap
te
r 
3
.2
 |
 A
rt
er
ia
l s
tif
fn
es
s 
is
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 b
on
e 
m
ea
su
re
s
Ta
b
le
 3
. 
C
ro
ss
-s
ec
tio
na
l l
in
ea
r 
re
gr
es
si
on
 a
na
ly
si
s 
be
tw
ee
n 
bo
ne
 a
nd
 v
as
cu
la
r 
pa
ra
m
et
er
s 
at
 b
as
el
in
e
N
um
be
r 
of
 s
us
ta
in
ed
 f
ra
ct
ur
es
 in
 h
is
to
ry
M
od
el
 1
M
od
el
 2
PW
V
 (
m
/s
)
0.
00
7 
[-
0.
01
8;
 0
.0
32
0.
00
6 
[-
0.
01
9;
 0
.0
31
]
A
Ix
 (
%
)
0.
00
3 
[-
0.
00
7;
 0
.0
13
]
0.
00
2
[-
0.
00
8;
 0
.0
12
]
A
or
tic
 P
P 
(m
m
H
g)
-0
.0
03
 
[-
0.
00
9;
 0
.0
04
]
-0
.0
04
 
[-
0.
01
2;
 0
.0
04
]
FN
-B
M
D
 (
g/
cm
2 )
LS
-B
M
D
 (
g/
cm
2 )
M
od
el
 1
M
od
el
 2
M
od
el
 1
M
od
el
 2
PW
V
 (
m
/s
)
4.
63
·1
0-
4  
[-
0.
00
3 
; 
0.
00
2]
 
-0
.0
01
 
[-
0.
00
3 
; 
0.
00
2]
0.
00
2
[-
0.
00
3 
; 
0.
00
6]
0.
00
2
[-
0.
00
1 
; 
0.
00
6]
A
Ix
 (
%
)
-0
.0
01
[-
0.
00
2 
; 
2.
70
·1
0-
4  
]
-0
.0
01
[-
0.
00
2 
; 
1.
62
10
-4
 ]
-0
.0
01
[-
0.
00
3 
; 
3.
84
·1
0-
4 ]
-0
.0
02
[-
0.
00
3 
; 
1.
97
·1
0-
4 ]
A
or
tic
 P
P 
(m
m
H
g)
-1
.3
1·
10
-4
 
[-
0.
00
1 
; 
0.
00
1]
-4
.1
4·
10
-4
 
[-
0.
00
1 
; 
4.
35
·1
0-
4  
]
-1
.9
2·
10
-4
 
[-
0.
00
1 
; 
0.
00
1 
]
-4
.6
4·
10
-4
 
[-
0.
00
2 
; 
0.
00
1 
]
B
U
A
 (
dB
/m
H
z)
S
O
S
 (
m
/s
)
M
od
el
 1
M
od
el
 2
M
od
el
 1
M
od
el
 2
PW
V
 (
m
/s
)
-0
.0
78
[-
0.
45
8 
; 
-0
.3
02
]
-0
.0
21
[-
0.
40
9 
; 
0.
36
7]
-0
.3
06
[-
0.
99
0 
; 
0.
37
8]
-0
.2
38
 
[-
0.
93
1 
; 
0.
45
5]
A
Ix
 (
%
)
0.
03
0
[-
0.
15
1 
; 
0.
21
1]
0.
04
4 
[-
0.
13
8 
; 
0.
22
6]
0.
14
2
[-
0.
19
9 
; 
0.
48
3]
0.
16
7
[-
0.
17
5 
; 
0.
50
9]
A
or
tic
 P
P 
(m
m
H
g)
-0
.0
26
 
[-
0.
07
6 
; 
0.
12
8]
0.
00
1 
[-
0.
12
3 
; 
0.
12
6]
0.
07
5 
[-
0.
11
7 
; 
0.
26
8]
0.
04
3 
[-
0.
19
1 
; 
0.
27
8]
D
at
a 
ar
e 
pr
es
en
te
d 
as
 b
et
a’
s 
±
 9
5
%
 C
I.
 M
od
el
 1
: 
ad
ju
st
ed
 f
or
 a
ge
, 
ge
nd
er
 a
nd
 s
tu
dy
 c
en
te
r.
 M
od
el
 2
: 
ad
ju
st
ed
 f
or
 a
ge
, 
ge
nd
er
, 
st
ud
y 
ce
nt
er
, 
tr
ea
t-
m
en
t,
 s
m
ok
in
g 
st
at
us
, 
al
co
ho
l u
se
, 
eG
FR
, 
B
M
I,
 d
ia
be
te
s,
 c
ho
le
st
er
ol
 a
nd
 h
yp
er
te
ns
io
n.
 A
bb
re
vi
at
io
ns
 a
s 
in
 T
ab
le
 1
 a
nd
 2
.
66
Ta
b
le
 4
. 
Lo
ng
itu
di
na
l l
in
ea
r 
re
gr
es
si
on
 a
na
ly
si
s 
w
ith
 b
on
e 
m
ea
su
re
s 
af
te
r 
2 
yr
s 
as
 o
ut
co
m
e 
an
d 
va
sc
ul
ar
 p
ar
am
et
er
s 
at
 b
as
el
in
e 
as
 in
de
-
pe
nd
en
t
FN
-B
M
D
 (
g/
cm
2 )
LS
-B
M
D
 (
g/
cm
2 )
M
od
el
 1
M
od
el
 2
M
od
el
 1
M
od
el
 2
PW
V
 (
m
/s
)
1.
86
·1
0-
5  
[-
0.
00
1 
; 
0.
00
1]
 
-3
.1
4·
10
-5
 
[-
0.
00
1 
; 
0.
00
1]
3.
72
·1
0-
4  
[-
0.
00
1 
; 
0.
00
1]
4.
64
·1
0-
4  
[-
0.
00
1 
; 
0.
00
2]
A
Ix
 (
%
)
5.
31
·1
0-
5  
[-
2.
16
·1
0-
4  
; 
3.
22
·1
0-
4  
]
8.
32
·1
0-
5  
[-
1.
90
·1
0-
4  
; 
3.
56
·1
0-
4  
]
1.
45
·1
0-
4
[-
2.
62
·1
0-
4  
; 
0.
00
1]
2.
58
·1
0-
4  
[-
1.
54
·1
0-
4  
; 
0.
00
1]
A
or
tic
 P
P 
(m
m
H
g)
8.
99
·1
0-
5  
[-
2.
63
·1
0-
4  
; 
0.
83
·1
0-
4  
]
-1
.0
6·
10
-4
 
[-
3.
12
·1
0-
4  
; 
1.
00
·1
0-
4  
]
-1
.7
0·
10
-4
 
[-
4.
33
·1
0-
4  
; 
0.
93
·1
0-
4  
]
-2
.3
2·
10
-4
 
[-
0.
00
1 
; 
0.
79
·1
0-
4  
]
B
U
A
 (
dB
/m
H
z)
S
O
S
 (
m
/s
)
M
od
el
 1
M
od
el
 2
M
od
el
 1
M
od
el
 2
PW
V
 (
m
/s
)
-0
.2
39
 
[-
0.
46
4 
; 
-0
.0
15
]*
-0
.2
13
 
[-
0.
44
3 
; 
0.
01
7]
-0
.1
62
 
[-
0.
63
3 
; 
0.
30
9]
-0
.2
22
 
[-
0.
70
4 
; 
0.
26
1]
A
Ix
 (
%
)
0.
00
4 
[-
0.
09
8 
; 
0.
10
6]
0.
00
1 
[-
0.
10
3 
; 
0.
10
5]
-0
.0
61
 
[-
0.
28
2 
; 
0.
16
0]
-0
.0
60
 
[-
0.
28
7 
; 
0.
16
6]
A
or
tic
 P
P 
(m
m
H
g)
-0
.0
14
 
[-
0.
07
2 
; 
0.
04
4]
-0
.0
04
 
[-
0.
07
5 
; 
0.
06
6]
0.
00
9 
[-
0.
11
7 
; 
0.
13
4]
0.
02
7 
[-
0.
12
6 
; 
0.
18
0]
D
at
a 
ar
e 
pr
es
en
te
d 
as
 b
et
a’
s 
±
 9
5
%
 C
I.
 M
od
el
 1
: 
ad
ju
st
ed
 f
or
 b
as
el
in
e 
m
ea
su
re
, 
ag
e,
 g
en
de
r,
 s
tu
dy
 c
en
te
r 
an
d 
tr
ea
tm
en
t.
 M
od
el
 2
: 
ad
ju
st
ed
 f
or
 
ba
se
lin
e 
m
ea
su
re
 o
f 
B
M
D
/Q
U
S,
 a
ge
, 
ge
nd
er
, 
st
ud
y 
ce
nt
er
, 
tr
ea
tm
en
t,
 s
m
ok
in
g 
st
at
us
, 
al
co
ho
l u
se
, 
eG
FR
, 
B
M
I,
 d
ia
be
te
s,
 c
ho
le
st
er
ol
 a
nd
 h
yp
er
te
n-
si
on
. 
A
bb
re
vi
at
io
ns
: 
as
 in
 T
ab
le
 1
 a
nd
 2
.
67
 C
h
ap
te
r 
3
.2
 |
 A
rt
er
ia
l s
tif
fn
es
s 
is
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 b
on
e 
m
ea
su
re
s
other bone parameters (data not shown). Stratified analysis for homocysteine 
level <18 μmol/L and ≥18 μmol/L did also not demonstrate any significant 
association of the vascular parameters in the strata (data not shown). For 
the incident fractures during follow-up, we did not see any interactions with 
the homocysteine change. 
3.2.5 dIsCussIon
Our study showed that in an elderly population with hyperhomocysteinemia, 
arterial stiffness is not associated with prevalent or incident fractures, BMD 
or quantitative ultrasound bone measures (QUS), neither cross-sectionally 
nor longitudinally. Although homocysteine level was significantly interacting 
in the association between aortic PP and FN-BMD and fracture history, strati-
fied analysis based on homocysteine level did not confirm this interaction ef-
fect. Furthermore, adjustment for homocysteine did not change the results. 
Therefore it is unlikely that homocysteine is a pleiotropic factor or mediator 
in the relation between bone and vasculature. 
To our knowledge, this is the first study investigating the possible associa-
tion of measures of arterial stiffness markers in relation to bone parameters 
in hyperhomocysteinemic elderly. Contradictory to our study, most of the 
cross-sectional studies in literature used small sample sizes, often middle-
aged women were included and most studies used calcaneus ultrasound for 
their BMD-measures instead of measuring the golden standard BMD with 
dual X-ray absorptiometry [31-38]. Furthermore, data regarding a hyperho-
mocysteinemic population are lacking and a major strength is that we used 
fractures, bone density and bone quality as outcome variables, thus a broad 
perspective regarding the association between the vasculature and bone. 
Other cross-sectional studies, which did show associations between bone 
and arterial stiffness, often demonstrated only weak associations of which 
the clinical relevance can be discussed [31-38]. The lack of an association 
between arterial stiffness and osteoporosis parameters both cross-section-
ally and longitudinally in our study endorses recent studies regarding BMD 
and cardiovascular mortality, which also observed no association [11, 12]. 
Arterial stiffness is presumably not the underlying pathway, in the potential 
association between bone and cardiovascular disease, because we observed 
no relation between arterial stiffness and several bone parameters. Because 
arterial stiffness is an important pre-clinical phase of cardiovascular disease 
68
and we did also not observed a longitudinal association, we might conclude 
that a (causal) association between bone and cardiovascular disease is not 
likely.
The major aim of this study was to investigate whether homocysteine levels 
underlie or influence the assumed associations between bone and vascula-
ture. Hyperhomocysteinemia has been hypothesized to form an underlying 
condition, because as mentioned above it is associated with both osteoporosis 
and with cardiovascular disease via dysregulation of the RANK-ligand/RANK 
axis and via inflammation [17-19]. Increased homocysteine levels have 
been shown to down-regulate bone collagen-crosslinking and methylation 
[16] and it causes increased thrombogenecity, increased oxidative stress, 
impaired endothelial function, platelet aggregation and finally atherothrom-
bosis [39-42]. Nevertheless, in our study, homocysteine did only modify the 
association between FN-BMD with aortic PP, but no interaction was seen with 
other outcome variables. Because this modification was only found in one 
parameter, it may well be a chance finding. Especially since stratification 
based on homocysteine level did not change the results. Although this also 
can imply the cut-off value of 18 µmol/l was not high enough to demonstrate 
an association in persons with high homocysteine levels, it does show that 
this potential pathway is not relevant for the majority of the population. 
Homocysteine adjustment did also not change the results, making it unlikely 
to be a potential pleiotropic factor. Therefore we can conclude that homocys-
teine is neither an mediator or pleiotropic factor in the association between 
arterial stiffness and bone parameters. 
There are some limitations to our study. First, our study population consisted 
of hyperhomocysteinemic elderly only. Nevertheless, as explained above, 
this type of population is of particular interest in order to explore the role of 
homocysteine explaining the association between bone and vasculature and 
may therefore also be interpreted as a strength. Our results might therefore 
not be applicable for the general older population. However, hyperhomo-
cysteinemia is very common among elderly, with a prevalence of 25-50% 
in European countries [43], thus a large part of the older population was 
included. Third, due to the trial design, all participants received low dose 
vitamin D during the study and were allocated in a B-vitamin treatment 
group or placebo [24]. Although the B-vitamin treatment did not influence 
the arterial stiffness and bone parameters [29, 30], a potential attenuating 
effect of vitamin D supplementation on the longitudinal analysis cannot be 
69
 C
h
ap
te
r 
3
.2
 |
 A
rt
er
ia
l s
tif
fn
es
s 
is
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 b
on
e 
m
ea
su
re
s
excluded. An effect of vitamin D therapy on bone health has been studied 
extensively [44] and could therefore have masked the influence of arterial 
stiffness on the investigated bone parameters. 
In conclusion, contrary to our expectations, arterial stiffness was not as-
sociated with bone measures in an older, hyperhomocysteinemic popula-
tion. In the potential association between bone and cardiovascular status, 
homocysteine is probably not a common factor and may either be dependent 
on other mechanisms or may not be causal. More research is warranted in 
order to elucidate the exact mechanisms that explain relationships between 
the vasculature and bone. 
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3.3.1 AbstrACt
Background 
Several studies have been pointing towards a non-linear relationship between 
serum 25(OH)D and cardiovascular disease. Next to vitamin D deficiency, 
also higher levels of 25(OH)D have been reported to be associated with 
increased cardiovascular risk. We aimed to investigate the nature of the 
relationship between serum 25(OH)D and measures of arterial stiffness and 
arteriosclerosis in an elderly population.
Design: cross-sectional.
Setting/subjects: a subgroup of the B-PROOF study was included to 
determine associations between serum 25(OH)D and arterial stiffness and 
atherosclerosis (n = 567, 57% male, age 72.6 ± 5.6 years, mean serum 
25(OH)D 54.6 ± 24.1 nmol/l).
Methods
Carotid intima media thickness (IMT) was assessed using ultrasonography 
and pulse wave velocity (PWV) was determined with applanation tonometry. 
Associations were tested using multivariable restricted cubic spline functions 
and stratified linear regression analysis.
Results
The associations between serum 25(OH)D and carotid IMT or PWV were 
non-linear. Spline functions demonstrated a difference between 25(OH)D 
deficient and sufficient individuals. In serum 25(OH)D sufficient participants 
(≥50 nmol/l; n = 287), a positive association with IMT and serum 25(OH)D 
was present (β 1.24; 95%CI [0.002; 2.473]). PWV levels were slightly lower 
in vitamin D deficient individuals, but the association with 25(OH)D was not 
significant.
Conclusion 
Our study demonstrates that associations of serum 25(OH)D and PWV and 
IMT in an elderly population are not linear. In particular from serum 25(OH)
D levels of 50 nmol/l and up, there is a slight increase of IMT with increasing 
25(OH)D levels.
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3.3.2 IntroduCtIon
Cardiovascular disease is more common among individuals with low se-
rum 25(OH)D levels compared with 25(OH)D sufficient individuals [1–6]. 
However, not only vitamin D deficiency has reported to be associated with 
increased cardiovascular risk but high serum 25(OH)D levels have been as 
well. Taken these findings together, evidence of the recent years has been 
pointing towards a non-linear association between serum 25(OH)D level 
and cardiovascular disease [7]. High serum 25(OH)D levels could affect the 
vascular wall, either indirectly or via a direct effect of serum 25(OH)D. These 
processes may also have a role in the arterial stiffening process [8, 9].
Up till now, only inverse linear associations between serum 25(OH)D level and 
arterial stiffness have been reported. Earlier studies have been performed 
in younger subjects and disease-specific populations, like diabetics [8–12].
Very recently, the Baltimore Longitudinal Study of Ageing confirmed such an 
inverse linear association in an older population [13]. An inverse association 
between serum 25(OH)D and arteriosclerosis has only been described in 
serum 25(OH)D deficient individuals [14–16]. Because both arterial stiff-
ness and atherosclerosis are important pre-clinical stages of cardiovascular 
disease, we aimed to investigate the nature of the relationship (e.g. linear, 
monotone or other) between serum 25(OH)D levels and indices of arterial 
stiffness and arteriosclerosis in older individuals.
3.3.3 Methods
Study participants
The present study was conducted as a cross-sectional baseline analysis within 
the framework of the vascular subgroup of the B-PROOF (B vitamins for the 
prevention of osteoporotic fractures) study (n = 567). A detailed description 
of this randomized controlled trial has been reported elsewhere [17].
In short, B-PROOF is a multi-centre, randomised, placebo controlled, 
double-blinded trial including 2919 participants from three areas in the Neth-
erlands. Main inclusion criteria were age 65 years and older, and an elevated 
homocysteine level (12–50 μmol/l). Main exclusion criteria were renal insuf-
ficiency (creatinine level > 150 μmol/l) and presence of a malignancy. All 
participants gave written informed consent before the start of the study. 
The Wageningen Medical Ethics Committee approved the study protocol, and 
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the Medical Ethics committees of Rotterdam and Amsterdam gave approval 
for local feasibility. At the Erasmus Medical Center (Rotterdam) and VU Uni-
versity Medical Center (Amsterdam), a random subsample of participants 
underwent vascular measurements (n = 567).
Clinical characteristics
Height was measured in duplicate to the nearest 0.1 cm while standing erect 
and wearing no shoes, using a stadiometer [17]. Weight was measured with 
the participant wearing light garments without shoes and empty pockets to 
the nearest 0.5 kg using a calibrated weighing device (SECA 761) [17].
Body mass index (BMI) was calculated as weight divided by squared height 
and expressed as kg/m2.
Self-reported medication use, alcohol intake and smoking habits were de-
termined using a questionnaire [17]. Alcohol intake was assessed using the 
Garret structure classifying alcohol use into four categories (very excessive, 
excessive, moderate and light) [18]. Questions regarding cardiovascular 
disease history, like angina pectoris, myocardial infarction, transient isch-
aemic attack and/or stroke were also included in this questionnaire [17]. 
Furthermore, cardiovascular risk factors such as hypertension, hypercholes-
terolemia and diabetes mellitus were assessed with this questionnaire [17].
Serum 25(OH) vitamin D
Morning venous blood samples were obtained when participants were in a 
fasted state, or after a restricted breakfast [17]. Samples were stored at 
−80°C until determination in 2012. In short, measurement of serum 25(OH)
D occurred by releasing it from its binding protein(s) and by adding a de-
naturized internal standard IS: 25(OH)D3-d6. Samples were extracted and 
analysed by XLC–MS/MS (a Symbiosis online SPE system (Spark Holland, 
Emmen, the Netherlands) coupled to a Quattro Premier XE tandem mass 
spectrometer (Waters Corp., Milford, MA, USA). The inter-assay coefficient 
of variation was 9% at a level of 10 ng/mL (=24.9 nmol/l) and 6% at a level 
of 25 ng/mL (=62.4 nmol/l). All analyses were performed in the Endocrine 
Laboratory of the VU University Medical Center. Vitamin D deficiency was 
defined as a serum 25(OH)D level < 50 nmol/L according to literature since 
25 (OH)D levels <50 nmol/l have reported to be related to several clinical 
disorders such as osteoporosis [19].
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Serum creatinine
Serum creatinine was measured with the enzymatic colorimetric Roche CREA 
plus assay (CV = 2%). The estimated glomerular filtration rate (eGFR) was 
estimated with the Modification of Diet in Renal Disease (MDRD) and was 
calculated in ml/min/1.73 m2 with the formula: 186 × (serum creatinine 
(μmol/l)/88.4)–1.154 × age (years)–0.203 × 0.742 (for females) [20].
Vascular measurements
Only a random subsample of the B-PROOF study underwent vascular mea-
surements (n = 567). Participants with cardiac rhythmic disturbances were 
excluded from these additional measurements. During the measurements, 
participants were situated in supine position on a flat examination couch in a 
quiet laboratory room for at least 5–10 min prior to the measurements. They 
were not allowed to speak during the measurements. Use of alcohol or coffee 
during 12 h before the measurements was prohibited [21].
Blood pressure measurement
Peripheral blood pressure at the time of vascular function tests was measured 
once with a semi-automatic oscillometric device (Datascope Accurator Plus 
device, Datascope Corp., NJ, USA) after at least 5 min of supine rest. Blood 
pressure measurements were conducted at the right arm and measured in 
mmHg. The mean arterial pressure (MAP) was measured and pulse pressure 
was calculated as systolic minus diastolic blood pressure.
Applanation tonometry
Arterial tonometry was obtained from the right carotid and right femoral ar-
tery using the Sphygmocor device (Sphygmocor version 7.1, AtCor Medical, 
Sydney, Australia). Aortic pulse wave velocity (aPWV) was measured with 
a three-channel ECG recording and simultaneously recording of the right 
carotid artery pulse wave form and subsequently the femoral artery pulse 
waveform. The aPWV was calculated as the delay between the femoral pulse 
wave and the carotid pulse wave, divided by the transit distance (intra-CV 
= 5%, inter-CV = 8%). Transit distance was assessed with body surface 
measurement from the carotid artery to the femoral artery [21].
Increased arterial stiffness was defined as a PWV>12 m/s, as this level is 
associated with increased cardiovascular risk [22].
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Carotid intima media thickness
For carotid B-mode ultrasonography, the L105 40 mm 7.5 MHz array trans-
ducer was used (Picus, Pie Medical Equipment, Maastricht, the Netherlands) 
on the right carotid artery. Intima media thickness (IMT) is evaluated as the 
distance luminal − intimal interference and the media − adventitial interface 
(Art.Lab, Esoate Europe, Maastricht, the Netherlands) at ~1 cm proximal 
from the carotid bifurcation. In order to obtain accurate measurements, the 
standard deviation of the mean values of six independent measurements had 
to be <10% of the mean (intra-CV = 8%, inter-CV = 15%).
Statistical analysis
We have included all participants who had data available regarding serum 
25(OH)D and carotid IMT and PWV measures in order to do a complete case 
analysis. For missing covariates, the statistical program automatically uses 
the mean for missing cases.
First, normal distribution was tested in all continuous variables and sub-
sequently curve estimation models were created in order to investigate 
whether the associations between serum 25(OH)D levels and arterial stiff-
ness parameters and carotid IMT were linear. Curve estimation models were 
tested by analysis of variance of the linear and non-linear component of 
the association between serum 25(OH)D and variables of interest. Statistics 
were performed using the statistical package SPSS 20.0 (SPSS Inc., Chicago, 
IL, USA). In case the associations were not linear, cubic spline analysis was 
performed to investigate non-linear associations between serum 25(OH)D 
and arterial stiffness measures and carotid IMT using R version 3.0.0. Spline 
regression models are piecewise polynomial functions that join smoothly at 
points called knots. In contrast to categorical models that assume a constant 
association within categories, in spline models all data points are used, 
providing a better estimate of dose–effect relationships [23]. Spline models 
were visually tested with three to five knots. In the final analyses, we used 
three knots based on the size of our study sample and because this gave 
the best fit, measured with the likelihood ratio. We adjusted for covariates 
that were considered clinically relevant or gave a considerable change of the 
likelihood ratio.
After this, we performed a multivariable linear regression analysis using 
SPSS 20.0, stratified for serum 25(OH)D levels based on the depicted spline 
plots. We accounted for confounders that were considered clinically relevant 
or contributed to a >10% change of the point estimate. Potential confound-
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ers were age, gender, study centre, BMI, eGFR, MAP, heart rate, smoking, 
alcohol use, CRP and physical performance.
Smoking was added to the model as a binary variable: yes or no and this 
was also done for alcohol use: yes (moderate—very excessive) and no use 
(light). Furthermore, we tested whether age, gender, cardiovascular disease 
history, diabetes, hypercholesterolemia and use of calcium and/or vitamin 
D supplementation use significantly interacted with the association between 
serum 25(OH)D and pre-clinical measures of cardiovascular disease. If a 
variable interacted, stratified analysis was performed. Concerning all analy-
ses, two-sided P-values of <0.05 were considered statistically significant.
3.3.4 results
Characteristics of the study population (n = 567) are shown in Table 1. 
Mean age was 72.5 ± 5.6 years and gender was equally distributed. The 
mean serum 25(OH)D level in our population was 54.6 ± 24.1 nmol/l and 
50.3% of the participants were vitamin D deficient (<50 nmol/l).
Curve estimation modelling showed that the relationship between carotid 
IMT and serum 25(OH)D was not linear, and that a cubic model had the best 
fit (Table 2). The association between serum 25(OH)D and PWV was also 
not linear, but rather quadratic or cubic because of the explained variability, 
although neither of the models fitted the data well (Table 2).
In Figure 3.3.1, the spline curves created for each variable are depicted. 
As demonstrated, high levels of serum 25(OH)D were associated with higher 
measures of carotid IMT. Furthermore, both low and high levels of serum 
25(OH)D were associated with lower levels of PWV. Since the association be-
tween serum 25(OH)D and carotid IMT visually appeared to be linear above 
a level of serum 25(OH)D of 50 nmol/l, we performed a stratified linear 
regression analysis for vitamin D deficient versus vitamin D sufficient par-
ticipants. This analysis showed a positive association between serum 25(OH)
D and carotid IMT (β 1.24; 95% CI: [0.002; 2.473]) in participants with 
serum 25(OH)D levels ≥ 50 nmol/l. In vitamin D sufficient older persons, 
an increase of 1 nmol/L of serum 25(OH)D corresponded to an increase of 
1.24 μm carotid IMT (Table 3). Age was a significant effect modifier in this 
association (p = 0.01), showing that the association was only present in 
participants under the age of 80 (β 1.51 95% CI: [0.25; 2.77]) (data not 
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Table 1. Clinical and hemodynamic characteristics total population (n = 567)
Variable Mean ± SD
Age (years)
 80+
72.5 ± 5.6
61 (10.8%)
Gender (n, %)
 Males 315 (55.6%)
BMI (kg/m2) 27.3 ± 3.7
Smoking behavior (n, %)
 Never
 Former
 Current
198 (34,9%)
53 (9,3%)
316 (55,7%)
Alcohol use (n, %)
 Light
 Moderate
 Excessive
 Very excessive
358 (63,1%)
179 (31,6%)
25 (4,4%)
5 (0,9%)
Self-reported medical history of
 Cardiac disease
 TIA or stroke
 Diabetes
 Hypertension
 Hypercholesterolemia 
61 (10.8%)
45 (7.9%)
65 (11.5%)
211 (38.1%)
151 (26.6%)
Self-reported use of
 Vitamin D supplementation
 Calcium supplementation
 Calcium + vitamin D supplementation
 Mean dosage of used vitamin D (IE)
9 (1.6%)
20 (3.5%)
18 (3.2%)
39.1 ± 144.8
Serum vitamin D level (nmol/l)
 Vitamin D deficiency (< 50 nmol/l)
54.6 ± 24.1
274 (48.3%)
Serum creatinine level (μmol/l) 83.2 ± 17.2
eGFR (ml/min per 1.73m2) 91.3 ± 35.9
Blood pressure 
 SBP (mmHg)
 DBP (mmHg)
 Hypertension during measurement*
137.7 ± 18.1
77.3 ± 9.6
339 (59.8 %)
PWV (m/s)
 PWV > 12 m/s
14.3 ± 4.5
313 (55.2%)
Carotid IMT (μm) 717.0 ± 163.2
Data are presented as number and percentage or as mean ± SD.
Abbreviations: eGFR: estimated glomerular filtration rate; BMI: body mass index; SBP: sys-
tolic blood pressure; DBP: diastolic blood pressure; PP: Pulse Pressure; PWV: aortic pulse 
wave velocity; IMT: intima media thickness.
*Hypertension defined as SBP > 140 and/or DBP > 90 mmHg.
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Table 2. Curve estimation models for both carotid IMT and PWV
R2 p-value
Carotid IMT
Linear 0.001 0.65
Logarithmic 0.46·10-4 0.89
Quadratic 0.028 0.004
Cubic 0.045 0.40·10-3
PWV
Linear 0.23·10-3 0.73
Logarithmic 0.66·10-4 0.85
Quadratic 0.003 0.41
Cubic 0.009 0.20
equally distributed. The mean serum 25(OH)D level in our
population was 54.6 ± 24.1 nmol/l and 50.3% of the partici-
pants were vitamin D deficient (<50 nmol/l).
Curve estimation modelling showed that the relationship
between carotid IMT and serum 25(OH)D was not linear,
and that a cubic model had the best fit (Supplementary data
are available in Age and Ageing online, Table S3). The associ-
ation between serum 25(OH)D and PWV was also not
linear, but rather quadratic or cubic because of the explained
variability, although neither of the models fitted the data well
(Supplementary data are available in Age and Ageing online,
Table S3).
In Figure 1, the spline curves created for each variable are
depicted. As demonstrated, high levels of serum 25(OH)D
were associated with higher measures of carotid IMT.
Furthermore, both low and high levels of serum 25(OH)D
were associated with lower levels of PWV.
Since the association between serum 25(OH)D and
carotid IMT visually appeared to be linear above a level of
serum 25(OH)D of 50 nmol/l, we performed a stratified
linear regression analysis for vitamin D deficient versus
vitamin D sufficient participants. This analysis showed a
positive association between serum 25(OH)D and carotid
IMT (β 1.24; 95% CI: [0.002; 2.473]) in participants with
serum 25(OH)D levels ≥ 50 nmol/l. In vitamin D sufficient
older persons, an increase of 1 nmol/L of serum 25(OH)D
corresponded to an increase of 1.24 µm carotid IMT
(Table 2).
Table 1. Clinical and hemodynamic characteristics total
population (n = 567)
Age (years) 72.5 ± 5.6
80+ 61 (10.8%)
Gender
Males 315 (55.6%)
BMI (kg/m2) 27.3 ± 3.7
Smoking
Never 198 (34.9%)
Current 53 (9.3%)
Former 316 (55.7%)
Alcohol use
Light 358 (63.1%)
Moderate 179 (31.6%)
Excessive 25 (4.4%)
Very excessive 5 (0.9%)
Self-reported medical history of
Cardiac disease 61 (10.8%)
TIA or stroke 45 (7.9%)
Diabetes 65 (11.5%)
Hypertension 211 (38.1%)
Hypercholesterolemia 151 (26.6%)
Self-reported use of
Vitamin D supplementation 9 (1.6%)
Calcium supplementation 20 (3.5%)
Calcium + vitamin D supplementation 18 (3.2%)
Mean dosage of used vitamin D (IE) 39.1 ± 144.8
Serum vitamin D level (nmol/l) 54.6 ± 24.1
Vitamin D deficiency (<50 nmol/l) 274 (48.3%)
Serum creatinine level (µmol/l) 83.2 ± 17.2
eGFR (ml/min/1.73 m2) 91.3 ± 35.9
Blood pressure
SBP (mmHg) 137.7 ± 18.1
DBP (mmHg) 77.3 ± 9.6
Hypertension during measurementa 339 (59.8%)
PWV (m/s) 14.3 ± 4.5
PWV> 12 m/s 313 (55.2%)
Carotid IMT (µm) 717.0 ± 163.2
Data are presented as number and percentage or as mean ± SD.
eGFR, estimated glomerular filtration rate; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; PWV, aortic
pulse wave velocity; IMT, intima media thickness.
aHypertension defined as SBP >140 and/or DBP >90 mmHg.
Figure 1. Spline plots of serum 25(OH)D level with carotid
IMT and PWV. (A) Carotid IMT. (B) PWV. Carotid IMT data
were adjusted for age, gender and eGFR. PWV data were
adjusted for age, gender, study centre, eGFR, MAP and heart
rate. Abbreviations: as in Table 1.
Table 2. Linear regression analysis of the associations
between serum 25(OH)D level and IMT and aPWV
stratified per vitamin D category
Serum 25(OH)D< 50 nmol/l, (n = 274)
Carotid IMT −0.79 [−3.217; 1.644]
PWV 0.04 [−0.020; 0.090]
Serum 25(OH)D≥ 50 nmol/l, (n = 287)
Carotid IMT 1.24 [0.002; 2.473]*
PWV −0.31 × 10−3 [−0.030; 0.029]
Values are presented as β ± 95% CI and according to carotid IMT adjusted for
age, gender and eGFR. Adjustments made for the analysis with aPWV were age,
gender, study centre, eGFR, MAP and heart rate. *P < 0.05. Abbreviations: as in
Table 1.
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Figuur 3.3.1.
A. Carotid IMT. B. PWV. Carotid IMT data were adjusted for age, gender and eGFR. PWV data 
were adjusted for age, gender, study center, eGFR, MAP and heart rate. Abbreviations: as in 
table 1.
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shown). In vitamin D insufficient participants, calcium use was a significant 
effect modifier (P = 0.02); however, stratified analysis did not demonstrate 
any differences between users and non-users. Gender, cardiovascular dis-
ease history, diabetes and hypercholesterolemia did not interact with the 
association between serum 25(OH)D and carotid IMT.
Furthermore, the direction of the association between serum 25(OH)D and 
PWV also changed at the level of 50 nmol/l, showing an inverse association 
between PWV levels and 25(OH)D below the concentration of serum 25(OH)
D level of 50 nmol/l. In order to further investigate this association, we per-
formed a stratified linear regression analysis for vitamin D deficient versus 
vitamin D sufficient individuals; however, we found no significant associations 
between serum 25(OH)D level and PWV for the separate groups (Table 2). 
Age, gender, cardiovascular disease history, diabetes, hypercholesterolemia 
or calcium use was not interacting within the association between serum 
25(OH)D and PWV.
3.3.5 dIsCussIon
Our study shows that the association between serum 25 (OH)D and pre-
clinical stages of cardiovascular disease in elderly subjects is non-linear. In 
particular, we have shown that high levels of serum 25(OH)D, starting from 
serum 25(OH)D levels of ≥50 nmol/l, were associated with higher values of 
carotid IMT in vitamin D sufficient individuals. Also, the association between 
serum 25(OH)D and PWV was non-linear, potentially monotone; however, 
Table 3. Linear regression analysis of the associations between serum 25(OH)D level 
and IMT and PWV stratified per vitamin D category
Serum 25(OH)D < 50 nmol/l n = 274
Carotid IMT -0.79 [-3.217 ; 1.644]
PWV 0.04 [-0.020 ; 0.090]
Serum 25(OH)D ≥ 50 nmol/l n = 287
Carotid IMT 1.24 [0.002 ; 2.473]*
PWV -0.31·10-3 [-0.030 ; 0.029]
Values are presented as beta ± 95% CI and according to carotid IMT adjusted for age, gender 
and eGFR. Adjustments made for the analysis with PWV were age, gender, study center, eGFR, 
MAP and heart rate. * = p<0.05. Abbreviations: as in Table 1.
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in contrast with the effect on IMT the effect size for PWV was small and not 
within clinically relevant ranges.
In contrast to other studies, we did not find linear associations between 
serum 25(OH)D and indices of arterial stiffness or arteriosclerosis [10, 12, 
13]. Our study supports the abovementioned non-linear association with 
cardiovascular morbidity and mortality [7] because in particular for vitamin 
D sufficient individuals (serum 25(OH)D ≥ 50 nmol/l) an increase in carotid 
IMT per point increase of serum 25(OH)D level was present. Although this 
association was clear, one may argue about the clinical relevance because 
the carotid IMT only increased 1.24 μm per 1 nmol/l of serum 25(OH)D. 
Nevertheless, our finding gives an insight into potential mechanisms in which 
serum 25(OH)D might lead to increased cardiovascular risk.
Although it has been reported that vitamin D deficiency is associated with 
cardiovascular disease and with higher IMT levels [1–3, 14–16, 24], we were 
not able to confirm the latter in our study. The spline plot of carotid IMT 
did however show a significant positive association between serum 25(OH)
D levels with carotid IMT in high-normal ranges of serum 25(OH)D. Several 
mechanisms may explain why high serum 25(OH)D levels are associated 
with an elevated carotid IMT. First, an increase of vitamin D levels will lead 
to an increased calcium absorption in the gastrointestinal tract, which in turn 
may result in higher circulating calcium concentrations. These higher calcium 
levels could contribute to vascular calcification, in particular in atheroscle-
rotic plaques in the vessel wall. This may be further aggravated because 
high levels of vitamin D are known to up-regulate vitamin D receptors in 
vascular smooth muscle cells, reducing the activity of matrix metalloprotein-
ases, which also contributes to calcium deposition in the vessel wall [25]. 
Furthermore, extrarenal activated macrophages express 1,α-hydroxylase, 
converting 25(OH)D into the hormonally active 1.25(OH)D form and activate 
pro-calcification in the vessel wall, which also contributes to arterial stiffness 
[8, 9].
In comparison with the recently published Baltimore study [13], we were 
not able to confirm a linear association between serum 25(OH)D and PWV. 
Visually, the association between 25(OH)D and PWV even appeared to be 
opposed compared with the association of carotid IMT with serum 25(OH)
D. However, the differences in PWV levels between vitamin D sufficient and 
insufficient were very small and not likely to be clinically relevant. The small 
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difference in PWV levels may also explain why the serum 25(OH)D stratified 
analysis with continuous PWV measures did not demonstrate a significant as-
sociation with serum 25(OH)D. Therefore, we may conclude that an associa-
tion between serum 25(OH)D and PWV level is absent in our study, indicating 
that serum 25(OH)D within relatively large ranges does not directly affect 
the arterial stiffening process.
Calcium supplement use was significantly interacting in the association be-
tween serum 25(OH)D and carotid IMT in vitamin D deficient individuals. 
A meta-analysis demonstrated that calcium usage is potentially unsafe in 
terms of higher cardiovascular risk [26]; however, in our study we could not 
confirm calcium use being harmful for arteriosclerotic processes. The lack 
of interaction in vitamin D sufficient individuals potentially has to do with 
the lower number of calcium users within the vitamin D sufficient group 
compared with the group with low levels of serum 25(OH)D.
Our study has several limitations. First, this study has a cross-sectional 
design. Therefore, causality cannot be ascertained. In order to investigate 
the causal pathway of the association between serum 25(OH)D and indices 
of arterial stiffness and arteriosclerosis in older individuals, a prospective, 
preferably randomised controlled trial, comparing vitamin D supplementa-
tion with placebo, within this age group is needed. A second limitation is that 
our findings cannot be easily translated to the general population because 
our study population consists of mildly hyperhomocysteinemic elderly, which 
is an inclusion criteria of the B-PROOF study. Third, one might argue about 
the sample size of our study. Although a sample size calculation is not appro-
priate because of the non-linearity of the models, other studies investigating 
this relation had equal population sizes, making a power issue less likely. 
Furthermore, the number of participants was quite equal between the groups 
and can therefore not explain the lack of an association in participants with 
low serum 25(OH)D levels. Also, with regard to the vascular measurements, 
we followed the restrictions as provided by the manufacturer. Since detailed 
restrictions were not clearly included in guidelines at the time of the mea-
surements as they are today, our measures may not be fully comparable 
with other, more recent studies. However, we tried to minimize the potential 
influence for example of smoking and physical exercise by considering these 
factors as potential covariates. The main strengths of our study are our 
accurately measured cardiovascular parameters and multiple measures of 
pre-clinical cardiovascular disease.
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Conclusion
Overall, the association between serum 25(OH)D and parameters of arterial 
stiffness and arteriosclerosis in elderly was non-linear. Caution is therefore 
warranted when investigating this association. In particular, we demon-
strated that vitamin D sufficient participants have higher carotid IMT levels 
compared with vitamin D deficient individuals. This finding suggests that also 
normal ranged vitamin D levels might potentially increase cardiovascular risk 
because of its association with pre-clinical cardiovascular disease.
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4.1.1 AbstrACt
Objective
Homocysteine has been shown to be a more accurate predictor of cardio-
vascular mortality in very old persons than models based on classical risk 
factors. Arterial stiffening is a structural abnormality involved in the pathway 
of cardiovascular disease. We expect this underlying pathophysiology to be 
a possible explanation for the association between homocysteine and cardio-
vascular risk, particularly in older populations.
Methods
Baseline cross-sectional data of the B-PROOF study were used to determine 
associations between homocysteine and outcomes of vascular function and 
structure. The cardiovascular subgroup of the B-PROOF study was included 
[n = 560, 58% men, age 72.6 ± 5.5 years, median homocysteine level 
14.2 μmol/l (IQR 13.0–16.6)]. We assessed carotid distensibility coefficient, 
carotid compliance coefficient, aortic pulse wave velocity (aPWV), augmen-
tation index (AIx) and aortic pulse pressure (aortic PP). Associations were 
tested using linear regression analysis and ANCOVA and were adjusted for 
possible confounders including age, sex, renal function, mean arterial pres-
sure and heart rate.
Results 
Ln-homocysteine was strongly associated with aPWV [β 0.005 95% confi-
dence interval (0.001–0.009)]. Furthermore, this association was shown to 
be agedependent (P = 0.02) and it was most strong in the upper tertile of 
age (77–98 years). No significant associations with ln-homocysteine were 
observed for AIx, carotid distensibility coefficient and compliance coefficient 
and aortic PP. Sex stratification shows the association between ln-homocys-
teine and aPWV is only significant in men.
Conclusion
In older persons, homocysteine is associated with aortic stiffness, predomi-
nantly in the oldest old. This suggests that the strong association between 
homocysteine and cardiovascular mortality in the elderly may be mediated 
by aortic stiffness.
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4.1.2 IntroduCtIon
Hyperhomocysteinemia and cardiovascular disease are both highly preva-
lent among elderly persons. Elevated homocysteine has been shown to be 
a moderately strong and independent cardiovascular risk factor in healthy 
populations [1]. The association of homocysteine level with cardiovascular 
disease appears to be particularly strong in the very old and homocysteine 
level has even been shown to be a better predictor of cardiovascular mortal-
ity in this age group than models based on classical Framingham risk fac-
tors [2]. However, underlying mechanisms remain unclear, especially after 
homocysteine-lowering intervention trials reported a lack of short-term (3–5 
years) benefit of B-vitamins in middle-aged populations [3].
Arterial stiffness, which is another strong predictor of cardiovascular dis-
ease especially in older populations [4,5], may be the link between hyper-
homocysteinemia and adverse cardiovascular outcomes. Arterial stiffness is
involved in the pathogenesis of cardiovascular disease and acts as a major 
marker for cardiovascular risk [4,6–9]. Particularly for aortic stiffness this 
association is consistent, with aortic pulse wave velocity (aPWV) emerging as 
the most potent predictor of cardiovascular events [7–9]. As arterial stiffness 
is a structural abnormality that is not easily reversible, an association be-
tween homocysteine and arterial stiffness might help explain why B-vitamins 
fail to exert beneficial effects on cardiovascular outcomes within the follow-
up period of the intervention trials.
Evidence exists that homocysteine level may be associated with aortic 
stiffness in the general population; however, these studies were equivocal 
[10–13]. These studies were performed in relatively young populations and 
homocysteine levels were normal in a large proportion of studied patients. 
In order to gain more knowledge about the pathophysiological background 
of the association between homocysteine level and cardiovascular disease, 
specifically in older persons, we investigated whether homocysteine level 
is associated with arterial stiffness within the B-PROOF study [14]. The 
B-PROOF study consists of an elderly population (age 65–98 years) with 
elevated homocysteine levels (>12µmol/l). As mentioned, arterial stiffness 
and hyperhomocysteinemia are both common conditions and risk indicators 
for cardiovascular disease in this age group. Because the association between 
arterial stiffness and homocysteine level is not always present and not yet 
investigated in elderly, we will explore this association in older individuals.
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4.1.3 Methods
Study participants
The present study was conducted as a cross-sectional baseline analysis within 
the framework of the B-PROOF (B-vitamins for the Prevention of Osteoporotic 
Fractures) study. A detailed description of this randomized controlled trial has 
been reported elsewhere [14]. In short, B-PROOF is a multicenter, random-
ized, placebo-controlled, double-blind trial including 2919 participants from 
three areas in the Netherlands. Main inclusion criteria were age 65 years and 
older, and an elevated homocysteine level (12–50µmol/l). Fifty-one percent 
of the approached population could be included based on their homocyste-
ine level. Main exclusion criteria were renal insufficiency (creatinine level 
>150µmol/l) and presence of a malignancy. All participants gave written 
informed consent before the start of the study. The Wageningen Medical 
Ethics Committee approved the study protocol, and the Medical Ethics com-
mittees of Rotterdam and Amsterdam gave approval for local feasibility.
At the Erasmus Medical Center (Rotterdam) and VU University Medical 
Center (Amsterdam), a subsample of participants underwent vascular mea-
surements (n = 560). Participants with cardiac arrhythmia were excluded 
from these additional measurements. During the measurements, partici-
pants were situated in supine position on a flat examination couch in a quiet 
laboratory room for at least 5–10 min prior to the measurements, and the 
participants were not allowed to speak during the measurements. Use of 
alcohol or coffee during 12 h before the measurements was prohibited.
Clinical characteristics
Height was measured in duplicate to the nearest 0.1 cm using a stadiometer, 
with the participant standing erect and wearing no shoes [14]. Weight was 
measured using a calibrated weighing device (SECA 761), with the par-
ticipant wearing light garments without shoes and empty pockets, to the 
nearest 0.5 kg [14]. BMI was calculated as weight divided by squared height 
and expressed as kg/m2. Self-reported medical history, alcohol intake and 
smoking habits were determined using a questionnaire [14]. 
Homocysteine and renal function
Venous blood samples were obtained in the morning, when the participants 
were in a fasted state, or had taken a restricted breakfast [14]. For to-
tal homocysteine analysis, a plasma ethylenediaminetetraacetic acid tube 
was stored in ice immediately after blood drawing [14], and samples were 
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processed within 4 h in order to prevent a temperaturedependent and 
time-dependent increase in plasma homocysteine [15]. Plasma homocys-
teine was measured using the Architect i2000 RS analyzer (VU University 
Medical Center, intra-assay CV=2%, inter-assay CV=4%) and LC-MS/MS 
(Erasmus Medical Center, CV=3.1%). Outcomes of the centers did not dif-
fer significantly at cross-calibration. Serum creatinine was measured with 
the enzymatic colorimetric Roche CREA and assay (CV=2%). The estimated 
glomerular filtration rate (eGFR) was estimated with the Modification of Diet 
in Renal Disease (MDRD) and was calculated in ml/min per 1.73m2 with the 
formula: 186 * (serum creatinine (μmol/l)/88.4) – 1.154 * age (years) – 0.203 
* 0.742 (for women) [7].
Carotid distensibility coefficient and compliance coefficient
The vessel wall movement–detector system has been described in detail 
previously by Hoeks et al [16]. This system consists of a wall track sys-
tem and data-acquisition system (Art.Lab, Esoate Europe, Maastricht, the 
Netherlands). With the L105 40mm 7.5MHz transducer, with the M-mode, a 
M-mode line perpendicular to the right vessel was selected. Measurements 
were conducted during the cardiac cycles and in order to obtain accurate 
measurements, the SD of the mean values of six independent measurements 
was less than 10% of the mean (intra-CV=8%, inter-CV=10%). Distensibil-
ity coefficient was calculated using the following equation: distensibility coef-
ficient = (2DD/D)/PP (10-3/kPa) [17,18], where D is diameter during diastole 
and DD is the measured distensibility (systolic diameter – diastolic diameter) 
and PP is the aortic pulse pressure. The compliance coefficient was calculated 
as: compliance coefficient = (π*ΔD*D)/2PP (in mm2/kPa) [19]. The aortic PP 
was derived from radial applanation and was used in both equations.
Applanation tonometry
Arterial tonometry was obtained from the right radial, right carotid and right 
femoral artery using the Sphygmocor device (Sphygmocor version 7.1, AtCor 
Medical, Sydney, Australia). An estimate of the corresponding central aortic 
pulse wave was calculated, using a validated generalized transfer function 
incorporated in the device. With the integral software, the central augmented 
pressure was calculated as the difference between the early and late systolic 
peaks of the estimated central pressure wave form.
Central aortic augmentation index (AIx) was calculated as the augmented 
pressure expressed as a percentage of the pulse pressure (intra-CV=3%, 
inter-CV=5%). Aortic pulse wave velocity (aPWV) was measured with 
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a three-channel ECG recording and simultaneously recording of the right 
carotid artery pulse wave form and subsequently the femoral artery pulse 
waveform. The aPWV was calculated as the delay between the femoral pulse 
wave and the carotid pulse wave, divided by the transit distance (intra-
CV=5%, inter-CV=8%). Transit distance was assessed with body surface 
measurement from the carotid artery to the femoral artery [20].
Blood pressure measurement
Peripheral blood pressure at the time of vascular function tests was mea-
sured once with a semiautomatic oscillometric device (Datascope Accurator 
Plus device; Datascope Corp. New Jersey, USA) after at least 5 min of supine 
rest. All blood pressure measurements were conducted at the right arm. The 
mean arterial pressure was measured and the pulse pressure was calculated 
as the SBP minus the DBP.
Statistical analysis
The association between homocysteine level arterial stiffness was investi-
gated using multiple steps. First, normal distribution of all variables was 
tested by histograms and Kolmogorov–Smirnov tests. Because of skewed 
distribution, we used both homocysteine level and ln-homocysteine level 
for analysis. Second, associations between homocysteine level and aortic 
pulse pressure (PP), carotid distensibility coefficient and compliance coeffi-
cient, aPWV and AIx were investigated with linear regression analysis. Third, 
analysis of covariance (ANCOVA) was performed to compare mean values 
of these variables per tertiles of homocysteine level. Potential confound-
ers were evaluated in a stepwise model and included age, sex, creatinine, 
eGFR, mean arterial pressure (MAP), heart rate, smoking, medical history 
of cardiovascular disease, hypertension, hypercholesterolemia and diabetes 
mellitus. In the end, we ran a multivariable model containing all variables 
that caused a change in the point estimate (β coefficient) of more than 10%, 
or were considered clinically relevant.
Finally, we used age, sex, creatinine, MAP and heart rate in this multi-
variate model. We also performed a stratified analysis with sex, in order to 
investigate the effect of sex in the association between homocysteine and 
arterial stiffness.
We investigated tertiles of homocysteine levels and its association with 
aPWV per tertile of age with ANCOVA. Furthermore, we tested whether age 
was an interactionterm in the association between homocysteine and aPWV. 
Next, in order to investigate the correlation between all arterial stiffness 
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parameters, we used Pearson correlation and univariate linear regression. 
The aPWV is considered as the ‘golden standard’. Statistical analysis was 
performed using the statistical software package of SPPS 17.0 (SPPS Inc., 
Chicago, Illinois, USA). P values of less than 0.05 were considered statisti-
cally significant.
4.1.4 results
Baseline characteristics of the participants (n = 560) are shown in Table 1. 
Mean age was 72.5 ± 5.6 years and sex was equally distributed. The median 
plasma homocysteine level was 14.2µmol/l. Mean brachial SBP and DBP were 
137.7 ± 18.1 and 77.3 ± 9.6 mmHg, respectively (Table 1). Sex stratifica-
tion showed a median plasma homocysteine level of 14.6 (13.1–16.8) μmol/l 
for men and 14.1 (12.9–16.3) μmol/l for women (p = 0.06).
In univariate analysis, ln-homocysteine was positively associated with aPWV 
(p < 0.01) (Figure 1), but not with AIx, distensibility coefficient, compliance 
coefficient and aortic PP. In the final model of the multivariate analysis, the 
Table 1. Baseline characteristics of the B-PROOF vascular sub-population; n = 560
Variable Mean ± SD
Age (years and range) 72.5 ± 5.6 [65-98)
Sex (n, %)
 Male 314 (56.1%)
BMI (kg/m2) 26.5 ± 3.7
Plasma homocysteine (μmol/L) 14.2 (13.0 – 16.6)
Creatinine (μmol/L) 83.2 ± 17.0
eGFR (ml/min per 1.73m2) 90.8 ± 38.3
Brachial blood pressure (mmHg)
 SBP
 DBP
137.7 ± 18.1
77.3 ± 9.6
Aortic PP (mmHg) 50.1 ± 15.1
Carotid DC (10-3/kPa) 14.5 ± 8.6
Carotid CC (mm2/kPa) 618.9 ± 1106.5
AIx (%) 26.2 ± 10.0
aPWV (m/s) 14.3 ± 4.5
Values are presented as number and percentage or as mean_SD, except for homocysteine: 
median (IQR) and age: mean± SD and (range). AIx, augmentation index; aPWV, aortic pulse 
wave velocity; CC, compliance coefficient; DC, distensibility coefficient; mean ± SD; eGFR, 
estimated glomerular filtration rate; PP, pulse pressure.
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positive association between ln-homocysteine and aPWV remained significant 
[β 0.005 95% CI (0.001–0.009)] (Table 2, Figure 4.1.1). None of the other 
arterial stiffness markers were significantly associated with ln-homocysteine.
Furthermore, there was an interaction effect of age on the association be-
tween ln-homocysteine and aPWV (p = 0.02), as demonstrated in Figure 
4.1.2. This was confirmed by the stratified multivariate linear analysis of this 
association per tertile of age [tertile 1: β 0.004 95%CI (-0.002 to 0.010); 
tertile 2: β 0.007 95%CI (-0.004 to 0.014) and tertile 3: β 0.008 95% CI 
(0.001–0.016)]. The associations between ln-homocysteine and AIx, disten-
sibility coefficient, compliance coefficient and aortic PP did not change with 
increasing age.
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(P¼ 0.04), r¼ 0.20 (P< 0.01), r¼�0.16 (P¼ 0.01). Com-
pliance coefficient and aPWV were not correlated.
Although overall significant, the strength of the associ-
ation between AIx and aPWV reduced with increasing age
and did not reach significance in between the tertiles. Per
tertile of age the associations between AIx and aPWV were,
respectively, b 0.19 for the tertile 1 (P¼ 0.31); b 0.04 for the
tertile 2 (P¼ 0.86); b 0.01 for the tertile 3 (P¼ 0.93). Such an
age-dependent effect was also seen for the association
between aortic PP and aPWV [tertile 1 b 0.94 (P< 0.01);
tertile 2 b 0.43 (P¼ 0.13); tertile 3 b 0.35 (P¼ 0.22)]. Age-
dependency was not present for the association between
distensibility coefficient or compliance coefficient and
aPWV.
DISCUSSION
Our study in older participants with elevated homocysteine
levels shows a positive association between plasma
homocysteine level and aPWV, as a measure of aortic
stiffness. This association was the strongest in the oldest
old. Importantly, this association between homocysteine
and aortic stiffness was independent of renal function and
blood pressure. The association with homocysteine level
was not present for other estimates of arterial stiffness.
Stratification for sex shows this association is only signifi-
cant in men.
To our knowledge, this is the first study showing that
the positive association between homocysteine level and
aortic stiffness holds true in a hyperhomocysteinemic
population and is the strongest in the oldest old. The
association between homocysteine level and aPWV has
been investigated earlier in younger populations, however,
these findings were conflicting [11–13]. One study, exclu-
sively performed in men, did not report a relation between
homocysteine level and PWV [13]. However, this is in
contrast with the findings of the Framingham Heart
Study, where an association between homocysteine and
aortic stiffness was demonstrated in men, but not in women
[11]. Furthermore, within a Czech study, homocysteine was
strongly and independently associated with PWV in both
men and women [12]. Nevertheless, all these studies have
been performed in younger populations with mean ages
between 40 and 60 years. Our study endorses that homo-
cysteine level is independently and significantly associated
with aortic stiffening in elderly and particularly in the oldest
old.
There are several potential mechanisms, which may
explain the relation between hyperhomocysteinemia
and aortic stiffness. Main hypotheses are a direct effect
of homocysteine via the combination of increased
thrombogenicity, increased oxidative stress and overacti-
vation of redox-sensitive inflammatory pathways, leading
to impaired endothelial function and platelet aggregation,
and finally atherothrombosis [21–26,15]. During age,
homocysteine is more important in the association with
aPWV. This age-dependent effect might be explained by
the fact that homocysteine is a more important cardio-
vascular risk indicator with advancing age, in comparison
with traditional indictors. Nevertheless, future research will
be necessary to investigate the underlying mechanisms.
The sex-effect of the association between ln-homocys-
teine and aortic stiffness might be due to the fact that there
are more extreme aPWV measurements and higher homo-
cysteine levels in males. In our study, higher homocysteine
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FIGURE 1 Scatterplots of aortic pulse wave velocity measurements stratified by
tertile of age. AIx, augmentation index; aPWV, aortic pulse wave velocity; CC,
compliance coefficient; DC, distensibility coefficient; eGFR, estimated glomerular
filtration rate; PP, pulse pressure.
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(P¼ 0.04), r¼ 0.20 (P< 0.01), r¼�0.16 (P¼ 0.01). Com-
pliance coefficient and aPWV were not correlated.
Although overall significant, the strength of the associ-
ation between AIx and aPWV reduced with increasing age
and did not reach significance in between the tertiles. Per
tertile of age the associations between AIx and aPWV were,
respectively, b 0.19 for the tertile 1 (P¼ 0.31); b 0.04 for the
tertile 2 (P¼ 0.86); b 0.01 for the tertile 3 (P¼ 0.93). Such an
age-dependent effect was also seen for the association
between aortic PP and aPWV [tertile 1 b 0.94 (P< 0.01);
tertile 2 b 0.43 (P¼ 0.13); tertile 3 b 0.35 (P¼ 0.22)]. Age-
dependency was not present for the association between
distensibility coefficient or compliance coefficient and
aPWV.
DISCUSSION
Our study in older participants with elevated homocysteine
levels shows a positive association between plasma
homocysteine level and aPWV, as a measure of aortic
stiffness. This association was the strongest in the oldest
old. Importantly, this association between homocysteine
and aortic stiffness was ind pendent of renal function and
blood pressure. The association with homocysteine level
was not present for other estimates of arterial stiffness.
Stratification for sex shows this association is only signifi-
cant in men.
To our knowledge, this is the first study showing that
the positive association between homocysteine level and
aortic stiffness holds true in a hyperhomocysteinemic
population and is the strongest in the oldest old. The
association between homocysteine level and aPWV has
been investigated earlier in younger populations, however,
these findings were conflicting [11–13]. One study, exclu-
sively performed in men, did not report a relation between
homocysteine level and PWV [13]. However, this is in
contrast with the findings of the Framingham Heart
Study, where an association between homocysteine and
aortic stiffness was demonstrated in men, but not in women
[11]. Furthermore, within a Czech study, homocysteine was
strongly and independently associated with PWV in both
men and women [12]. Neverthel ss, all these studies have
been performed in younger populations with mean ages
between 40 and 60 years. Our study endorses that homo-
cysteine level is independently and significantly associated
with aortic stiffening in elderly and particularly in the oldest
old.
There are several potential mechanisms, which may
explain the relation between hyperhomocysteinemia
and aortic stiffness. Main hypotheses are a direct effect
of homocysteine via the combination of increased
thrombogenicity, increased oxidative stress and overacti-
vation of redox-sensitive inflammatory pathways, leading
to impaired endothelial function and platelet aggregation,
and finally atherothrombosis [21–26,15]. During age,
homocysteine is more important in the association with
aPWV. This age-dependent effect might be explained by
the fact that homocysteine is a more important cardio-
vascular risk indicator with advancing age, in comparison
with traditional indictors. Nevertheless, future research will
be necessary to investigate the underlying mechanisms.
The sex-effect of the association between ln-homocys-
teine and aortic stiffness might be due to the fact that there
are more extreme aPWV measurements and higher homo-
cysteine levels in males. In our study, higher homocysteine
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FIGURE 1 Scatterplots of aortic pulse wave velocity measurements stratified by
tertile of age. AIx, augmentation index; aPWV, aortic pulse wave velocity; CC,
compliance coefficient; DC, distensibility coefficient; eGFR, estimated glomerular
filtration rate; PP, pulse pressure.
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(P¼ 0.04), r¼ 0.20 (P< 0.01), r¼�0.16 (P¼ 0.01). Com-
pliance coefficient and aPWV were not correlat d.
Although overall significant, the strength of the associ-
ation between AIx and aPWV reduced with increasing age
and did not reach significance in between the tertiles. Per
tertile of age he associations between AIx and aPWV were,
respectively, b 0.19 for the tertile 1 (P¼ 0.31); b 0.04 for the
tertile 2 (P¼ 0.86); b 0.01 for the tertile 3 (P¼ 0.93). Such an
age-dependent effect was also seen for the association
between aortic PP and aPWV [tertile 1 b 0.94 (P< 0.01);
tertile 2 b 0.43 (P¼ 0.13); tertile 3 b 0.35 (P¼ 0.22)]. Age-
dependency was not present for the association between
distensibility coefficient or compliance coefficient and
aPWV.
DISCUSSION
Our study in older participants with elevated homocysteine
levels shows a positive association between plasma
homocysteine level and aPWV, as a measure of aortic
stiffness. This association was the strongest in the oldest
old. Importantly, this association between homocysteine
and aortic stiff ess was independent of renal function and
blood pressure. The association with homocysteine level
was not present for other estimates of arterial stiffness.
Stratification for sex shows this association is only signifi-
cant in men.
To our knowledge, this is the first study showing that
the positive association b tween homocysteine level and
aortic stiffness holds true in a hyperhomocysteinemic
population and is the strongest in the oldest old. The
association between homocysteine level and aPWV has
been investigated earlier in younger populations, however,
these findings were conflicting [11–13]. One study, exclu-
sively performed in men, did not report a relation between
homocystein lev l and PWV [13]. However, this is in
contr st with th findings of the Framingham Heart
Study, wher an association between homocysteine and
ortic stiffn ss was demonstrated in men, but not in women
[11]. Furthermore, withi a Czech study, homocysteine was
strongly and indep ndently associated with PWV in both
men and women [12]. Nevertheless, all these studies have
been performed in ounger populations with mean ages
between 40 and 60 years. Our study endorses that homo-
cysteine level is independently and significantly associated
with a rtic stiff ning in lderly and particularly in the oldest
old.
There are several potential mechanisms, which may
explain the relation between hyperhomocysteinemia
and aortic stiffness. Main hypotheses are a direct effect
of homocysteine via the combination of increased
thromb genicity, i cr ased oxidative stress and overacti-
vation of redox-sensitive inflammatory pathways, leading
t impaired endot elial function and platelet aggregation,
and finally atherothrombosis [21–26,15]. During age,
homocysteine is more i portant in the association with
aPWV. This age-dep dent effect might be explained by
the fact that omocysteine is a more important cardio-
vascular risk indicator with advancing age, in comparison
with tr ditional indictors. N vertheless, future research will
be necessary to investigate the underlying mechanisms.
The sex-effect of the ssociation between ln-homocys-
tei e and aortic stiffness might be due to the fact that there
are more extreme aPWV measurements and higher homo-
cysteine levels in males. In our study, higher homocysteine
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Figuur 4.1.1.
Scatterplots of aortic pulse wave velocity measurements stratified by tertile of age. Abbrevia-
tions as in Table 1. 
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A stratified analysis with sex showed the association between ln-homocyste-
ine and aPWV is only present in men (Figure 4.1.3, Table 3). 
In our population, AIx and aortic PP were positively, and distensibility 
coefficient was negatively correlated with aPWV. The respective correlation 
coefficients were r = 0.09 (p = 0.04), r = 0.20 (p<0.01), r = -0.16 (p = 
0.01). Compliance coefficient and aPWV were not correlated. Although overall 
significant, the strength of the association between AIx and aPWV reduced 
Table 2. Multivariate linear regression analysis of ln-homocysteine to vascular param-
eters
Model 1 Model 2 R2
Variable β (95%CI) β (95%CI)
Aortic PP (mmHg) -0.00040 
(-0.00100 to 0.00100)
-0.00100 
(-0.00200 to 0.00030)
0.095
Carotid DC (10-3/kPa) -0.00060
(-0.00200 to 0.00200)
0.00100
(-0.00100 to 0.00300)
0.115
Carotid CC (mm2/kPa) -0.00010 
(-0.00020 to 0.00002)
-0.00010 
(-0.00030 to 0.00001)
0.119
AIx (%) -0.00020 
(-0.00200 to 0.00100)
-0.00100 
(-0.00200 to 0.00100)
0.096
aPWV (m/s) 0.00800 
(0.00500 to 0.01200)*
0.00500 
(0.00100 to 0.00900)*
0.113
Values are presented as beta (95% CI) and R2. Final model: adjusted for age, sex, MAP, heart 
rate and creatinine. 
* p-value less than 0.05. AIx, augmentation index; aPWV, aortic pulse wave velocity; CC, 
compliance coefficient; DC, distensibility coefficient; PP, Pulse Pressure.
Table 3. Stratified multivariate linear regression analysis for gender
Men Women
Model 1 Model 2 Model 1 Model 2
Variable β (95%CI) β (95%CI) β (95%CI) β (95%CI)
Aortic PP (mmHg) 0.00005 
(-0.001; 0.001)
-0.001 
(-0.002 to 0.001)
-0.001 
(-0.002 to 0.001)
-0.0003 
(-0.003 to 0.002)
Carotid DC (10-3/kPa) -0.001 
(-0.004 to 0.001)
-0.00002 
(-0.002 to 0.002)
0.003 
(-0.002 to 0.007)
0.002 
(-0.002 to 0.007)
Carotid CC (mm2/kPa) -0.00001 
(-0.00003 to 0.000004)
-0.00001
(-0.00003 to 0.000002)
-0.00003  
(-0.0001 to 0.00009)
-0.00002  
(-0.0001 to 0.0001)
AIx (%) 0.001 
(-0.001 to 0.003)
-0.001
(-0.003 to 0.001)
-0.001 
(-0.003 to 0.002)
-0.001 
(-0.004 to 0.002)
aPWV (m/s) 0.010 
(0.006 to 0.014)*
0.007 
(0.002 to 0.011)*
0.005 
(-0.0004 to 0.011)
0.003 
(-0.003 to 0.009)
Values are presented as beta (95% CI). Model 1: unadjusted; Model 2: adjusted for age, 
sex, MAP, heart rate and creatinine. *P value less than 0.05. AIx, augmentation index; aPWV, 
aortic pulse wave velocity; CC, compliance coefficient; DC, distensibility coefficient; PP, pulse 
pressure.
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with increasing age and did not reach significance in between the tertiles. Per 
tertile of age the associations between AIx and aPWV were, respectively, β 
0.19 for the tertile 1 (p = 0.31); β 0.04 for the tertile 2 (p = 0.86); β 0.01 for 
the tertile 3 (p = 0.93). Such an age-dependent effect was also seen for the 
association between aortic PP and aPWV [tertile 1 β 0.94 (p<0.01); tertile 
2 β 0.43 (p = 0.13); tertile 3 β 0.35 (p = 0.22)]. Age-dependency was not 
present for the association between distensibility coefficient or compliance 
coefficient and aPWV.
 4.1.5 dIsCussIon
Our study in older participants with elevated homocysteine levels shows a 
positive association between plasma homocysteine level and aPWV, as a 
measure of aortic stiffness. This association was the strongest in the oldest 
old. Importantly, this association between homocysteine and aortic stiffness 
was independent of renal function and blood pressure. The association with 
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
levels are more strongly related to higher aPWV levels,
therefore, this sex-effect strengths our hypothesis. A reason
we did not demonstrate this association in females might be
there are less females in our population. Therefore, we may
not definitively conclude there is no association between
ln-homocysteine and aPWV in women.
In our study, we did not observe an association between
homocysteine level and AIx. This may be explained by the
curvelinear pattern of the change of AIx with age, where a
plateau is reached after the age of 60 years [27] and because
augmentation is also influenced by other factors than
stiffness, including peripheral resistance and cardiac per-
formance [28]. Nevertheless, even though our participants
were older than 65 years, we did observe a small correlation
between AIx and aPWV. However, in concordance with
the curvelinear hypothesis, this correlation decreased with
advancing age.
Homocysteine level was not associated with distensibility
coefficient and compliance coefficient in our study. The
lack of an association between homocysteine level and
distensibility coefficient and compliance coefficient in our
study could possibly be explained by the fact that disten-
sibility coefficient and compliance coefficient are also
influenced by other factors, like systolic function. A second
explanation might be that carotid distensibility coefficient
and compliance coefficient are local measurements of the
carotid artery, which is an elastic artery. With aPWV, more
territories are reflected, providing information about mainly
elastic, but also muscular arteries. As structural and func-
tional properties of the arterial wall differ within the arterial
tree, it is plausible the pathophysiology of homocysteine
differs between elastic and muscular arteries. However,
this is hypothetical and there may be other underlying
mechanisms.
Even though aortic PP is closely related to arterial stiffness
[29], we found no association between homocysteine level
and aortic PP in our study and no age-dependent effect. This
might endorse the hypothesis that aortic PP is amore indirect
measurement of arterial stiffness than aPWV, as PP will also
be influenced by other factors like cardiac performance.
TABLE 2. Multivariate linear regression analysis of ln-homocysteine to vascular parameters
Model 1 Model 2 R2
Variable b (95% CI) b (95% CI)
Aortic PP (mmHg) �0.00040 (�0.00100 to 0.00100) �0.00100 (�0.00200 to 0.00030) 0.095
Carotid DC (10�3/kPa) �0.00060 (�0.00200 to 0.00200) 0.00100 (�0.00100 to 0.00300) 0.115
Carotid CC (mm2/kPa) �0.00010 (�0.00020 to 0.00002) �0.00010 (�0.00030 to 0.00001) 0.119
AIx (%) �0.00020 (�0.00200 to 0.00100) �0.00100 (�0.00200 to 0.00100) 0.096
aPWV (m/s) 0.00800 (0.00500 to 0.01200)� 0.00500 (0.00100 to 0.00900)� 0.113
Values are presented as beta�95% CI and R2. Final model: adjusted for age, sex, MAP, heart rate and creatinine. �P value less than 0.05. AIx, augmentation index; aPWV, aortic pulse
wave velocity; CC, compliance coefficient; DC, distensibility coefficient; PP, Pulse Pressure.
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FIGURE 2 Interactive effects of age and plasma homocysteine on aortic pulse wave velocity. Values are presented as adjusted means. Model adjusted for sex, MAP, heart
rate and creatinine. Overall P value for interaction for this model: P¼0.02. Tertiles of age: 1: 65–70 years; 2: 71–76 years; 3: 77–98 years. Tertiles of homocysteine: 1:
12.0–13.4mmol/l; 2: 13.5–15.6mmol/l; 3: 15.7–49.0mmol/l. AIx, augmentation index; aPWV, aortic pulse wave velocity; CC, compliance coefficient; DC, distensibility
coefficient; eGFR, estimated glomerular filtration rate; PP, pulse pressure.
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Figuur 4.1.2.
Interactive effects of age and plasma homocysteine on aortic pulse wave velocity. Values are 
presented as adjusted means. Model adjusted for sex, MAP, heart rate and creatinine. Overall 
P value for interaction for this model: P = 0.02. Tertiles of age: 1: 65–70 years; 2: 71–76 
years; 3: 77–98 years. Tertiles of homocysteine: 1: 12.0–13.4mmol/l; 2: 13.5–15.6mmol/l; 
3: 15.7–49.0mmol/l. Abbreviations as in Table 1. 
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homocysteine level was not present for other estimates of arterial stiffness. 
Stratification for sex shows this association is only significant in men.
To our knowledge, this is the first study showing that the positive association 
between homocysteine level and aortic stiffness holds true in a hyperhomo-
cysteinemic population and is the strongest in the oldest old. The associa-
tion between homocysteine level and aPWV has been investigated earlier 
in younger populations, however, these findings were conflicting [11–13]. 
One study, exclusively performed in men, did not report a relation between 
homocysteine level and PWV [13]. However, this is in contrast with the find-
ings of the Framingham Heart Study, where an association between homo-
cysteine and aortic stiffness was demonstrated in men, but not in women 
[11]. Furthermore, within a Czech study, homocysteine was strongly and 
independently associated with PWV in both men and women [12]. Neverthe-
less, all these studies have been performed in younger populations with 
mean ages between 40 and 60 years. Our study endorses that homocysteine 
level is independently and significantly associated with aortic stiffening in 
elderly and particularly in the oldest old.
There are several potential mechanisms, which may explain the relation be-
tween hyperhomocysteinemia and aortic stiffness. Main hypotheses are a di-
rect effect of homocysteine via the combination of increased thrombogenicity, 
increased oxidative stress and overactivation of redox-sensitive inflammatory 
pathways, leading to impaired endothelial function and platelet aggregation, 
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
A potential limitation of the current study is the cross-
sectional design; therefore, we cannot be certain that
the observed associations are truly causal. We will further
study the role of aortic stiffness in the currently running
randomized intervention trial (B-PROOF). A second limita-
tion is that, the B-PROOF trial included only participants
with hyperhomocysteinemia. It is conceivable that the
associations with cardiovascular disease and aortic stiffen-
ing will be different when lower homocysteine levels are
taken into account. However, the adjusted reference value
of aPWV for individuals aged 70 years and over is 12.1m/s
[30]. In our population the mean aPWV is 14.3m/s, which
is clearly higher compared with a general, nonhyperhomo-
cysteinemic population. Third, we cannot exclude the
possibility that the association between homocysteine
and aPWV is based on the play of chance, because other
parameters of arterial stiffness are not associated with
homocysteine. The relative small sample size of our
population might explain why AIx, aortic PP, distensibility
coefficient and compliance coefficient are not associated
with homocysteine. However, aPWV is the most power-
ful measurement of arterial stiffness and might better
reflect this condition compared with the other vascular
parameters.
In conclusion, this study demonstrated a clear associ-
ation between homocysteine level and aortic stiffness,
particularly in males. Overall, the strength of the association
increased with advancing age. Homocysteine level is
an important risk indicator of cardiovascular mortality in
elderly and our findings may indicate that aortic stiffness is a
mediator in this process. Nevertheless, our hypothesis
remains to be confirmed by the currently running B-PROOF
intervention trial.
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FIGURE 3 Stratified scatterplots of ln-homocysteine with sex. Abbreviations: as in
Table 1.
TABLE 3. Stratified multivariate linear regression analysis for gender
Men Women
Variable Model 1 Model 2 Model 1 Model 2
Aortic PP (mmHg) 0.00005 (0.001;0.001) 0.001 (0.002 to 0.001) 0.001 (0.002 to 0.001) 0.0003 (0.003 to 0.002)
Carot d DC
(103/kPA)
0.001 (0.004 to 0.001) 0.00002 (0.002 to 0.002) 0.003 (0.002 to 0.007) 0.002 (0.002 to 0.007)
Carotid CC
(mm2/kPa)
0.00001 (0.00003 to 0.000004) 0.00001 (0.00003 to 0.000002) 0.00003 (0.0001 to 0.00009) 0.00002 (0.0001 to 0.0001)
AIx (%) 0.001 (0.001 to 0.003) 0.001 (0.003 to 0.001) 0.001 (0.003 to 0.002) 0.001 (0.004 to 0.002)
aPWV (m/s) 0.010 (0.006 to 0.014) 0.007 (0.002 to 0.011) 0.005 (0.0004 to 0.011) 0.003 (0.003 to 0.009)
Values are presented as beta  95% CI. Model 1: unadjusted; Model 2: adjusted for age, sex, MAP, heart rate and creatinine. P value less than 0.05. AIx, augmentation index; aPWV,
aortic pulse wave velocity; CC, compliance coefficient; DC, distensibility coefficient; PP, pulse pressure.
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A potential limitation of the current study is the cross-
sectional design; therefore, we cannot be certain that
the observed associations are truly causal. We will further
study the role of aortic stiffne s n th currently running
randomized intervention trial (B-PROOF). A second limita-
tion is that, the B-PROOF trial included only participants
with hyperhomocysteinemia. It is conceivable that the
associations with cardiovascular disease and aortic stiffen-
ing will be different when lower homocysteine levels are
taken into account. However, the adjusted reference value
of aPWV for individuals aged 70 years and over is 12.1m/s
[30]. In our population the mean aPWV is 14.3m/s, which
is clearly higher compared with a general, nonhyperhomo-
cysteinemic population. Third, we cannot exclude the
possibility that the association between homocysteine
and aPWV is based on the play of chance, because other
parameters of arterial stiffness are not associated with
homocysteine. The relative small sample size of our
population might explain why AIx, aortic PP, distensibility
coefficient and compliance coefficient are not associated
with homocysteine. However, aPWV is the most power-
ful measurement of arterial stiffness and might better
reflect this condition compar d with the other vascular
parameters.
In conclusion, this study demonstrated a clear associ-
ation between homocysteine level and aortic stiffness,
particularly in males. Overall, the strength of the association
increased with advancing age. Homocyst ine level is
an important risk indicator of cardiovascul r mortality in
elderly and our findings may indicate that aortic stiffness is a
m diator in this process. Nevertheless, our hypothesis
remains to be confirmed by the currently running B-PROOF
intervention trial.
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TABLE 3. Stratified multivariate linear regression analysis for gender
Men Women
Variable Mo el 1 Model 2 Model 1 Model 2
Aortic PP (mmHg) 0.00005 (0.001;0.001) 0.001 (0.002 to 0.001) 0.001 (0.002 to 0.001) 0.0003 (0.003 to 0.002)
Carotid DC
(103/kPA)
0.001 (0.004 to 0.001) 0.00002 (0.002 to 0.002) 0.003 (0.002 to 0.007) 0.002 (0.002 to 0.007)
Carotid CC
(mm2/kPa)
0.00001 (0.00003 to 0.000004) 0.00001 (0.00003 to 0.000002) 0.00003 (0.0001 to 0.00009) 0.00002 (0.0001 to 0.0001)
AIx (%) 0.001 (0.001 to 0.003) 0.001 (0.003 to 0.001) 0.001 (0.003 to 0.002) 0.001 (0.004 to 0.002)
aPWV (m/s) 0.010 (0.006 to 0.014) 0.007 (0.002 to 0.011) 0.005 (0.0004 to 0.011) 0.003 (0.003 to 0.009)
Values are presented as beta  95% CI. Model 1: unadjusted; Model 2: adjusted for age, sex, MAP, heart rate and creatinine. P value less than 0.05. AIx, augmentation index; aPWV,
aortic pulse wave velocity; CC, compliance coefficient; DC, distensibility coefficient; PP, pulse pressure.
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Stratified scatterplots of ln-homocysteine with sex. Abbreviations: as in Tabl  1.
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and finally atherothrombosis [21–26,15]. During age, homocysteine is more 
important in the association with aPWV. This age-dependent effect might be 
explained by the fact that homocysteine is a more important cardiovascular 
risk indicator with advancing age, in comparison with traditional indictors. 
Nevertheless, future research will be necessary to investigate the underlying 
mechanisms.
The sex-effect of the association between ln-homocysteine and aortic stiff-
ness might be due to the fact that there are more extreme aPWV measure-
ments and higher homocysteine levels in males. In our study, higher homo-
cysteine levels are more strongly related to higher aPWV levels, therefore, 
this sex-effect strengths our hypothesis. A reason we did not demonstrate 
this association in females might be there are less females in our population. 
Therefore, we may not definitively conclude there is no association between 
ln-homocysteine and aPWV in women.
In our study, we did not observe an association between homocysteine level 
and AIx. This may be explained by the curvelinear pattern of the change 
of AIx with age, where a plateau is reached after the age of 60 years [27] 
and because augmentation is also influenced by other factors than stiffness, 
including peripheral resistance and cardiac performance [28]. Nevertheless, 
even though our participants were older than 65 years, we did observe a 
small correlation between AIx and aPWV. However, in concordance with the 
curvelinear hypothesis, this correlation decreased with advancing age. Homo-
cysteine level was not associated with distensibility coefficient and compliance 
coefficient in our study. The lack of an association between homocysteine level 
and distensibility coefficient and compliance coefficient in our study could 
possibly be explained by the fact that distensibility coefficient and compliance 
coefficient are also influenced by other factors, like systolic function. A second 
explanation might be that carotid distensibility coefficient and compliance 
coefficient are local measurements of the carotid artery, which is an elas-
tic artery. With aPWV, more territories are reflected, providing information 
about mainly elastic, but also muscular arteries. As structural and functional 
properties of the arterial wall differ within the arterial tree, it is plausible 
the pathophysiology of homocysteine differs between elastic and muscular 
arteries. However, this is hypothetical and there may be other underlying 
mechanisms. Even though aortic PP is closely related to arterial stiffness 
[29], we found no association between homocysteine level and aortic PP in 
our study and no age-dependent effect. This might endorse the hypothesis 
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that aortic PP is a more indirect measurement of arterial stiffness than aPWV, 
as PP will also be influenced by other factors like cardiac performance.
A potential limitation of the current study is the cross-sectional design; 
therefore, we cannot be certain that the observed associations are truly 
causal. We will further study the role of aortic stiffness in the currently run-
ning randomized intervention trial (B-PROOF). A second limitation is that, 
the B-PROOF trial included only participants with hyperhomocysteinemia. It 
is conceivable that the associations with cardiovascular disease and aortic 
stiffening will be different when lower homocysteine levels are taken into 
account. However, the adjusted reference value of aPWV for individuals aged 
70 years and over is 12.1 m/s [30]. In our population the mean aPWV is 14.3 
m/s, which is clearly higher compared with a general, nonhyperhomocystein-
emic population. Third, we cannot exclude the possibility that the association 
between homocysteine and aPWV is based on the play of chance, because 
other parameters of arterial stiffness are not associated with homocysteine. 
The relative small sample size of our population might explain why AIx, 
aortic PP, distensibility coefficient and compliance coefficient are not associ-
ated with homocysteine. However, aPWV is the most powerful measurement 
of arterial stiffness and might better reflect this condition compared with the 
other vascular parameters.
In conclusion, this study demonstrated a clear association between homo-
cysteine level and aortic stiffness, particularly in males. Overall, the strength 
of the association increased with advancing age. Homocysteine level is an 
important risk indicator of cardiovascular mortality in elderly and our findings 
may indicate that aortic stiffness is a mediator in this process. Nevertheless, 
our hypothesis remains to be confirmed by the currently running B-PROOF 
intervention trial.
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4.2.1 AbstrACt
Background and aims
Hyperhomocysteinemia is associated with arterial stiffness, but underlying 
pathophysiological mechanisms explaining this association are to be re-
vealed. This study was aimed to explore two potential pathways concerning 
the one-carbon metabolism. A potential causal effect of homocysteine was 
explored using a genetic risk score reflecting an individual’s risk of having 
a long-term elevated plasma homocysteine level and also associations with 
B-vitamin levels were investigated.
Methods and results
Baseline cross-sectional data of the B-PROOF study were used. In the 
cardiovascular subgroup (n=567, 56% male, age 72.6 ± 5.6 yrs) pulse 
wave velocity (PWV) was determined using applanation tonometry. Plasma 
concentrations of vitamin B12, folate, methylmalonic acid (MMA) and holo 
transcobalamin (holoTC) were assessed and the genetic risk score was 
based on 13 SNPs being associated with elevated plasma homocysteine. 
Associations were examined using multivariable linear regression analysis. 
B-vitamin levels were not associated with PWV. The genetic risk score was 
also not associated with PWV. However, the homocysteine – gene interaction 
was significant (p < 0.001) in the association of the genetic risk score and 
PWV. Participants with the lowest genetic risk of having long-term elevated 
homocysteine levels, but with higher measured homocysteine levels, had the 
highest PWV levels.
Conclusion 
Homocysteine is unlikely to be causally related to arterial stiffness, because 
there was no association with genetic variants causing hyperhomocyste-
inemia, whereas non-genetically determined hyperhomocysteinemia was 
associated with arterial stiffness. Moreover, the association between ho-
mocysteine and arterial stiffness was not mediated by B-vitamins. Possibly, 
high plasma homocysteine levels reflect an unidentified factor, that causes 
increased arterial stiffness.
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4.2.2 IntroduCtIon
Hyperhomocysteinemia has been shown to be an important cardiovascular 
risk indicator, especially in the oldest old [4]. Arterial stiffness is considered 
to be a pre-clinical state of cardiovascular disease and recently we have 
reported an association between plasma homocysteine level and arterial stiff-
ness within an older, mild hyperhomocysteinemic population [20]. Whether 
this association is truly causal is not yet known, in particular since trials with 
B-vitamin supplementation aimed to reduce plasma homocysteine concentra-
tions failed to demonstrate beneficial effects on cardiovascular outcomes [3]. 
A causal effect of homocysteine on the arterial stiffness process can be evalu-
ated by exploring the relation between genetic determinants of elevated 
homocysteine levels and arterial stiffness. Genetic polymorphisms are an 
inherited phenotype, being constant over time, reflecting long-term elevated 
homocysteine levels. Furthermore, genotypes are in principle not modified 
by disease processes and are not affected by non-genetic confounding, and 
is referred to as the Mendelian randomization principle [16]. Recently, van 
Meurs et al described a genetic risk score of hyperhomocysteinemia (GRS 
Hcy), consisting of a combination of the most common single nucleotide poly-
morphisms (SNPs), which are associated with high homocysteine levels [22]. 
An association between this risk score and arterial stiffness measurements 
would suggest a pathophysiological link as explained above. Such a causal 
effect of homocysteine could be initiated for example via the combination of 
increased thrombogenecity, increased oxidative stress and over-activation of 
redox-sensitive inflammatory pathways [8, 12, 15, 26]. Alternatively, homo-
cysteine may not be causally associated with arterial stiffness. A direct effect 
of vitamin B12 or folate on arterial stiffness is also possible, since these 
vitamins are essential in the one-carbon metabolism cycle and are strongly 
correlated with homocysteine. There are studies demonstrating an associa-
tion of B-vitamins levels with blood pressure [11, 17] and atherosclerosis [5, 
14], but to this date reports regarding arterial stiffness are lacking.
We aim to explore underlying mechanisms of different parts of the one-carbon 
metabolism cycle (Figure 4.2.1), that may underlie the association between 
plasma homocysteine and arterial stiffness. Therefore, we investigated the 
association between the genetic risk score of hyperhomocysteinemia and 
arterial stiffness and also the association between B-vitamin levels and arte-
rial stiffness.
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4.2.3 Methods 
Study population
The present study was conducted as a cross-sectional baseline analysis 
within the framework of the B-PROOF (B-vitamins for the Prevention of 
Osteoporotic Fractures) study. A detailed description of this randomized 
controlled trial has been reported elsewhere [23]. In short, B-PROOF is a 
multi-center, randomized, placebo controlled, double-blind trial including 
2919 participants from three areas in the Netherlands. Main inclusion crite-
ria were age 65 years and older, and a mildly elevated homocysteine level 
(12 – 50 μmol/l). Fifty-one percent of the approached population could be 
included based on their homocysteine level. Main exclusion criteria were 
renal insufficiency (serum creatinine level > 150 μmol/l) and presence of a 
malignancy. All participants gave written informed consent before the start 
of the study. The Wageningen Medical Ethics Committee approved the study 
protocol, and the Medical Ethics committees of Rotterdam and Amsterdam 
gave approval for local feasibility. 
Methionine
Homocysteine
Tetrahydrofolate
5-methyl-THF
5,10-methylene-THF
SAM
SAH
Cystathionine
Cysteine
MMA-CoA
Suc-CoA
MMA
FA
B2
B12
B6
B6 B12
Methionine-
synthase
MTHFR
Cystathionine-
β-synthase
Cystathionine-
y-lyase
methylmalonyl-
CoA mutase
Methionine-cycle
Folate-cycle
Figuur 4.2.1.
Vitamins, metabolites and enzymes which are involved in the one carbon metabolism. Ab-
breviations: THF: tetrahydrofolate; SAM: S-adenosylmethionine; SAH: S-adenosylhomocys-
teine; MTHFR: methylenetetrahydrofolate reductase; MMA: methylmalonic acid; MMA-CoA: 
methylmalonyl-CoA; Suc-CoA: succinyl-CoA; FA: folic acid; B12: vitamin B12; B2: vitamin 
B2; B6: vitamin B6. 
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At the Erasmus Medical Center (Rotterdam) and VU University Medical 
Center (Amsterdam), a subsample of participants underwent vascular mea-
surements (n = 567). Participants with cardiac arrhythmia were excluded 
from these additional measurements. During the measurements, partici-
pants were situated in supine position on a flat examination couch in a quiet 
laboratory room for at least 5-10 minutes prior to the measurements, and 
the participants were not allowed to speak during the measurements. Use of 
alcohol or coffee during 12 hours before the measurements was prohibited. 
Laboratory measurements
Venous blood samples were obtained in the morning, when the participants 
were in a fasted state, or had taken a restricted breakfast [23].
Measurements of folate and vitamin B12 status
Serum vitamin B12 and folate were measured using immunoelectrochemi-
luminescence assay (Elecsys 2010, Roche GmbH, Mannheim, Germany) (CV 
vitamin B12 5.1% at 125 pmol/l and 2.9% at 753 pmol/l; CV folate: 5.9% 
at 5.7 nmol/l and 2.8% at 23.4 nmol/l) [21]. Serum holotranscobalamin 
(HoloTC) was determined by the AxSYM analyser (Abbott) (CV<8%) and 
serum methylmalomic acid (MMA) was measured by LC-MS/MS (CV<9%) 
[6]. MMA also reflects vitamin B12 status, next to serum vitamin B12 level 
and homocysteine level and is considered as the most representative indica-
tor of metabolic vitamin B12 deficiency [1]. HoloTC is the fraction of vitamin 
B12 which is available for cells in the body, also referred to as active vitamin 
B12. HoloTC has a better diagnostic accuracy than vitamin B12 in order to 
detect vitamin B12 deficiency [6]. 
Homocysteine
For total homocysteine analysis, a plasma EDTA tube was stored in ice imme-
diately after blood drawing [23], and samples were processed within 4 hours in 
order to prevent a temperature- and time-dependent increase in plasma homo-
cysteine [13]. Plasma homocysteine was measured using the Architect i2000 
RS analyzer (VU University Medical Center, intra assay CV=2%, inter assay 
CV=4%) and LC-MS/MS (Erasmus intra assay CV=5.5%, inter assay CV=1.3%). 
Outcomes of the centers did not differ significantly at cross-calibration. 
Serum creatinine
Serum creatinine was measured with the enzymatic colorimetric Roche CREA 
plus assay (CV=2%). The estimated glomerular filtration rate (eGFR) was 
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calculated with the formula of Modification of Diet in Renal Disease in ml/
min/1.73m2: 186 * (serum creatinine (μmol/l) / 88.4) – 1.154 * age (years) 
– 0.203 * 0.742 (for females) [9].
Genotyping
DNA was isolated from buffycoats for genotyping. All participants were 
genotyped using the Illumina Omni-express array (Illumina Inc., San Diego, 
CA, USA) according to the manufacturers’ protocol and quality standards. 
The dataset was imputed to the HapMap v22 CEU reference panel (≈ 2.5 
million single-nucleotide polymorphisms [SNPs]). Hidden Markov Model-
based algorithms were used to infer unobserved genotypes probabilistically 
as implemented in either MACH [10]. Imputation quality control metrics 
included the ratio of observed/expected variance of the allele dosage ≤0.01. 
Genetic risk score of Hyperhomocysteinaemia (GRS Hcy) 
The GRS Hcy was generated as described by van Meurs et al [22]. The 
method outlined by Horne et al [7] was used, where the individual’s GRS 
is equal to the sum of the expected number of risk alleles at each SNP 
weighted by their effect sizes on plasma homocysteine (beta-coefficients, 
obtained from the homocysteine meta-analysis). The meta-analysis identi-
fied SNPs of 13 independent loci exceeding the GWAS threshold (p < 5∙10-8). 
These included 6 previously unreported loci in or near the genes MMACHC 
(p=2.1x10-9), SLC17A3 (1.0x10-8), GTPB10 (1.7x10-8), CUBN (p=7.5x10-10), 
HNF1A (1.2x10-12), and FUT2 (6.6x10-9). In addition, 7 loci previously re-
ported were confirmed to be associated with homocysteine levels at or near 
the MTHFR, MTR, CPS1, MUT, NOX4, DPEP1, and CBS genes.
The MTHFR genotype was explored also separately, because of its strong 
individual association with hyperhomocysteinemia [24].
Clinical measures
Height was measured in duplicate to the nearest 0.1 cm using a stadiometer, 
with the participant standing erect and wearing no shoes [23]. Weight was 
measured using a calibrated weighing device (SECA 761), with the participant 
wearing light garments without shoes and empty pockets, to the nearest 0.5 
kg [23]. Body Mass Index (BMI) was calculated as weight divided by squared 
height and expressed as kg/m2. Self-reported medical history, alcohol intake 
and smoking habits were determined using a questionnaire [23]. 
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Blood pressure measurement
Peripheral blood pressure at the time of vascular function tests was mea-
sured once with a semi-automatic oscillometric device (Datascope Accurator 
Plus device, Datascope Corp. New Jersey, USA) after at least five minutes of 
supine rest. Blood pressure measurements were conducted at the right arm 
and measured in mmHg. 
Applanation tonometry
Arterial tonometry was obtained from the right radial, right carotid and right 
femoral artery using the Sphygmocor device (Sphygmocor version 7.1, AtCor 
Medical, Sydney, Australia). Aortic pulse wave velocity (aPWV) was mea-
sured with a three channel ECG recording and simultaneously recording of 
the right carotid artery pulse wave form and subsequently the femoral artery 
pulse waveform. The aPWV was calculated as the delay between the femoral 
pulse wave and the carotid pulse wave, divided by the transit distance (intra 
CV = 5 %, inter CV = 8%). Transit distance was assessed with body surface 
measurement from the carotid artery to the femoral artery [19].
Statistical analysis
Normality of distributions was examined with histograms and Kolmogorov-
Smirnov tests. If a variable was not normally distributed, it was log-trans-
formed. Associations between B-vitamins and arterial stiffness measure-
ments were tested for linearity with curve estimation modeling. When linear 
relations had the best fit, we calculated Pearson correlation coefficients and 
subsequently tested the associations using multivariable linear regression 
analysis. Potential confounders were evaluated in a stepwise model and 
included age, gender, study center, eGFR, MAP, heart rate, smoking, alcohol 
consumption, presence of hypercholesterolemia and diabetes. Covariates 
were added to the final model as confounders if they caused a change of 
the point estimate (beta coefficient) of more than 10% or were considered 
clinically relevant. Furthermore, in a separate analysis, we tested whether 
homocysteine modified the association between B-vitamin levels and PWV 
measurements in order to further explore a potential direct effect of homo-
cysteine. If the interaction term homocysteine – B-vitamins was significant 
(p < 0.05), a stratified analysis was done comparing participants with ho-
mocysteine concentrations under and above the median. Because age was a 
significantly interacting in the association between homocysteine and PWV 
[20] we also tested the interaction between age and B-vitamin concentrations 
within the multivariable linear regression analysis and performed a stratified 
analysis based on the mean age if this interaction term was significant.
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Associations between GRS Hcy and PWV were also tested using multivari-
able linear regression analysis after confirmation of linearity. Next, ANCOVA 
was used to compare adjusted means of PWV values per quintile of GRS Hcy. 
Furthermore, the interaction between homocysteine level and GRS Hcy was 
examined in order to further explore causality. Stratification was performed 
based on homocysteine concentrations above and below the median if this 
interaction-term was significant (p < 0.05). Also we tested the interaction 
between age and GRS Hcy, because age was significantly interacting in the 
association homocysteine and PWV [20] and with this we could explore the 
survival effect of the SNPs. The same potential confounders mentioned above 
were used in a step-wise model. 
Statistical analyses were performed using the statistical software package 
of SPSS version 20.0 (SPSS Inc, Chicago, Illinois, USA). P-values < 0.05 
were considered to be statistically significant. 
4.2.4 results
Characteristics of the study population (n = 567) are shown in Table 1. The 
mean age of our population was 72.5 ± 5.6 years and 55.6% was male. The 
median homocysteine concentration was 14.2 [13.0 – 16.4] µmol/l. 
Plasma vitamin B12, folate, MMA and holoTC were all inversely correlated 
with plasma homocysteine concentrations (r = -0.29, p < 0.001 ; r = -0.30 
p < 0.001; r = 0.29, p < 0.001; r = -0.36, p < 0.001 respectively). MMA and 
holoTC were correlated with PWV (r = 0.13, p = 0.002; r = -0.10, p = 0.03), 
whereas vitamin B12 and folate were not. 
Multivariate linear regression analysis showed that folate, vitamin B12, MMA 
and holoTC were not associated with PWV (Table 2). In the associations 
between vitamin B12, folate, MMA and HoloTC with PWV, the interaction with 
homocysteine level was significant (p < 0.001, p < 0.001, p = 0.04, p = 0.004 
respectively). However, after stratification for low and high levels of homo-
cysteine we did not find any associations between B-vitamin levels and PWV. 
Although the age – B-vitamin level interaction was significant within all as-
sociations of B-vitamins with PWV, age-stratified analysis did not show other 
associations between different age groups (data not shown). 
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Homocysteine levels were higher in participants with the MTHFR-TT geno-
type, compared with the MTHFR-CC participants and MTHFR-CT genotype, 
but these differences were not significant ( p = 0.07 and p = 0.26 respec-
tively). PWV levels between the MTHFR genotypes did not differ ( p for trend 
= 0.08) (Figure 2). 
Table 1. Population characteristics vascular subgroup B-PROOF (n = 567)
Variable Mean ± SD
Age 72.5 ± 5.6 (range: 65 – 98)
Gender (n, %)
 Male
315 (55.6%)
BMI (kg/m2) 27.0 ± 3.7
SBP (mmHg) 137.7 ± 18.1
DBP (mmHg) 77.3 ± 9.6
Pulse wave velocity (m/s) 14.3 ± 4.5
Medical history of (n, %)
 CHD
 Hypertension
 TIA / Stroke
 Diabetes mellitus
 Hypercholesterolemia
61 (10.8%)
211 (37.2%)
45 (7.9%)
65 (11.5%)
151 (26.6%)
Laboratory values
Homocysteine (μmol/L) 14.2 [13.0 – 16.4]
Vitamin B12 (pmol/l) 291.6 ± 122.5
Folate (nmol/l) 20.5 ± 7.2
MMA (μmol/L) 0.26 ± 0.20
HoloTC (pmol/L) 68.1 ± 24.5
eGFR (ml/min per 1.73m2) 91.3 ± 35.9
Genotyping
MTHFR genotype (n = 508)
 CC
 CT
 TT
226 (44.5%)
205 (40.3%)
77 (15.2%)
GRS Hcy 0.90 ± 0.18
Values are presented as number and percentage or as mean ± SD or n (%), except for homo-
cysteine: median (IQR) and age: mean ± SD and (range). 
Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; PWV: pulse wave velocity; CHD: coronary heart disease; TIA: transient ischemic 
attack; MMA: methylmalomic acid; holoTC: holotranscobalamin; eGFR: estimated glomeru-
lar filtration rate; MTHFR: Methylenetetrahydrofolate reductase, GRS Hcy: genetic risk score 
homocysteine.
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The GRS Hcy explained approximately 1% of the variation in plasma ho-
mocysteine ( r = 0.10 ; p = 0.02) (Figure 4.2.3). No associations were 
observed between GRS Hcy and PWV levels (Table 3). Nevertheless, the 
lowest quintile of the GRS Hcy had signifi cant higher PWV levels compared to 
the highest quintile (p = 0.03) (PWV 14.2 m/s in quintile 1 compared to PWV 
13.9 m/s in quintile 5; data not shown). 
Subsequently, we investigated the ln-homocysteine - GRS Hcy interaction 
for the association between GRS Hcy and PWV. The interaction term was 
added to the model and was highly signifi cant (p = 0.54·10-4). Figure 4.2.4 
Table 2. Linear regression analysis of the association between B-vitamin status and the 
genetic risk score of hyperhomocysteinemia with PWV
Model 1 Model 2
Variable β (95%CI) β (95%CI)
Vitamin B12 (pmol/l) -0.003 [-0.006 ; 0.0001] -0.002 [-0.005 ; 0.001]
Folate (nmol/l) -0.022 [-0.079 ; 0.035] -0.027 [-0.079 ; 0.026]
MMA (μmol/l) -0.019 [-0.035 ; -0.002]* -0.010 [-0.026 ; 0.005]
HoloTC (pmol/l) 3.307 [1.209 ; 5.405] 1.600 [-0.391 ; 3.592]
GRS Hcy -2.09 [-4.34 ; 0.23] -0.63 [-2.77 ; 1.52]
B-vitamin status: Model 1: crude; Model 2: adjusted for age, gender, study center, MAP, heart 
rate, eGFR. 
GRS Hcy: Model 1: crude; Model 2: adjusted for age, gender and study center. 
* p < 0.05. 
Abbreviations: as in Table 1.
Figuur 4.2.2.
Values are depicted as Whiskers boxplots with estimated mean ± SE with 95% CI. Data are 
adjusted for age, gender, study center, MAP and heart rate. 
Abbreviations: as in Table 1.
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demonstrates the estimated adjusted PWV means per quintile of GRS Hcy, 
stratified by plasma homocysteine concentration. A trend of higher PWV 
levels was noticeable within the individuals with low genetic risk of higher 
homocysteine levels and higher measured plasma homocysteine concentra-
tions. However, the estimated means of PWV per stratum of homocysteine 
concentrations were not significantly different and the observed trend was 
Figuur 4.2.3.
54 38 36 55 46 46 39 50 47 46
Figuur 4.2.4.
Values are depicted as estimated means ± SE and are adjusted for age, gender, study center, 
MAP and heart rate. Lowest quintile indicates the lowest chance of having high Hcy levels and 
the highest quintile indicates the highest chance of having high Hcy levels. Number of subjects 
are presented in the bars. Abbreviations as in Table 1.
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also not significant (p = 0.09 for participants with homocysteine concentra-
tions above the median). 
Although the age – GRS Hcy interaction was significant in the association 
between GRS Hcy and PWV (p < 0.001), age-stratification analysis did not 
show any associations.
4.2.5 dIsCussIon
Our study demonstrates that in the association between the genetic risk 
score of hyperhomocysteinemia and PWV, the homocysteine – gene interac-
tion was significant. Therefore, the hypothesis that plasma homocysteine 
is causally related to arterial stiffness was not confirmed. Furthermore, in 
multivariable analysis we found no associations between B-vitamins and 
arterial stiffness and therefore the association between homocysteine and 
arterial stiffness is unlikely to be driven by B-vitamin levels.
To our knowledge, this is the first study addressing the association between 
B-vitamin levels and arterial stiffness in elderly. Despite the fact that folate 
has shown to affect endothelial function in vivo [25], we were not able to 
demonstrate an association of folate with PWV. Neither were vitamin B12, 
holoTC or MMA associated with this parameter. All in all, our results suggest 
that B-vitamins itself do not have a direct effect on the arterial stiffening 
process, which is supported by the fact that homocysteine is mediating the 
association between B-vitamin levels and PWV. Although, we should note we 
investigated these associations cross-sectionally.
Furthermore, we did not find evidence for a causal association between 
plasma homocysteine and arterial stiffness, as reflected by the lack of an as-
sociation between the GRS Hcy and arterial stiffness. Although a significant 
difference between the lowest and the highest quintile of the genetic risk 
score in PWV level was observed, this trend was opposite to the expected as-
sociation and the differences in PWV level between the quintiles were small. 
Thus, higher long-term plasma homocysteine concentrations according to 
the genetic risk score were associated with lower PWV levels. However, as 
was shown by stratification, most likely this inverse association was driven 
by participants with a low GRS Hcy, but with rather high measured plasma 
homocysteine levels. Since the plasma homocysteine – GRS Hcy interaction 
121
 C
h
ap
te
r 4
.2
 | 
B
-v
ita
m
in
 le
ve
ls
 a
nd
 G
R
S
 h
om
oc
ys
te
in
e 
no
t a
ss
oc
ia
te
d 
w
ith
 a
rt
er
ia
l s
tif
fn
es
s
significantly modified the association between GRS Hcy and PWV, this indi-
cates that the association between homocysteine and PWV is not causal. If 
homocysteine would be a causal factor in the arterial stiffness pathway, one 
would expect a positive association between GRS Hcy and PWV, instead of 
the negative association observed. It might be speculated that participants 
with genetically high homocysteine levels have other, undefined protective 
mechanisms regarding arterial stiffness. 
In our population, the GRS Hcy only explained about 10% of the variance 
in plasma homocysteine level, which accords with a previous report [22]. 
This relatively small effect may explain why our hypothesis of a causal effect 
of plasma homocysteine on arterial stiffness could not be confirmed. Fur-
thermore, as a consequence of the inclusion criteria of the B-PROOF study, 
our population only consisted of elderly with (mildly) elevated homocysteine 
levels and therefore is very selected. Because this GRS does not explain all 
the variance in homocysteine, the lack of an association does not definitely 
imply there is no causal relation between homocysteine and arterial stiff-
ness. Nevertheless, the fact that the homocysteine – GRS Hcy interaction 
was clearly present in the association between the GRS and PWV points 
more towards a non-causal relationship: possibly an unidentified factor may 
explain the association between homocysteine and arterial stiffness, other 
than being a direct B-vitamin or homocysteine effect. 
Furthermore, the absent association between the GRS Hcy and arterial stiff-
ness may be due to the relatively small sample size in terms of genetic 
analyses. Previously, we have reported a small effect of plasma homocysteine 
on the association with PWV [20] and since the GRS only explains 1% of the 
plasma homocysteine level, a strong association is not likely to be expected. 
Also, there is still the possibility that existing cardiovascular disease itself 
would increase plasma homocysteine levels and PWV. This reverse causa-
tion has been mentioned previously [2, 18]. Nevertheless, the fact that the 
homocysteine – GRS Hcy interaction was clearly present in the association 
between the GRS and PWV points towards a non-causal relationship. Possibly 
a yet unidentified factor may explain the association between homocysteine 
and arterial stiffness, other than being a direct B-vitamin or homocysteine 
effect. For example, via oxidative stress and activation of redox-inflammatory 
mechanisms, which lead to endothelial dysfunction or via thrombogenecity 
[8, 12, 15, 26].
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Despite the fact that a meta-analysis established an association between 
MTHFR and risk of cardiovascular disease [24], our study could not find an 
association with the MTHFR genotype and PWV, as being a preclinical marker 
for cardiovascular disease. Potentially the found association with clinical 
outcomes in the meta-analyses was driven by other factors than arterial 
stiffness. Last, we want to mention that we did not include blood pressure as 
an outcome variable, but only focused on arterial stiffness.
In conclusion, it is unlikely that homocysteine has a causal effect on arterial 
stiffness in older individuals. This is based on the lack of an association 
between genetic determinants of hyperhomocysteinemia and arterial stiff-
ness and in particular on the significant homocysteine – GRS Hcy interaction. 
Furthermore, B-vitamin levels were also not associated with measures of 
arterial stiffness. Homocysteine may rather be a risk indicator than a risk 
factor and potentially, high plasma homocysteine levels reflect an unidenti-
fied factor, that causes increased arterial stiffness at older age. 
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4.3.1 AbstrACt
Background
Hyperhomocysteinemia is an important cardiovascular risk indicator in the 
oldest old and is also associated with elevated arterial stiffness in this age 
group. Since several intervention trials reported a lack of benefit of B-vitamin 
supplementation on cardiovascular outcomes, we aimed to investigate the 
effect of B-vitamin supplementation on arterial stiffness and cardiovascular 
events in hyperhomocysteinemic elderly subjects. 
Methods and Results
The B-PROOF study is a double-blind randomized-controlled trial, including 
2919 elderly aged ≥ 65, with hyperhomocysteinemia (12-50 μmol/l), who 
were treated with B-vitamins (500 μg vitamin B12 and 400 μg folic acid) or 
placebo for 2 years. In a subgroup (n = 569) the effect of vitamin B12 and 
folic acid supplementation on pulse wave velocity (PWV) was investigated 
as measurement of arterial stiffness. Applanation tonometry was also used 
to assess central blood pressure and ultrasonography was used for carotid 
intima-media thickness measurement. In the total B-PROOF population in-
cidents of cardiovascular and cerebrovascular events were determined via 
structured questionnaires and blood pressure was measured. Compared to 
placebo, vitamin B supplementation lowered serum homocysteine by 3.6 
μmol/L (p<0.001). Analysis of covariance showed no effect of supplementa-
tion on PWV levels, but aortic pulse pressure was higher in the intervention 
than in the placebo group (49.6 mmHg vs. 47.2 mmHg; p =0.02). Further-
more, a significant reduction of cerebrovascular events in females (OR 0.33 
95%CI [0.15 ; 0.71]), but not in males was observed. 
Conclusions
Vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly 
has no effect on PWV and caused a modest increase in aortic pressure. 
However, this supplementation also leads to a reduction in cerebrovascular 
events in females. All in all, arterial stiffness is not likely to be the underlying 
pathway of the effect of vitamin B12 and folic acid supplementation on the 
observed treatment effects.
Clinical trial registration: Number: NCT00696514. URL: http://www.clini-
caltrials.gov/ct2/show/NCT00696514?term=NCT00696514&rank=1
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4.3.2 IntroduCtIon
Hyperhomocysteinemia has been shown to be an independent risk predictor 
of cardiovascular disease, in particular in the oldest old [1]. However, during 
the last decade, several trials failed to demonstrate a protective effect of 
homocysteine-lowering therapy with B-vitamin supplementation on cardio-
vascular disease and mortality outcomes, with the exception of stroke [2-4]. 
Whether this lack of overall benefit has to do with epidemiological and/or 
methodological issues or with nonexistence of a causal relationship between 
homocysteine and cardiovascular disease, is still under debate. 
A potential link between hyperhomocysteinemia and cardiovascular disease 
has been suggested to be arterial stiffness. Arterial stiffness is a risk factor 
for cardiovascular disease [6]. Recently, we have demonstrated that par-
ticularly in older individuals with elevated levels of arterial stiffness, that 
arterial stiffness and homocysteine level are associated [17]. Several trials 
investigating the effect of B-vitamin supplementation on arterial stiffness 
showed conflicting results [5-15]. Despite the fact that aortic-femoral pulse 
wave velocity (PWV) is considered to be the most robust marker of arterial 
stiffness [16], other measures of arterial stiffness have been used in these 
trials. 
Since in older populations elevated homocysteine levels are associated with 
both increased cardiovascular risk [1] and arterial stiffness [17], we aimed 
to investigate the effect of B-vitamin supplementation on arterial stiffness 
and cardiovascular events. The B-PROOF study, which is primarily designed 
to investigate the effect of homocysteine-lowering vitamin B12 and folic acid 
on fracture incidence [18], provided an excellent opportunity to investigate 
the effect of this intervention on arterial stiffness measures and other car-
diovascular outcomes.
4.3.3 Methods
Study participants
The B-PROOF trial is a multi-center, randomized, placebo-controlled, double-
blind, intervention study. B-PROOF is an acronym for ‘B-vitamins for the PRe-
vention Of Osteoporotic Fractures’. A detailed description of this randomized 
controlled trial has been reported elsewhere [18]. In short, the B-PROOF trial 
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included 2919 participants from three areas in the Netherlands from 2008 
till 2011 with a follow-up period of 2 years. Inclusion criteria were an age 
of 65 years or older, and an elevated homocysteine level (12 – 50 μmol/l). 
Fifty-one percent of the screened population could be included based on 
their homocysteine level. Main exclusion criteria were renal insufficiency 
(creatinine level > 150 μmol/l) and presence of a malignancy in the past five 
years. All participants gave written informed consent before the start of the 
study. The B-PROOF study has been registered within the Netherlands Trial 
Register (www.trialregister.nl) under identifier NTR 1333 since June 1, 2008 
and with ClinicalTrials.gov under identifier NCT00696514 since June 9, 2008.
The Wageningen Medical Ethics Committee approved the study protocol, and 
the Medical Ethics committees of Rotterdam and Amsterdam gave approval 
for local feasibility. In all B-PROOF participants, data regarding cardiovas-
cular events and blood pressure were collected and a random subsample of 
the B-PROOF participants underwent vascular measurements (n = 569) at 
the Erasmus MC (Rotterdam) or VU University Medical Center (Amsterdam). 
Intervention 
The intervention period comprised 2 years. Participants were randomly al-
located in a 1:1 ratio to the intervention group or to the placebo group. 
We stratified the randomization for study center, gender, age (65-80 years, 
≥ 80 years), and homocysteine concentration (12-18 μmol/L, ≥ 18 μmol/L). 
The random allocation sequence and randomization were generated and per-
formed using SAS 9.2 by an independent research dietician. The intervention 
group received a daily tablet with 500 μg vitamin B12 and 400 μg folic acid 
and the control group received a daily placebo tablet. Both tablets contained 
15 μg (600 IU) of vitamin D3 to ensure a normal vitamin D status [19]. The 
intervention and placebo tablets, were indistinguishable in taste, smell and 
appearance. Recruitment took place from August 2008 until March 2011. 
Baseline and follow-up evaluations
All data and measurements were obtained at baseline and at follow-up. Par-
ticipants were scheduled for a follow-up visit at 2 years after the intervention 
period. Adherence was judged by counting tablets, which the participants 
were asked to send back every 6 months. In case of non-reply, the partici-
pants were periodically phoned. Compliance was defined as more than 80% 
adherence over their two-year period, based on the total amounts of tablets 
returned during the study. 
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Clinical characteristics
Height was measured in duplicate to the nearest 0.1 cm, standing erect 
and wearing no shoes, using a stadiometer. Weight was measured with the 
participant wearing light garments without shoes and empty pockets to the 
nearest 0.5 kg using a calibrated weighing device (SECA 761). Body Mass In-
dex (BMI) was calculated as weight divided by squared height and expressed 
as kg/m2. All measurements were performed at the baseline visit and at the 
end of the intervention period after 2 years. 
Information regarding alcohol intake and smoking habits were collected 
using a structured questionnaire, which was administered both at the base-
line and follow-up measurements. 
Plasma homocysteine and serum vitamin B12, folate, methylmalomic acid 
(MMA), holo-transcobalamin (HoloTC) and creatinine were measured at 
baseline. Details regarding all laboratory measurements have been described 
elsewhere [18, 20]. The estimated glomerular filtration rate (eGFR) was 
calculated with the Modification of Diet in Renal Disease (MDRD) formula in 
ml/min/1.73m2: 186 * (serum creatinine (μmol/l) / 88.4) – 1.154 * age (years) 
– 0.203 * 0.742 (for females) [20].
Vascular measurements
As mentioned in the participant section, a random subsample of participants 
underwent vascular measurements at baseline (n = 569) at the Erasmus 
MC (Rotterdam) or VU University Medical Center (Amsterdam). Participants 
with cardiac arrhythmia were excluded from these additional measurements. 
During the measurements, participants were situated in supine position on a 
flat examination couch in a quiet laboratory room for at least 5-10 minutes 
prior to the measurements, and the participants were not allowed to speak 
during the measurements. Use of alcohol or coffee during 12 hours before 
the measurements was prohibited. The vascular measurements were again 
performed after the intervention period of two years. Also participants who 
dropped-out were invited to undergo the follow-up measurements. In total, 
497 participants had both baseline and follow-up measurements taken. 
Applanation tonometry
Arterial tonometry was obtained from the right radial, right carotid and right 
femoral artery using the Sphygmocor device (Sphygmocor version 7.1, AtCor 
Medical, Sydney, Australia). An estimate of the corresponding central aortic 
pulse wave was calculated, using a validated generalized transfer function 
incorporated in the device. With the integral software, the central augmented 
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pressure was calculated as the difference between the early and late systolic 
peaks of the estimated central pressure waveform. Central aortic augmenta-
tion index (AIx) was calculated as the augmented pressure expressed as a 
percentage of the pulse pressure (intra CV = 3%, inter CV = 5%). Aortic 
pulse wave velocity (PWV) was measured with three channel ECG recording 
and simultaneously recording of the right carotid artery pulse wave form and 
subsequently the femoral artery pulse waveform. The PWV was calculated 
as the delay between the femoral pulse wave and the carotid pulse wave, 
divided by the transit distance (intra CV = 5 %, inter CV = 8%). Transit dis-
tance was assessed with body surface measurement from the carotid artery 
to the femoral artery [16].
Carotid Intima Media Thickness (Carotid IMT)
For carotid B-mode ultrasonography, the L105 40 mm 7.5 MHz array trans-
ducer was used (Picus, Pie Medical Equipment, Maastricht, the Netherlands) 
on the right carotid artery. IMT is evaluated as the distance luminal - intimal 
interference and the media - adventitial interface (Art.Lab, Esoate Europe, 
Maastricht, the Netherlands) at approximately 1 cm from the carotid bifurca-
tion. In order to obtain accurate measurements, the standard deviation of 
the mean values of 6 independent measurements had to be < 10% of the 
mean (intra CV = 8%, inter CV = 15%).
Blood pressure measurement
In all participants (n = 2919), blood pressure levels were measured twice with 
a semi-automatic oscillometer (Omron M1 Plus, OMRON Corporation, Kyoto, 
Japan) and the levels of the measurement with the lowest diastolic value 
were used for analysis. The blood pressure measurement was performed at 
the baseline visit and after the 2-year intervention period. Hypertension was 
defined as a systolic blood pressure >140 mmHg and/or a diastolic blood 
pressure >90 mmHg, according to the guidelines of the WHO [21]. Pulse 
pressure was calculated as the systolic minus the diastolic blood pressure.
At the time of vascular function tests, peripheral blood pressure was mea-
sured once with a semi-automatic oscillometric device (Datascope Accurator 
Plus device, Datascope Corp. New Jersey, USA) after at least five minutes of 
supine rest. All blood pressure measurements were conducted at the right 
arm. The mean arterial pressure was measured and the pulse pressure was 
calculated as the systolic minus the diastolic blood pressure. 
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Cardiovascular disease incidence
Cardiovascular medical history and potential cardiovascular events of all 
B-PROOF participants (n = 2919) were determined using a structured ques-
tionnaire at both baseline and follow-up measurements by self-report from 
the participant. Furthermore, data regarding cardiovascular events were 
obtained prospectively from adverse events reports, which the participants 
could fill in at their calendars. Any type of cardiovascular disease was defined 
as myocardial infarction, angina pectoris, heart failure, cardiac valvular dis-
ease or arrythmia. Myocardial infarction was also used as a separate entity 
in our analyses. Cerebrovascular disease was defined as transient ischemic 
attack (TIA) or stroke. 
Statistical analysis
We calculated the vascular subgroup had to include 560 subjects in order 
to have a more than 90% power for a detection of an improvement of 0.3 
standard deviation (~ 2% change in PWV), taking into account an α-level of 
0.05. 
With regard to the analyses of the vascular outcomes, participants were 
included if both baseline and follow-up measurements were available. For 
cardiovascular disease incidence analysis, all randomized participants were 
included. 
PWV was defined as the primary outcome. Secondary outcomes included 
all other arterial stiffness parameters, cardiovascular disease outcomes and 
blood pressure. Both intention-to-treat (primary) and per protocol analyses 
(secondary) were performed for all primary and secondary outcome vari-
ables. In the intention-to-treat analyses, all participants were included. In 
the per-protocol analysis, all non-compliant participants were excluded. 
Normal distribution was checked for all outcome variables, and the treat-
ment groups were compared with respect to baseline characteristics. The 
student’s t-test was used for continuous variables and the chi-squared test 
for categorical variables. Mann-Whitney-U was used for variables, which 
were not normally distributed. 
Differences between treatment groups were analyzed with analyses of cova-
riance (ANCOVA), using the follow-up measurement as the dependent factor, 
the baseline measurement as covariate and the treatment allocation as the 
fixed between-subject factor. This analysis was done for all continuous out-
come measures. Before performing the ANCOVA, the assumption of linearity 
and homogeneity of variance was checked. The analysis of covariance was 
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first done unadjusted (but with adjustment for the baseline measurement). 
Secondly, covariates were included in the final model as potential confound-
ers when a variable was significantly different between the two treatment 
groups (p < 0.2) and contributed to a more than 10% change in F. Age, 
gender and study center were all added standard as covariate to the model. 
To investigate the effect of treatment in specific groups, interaction terms 
were tested for age, gender, cardiovascular disease history and homocysteine 
level. If an interaction term was significant (p < 0.05), a stratified analysis 
was done. Strata were created as age <80 vs. ≥ 80; men vs. women; the 
presence of a cardiovascular disease history vs. no cardiovascular disease 
history and homocysteine level < 18 μmol/l vs. ≥ 18 μmol/L. 
Binary logistic regression analysis was used for dichotomous variables, in 
which the follow-up measurement was used as the dependent and the treat-
ment group as fixed factor. Also this analysis was first analyzed unadjusted. 
Secondly, age, gender and study center were added as covariates and ad-
ditionally, all other covariates that differed between the treatment groups 
(p < 0.2) and led to a more than 10% change of the point estimate. Again, 
in order to investigate the effect of treatment in specific groups, interaction 
terms were tested and a stratified analysis was done if an interaction term 
was significantly associated with the outcome (p < 0.05) and strata were 
created as explained above. 
Statistical analyses were done with use of the statistical software package 
SPSS version 20.0 (SPSS Inc, Chicago, Illinois, USA). Two-sided p-values of 
< 0.05 were considered statistically significant for both ANCOVA and binary 
logistic regression analyses.
4.3.4 results
Characteristics of the study population
Participant disposition is demonstrated in Figure 4.3.1. In total, 2919 par-
ticipants could be included and were randomly allocated to the B-vitamin 
treatment (n = 1458) or placebo group (n = 1461). The mean age of the 
study population was 74 ± 6.5 years and 50% were male. Median homo-
cysteine level was 14.4 µmol/l. In Table 2 the vascular characteristics of 
the cardiovascular subgroup (n = 569) are depicted per allocation. In total, 
497 participants had both baseline and follow-up measurements available. 
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Mean age of this subpopulation was 73 years and 56% were male. Median 
homocysteine level was 14.3 µmol/l.
Both treatment groups were well-balanced regarding baseline characteristics 
and covariates both for the overall population as well as for the vascular 
subgroup (Table 1 & 2). Only holoTC concentrations were slightly different 
between the two groups in the overall group (p = 0.04) (Table 1). There 
were no differences between the two vascular subgroups with regard to 
covariates and the arterial stiffness measures (Table 2).
Comparing the vascular subgroup with the total B-PROOF population, the 
participants were somewhat younger (72.5 years vs 74.1 years in the overall 
population; p < 0.01) and more men were included (48.6% vs. 55.7% in the 
vascular subgroup; p < 0.01). Also, folic acid and holoTC levels were slightly 
higher in the vascular subgroup(p < 0.01 for all levels), whereas MMA levels 
Figuur 4.3.1.
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Table 1. Baseline characteristics of the B-PROOF study population
Placebo
(n = 1458)
Intervention
(n = 1461)
p-value
Age (yrs) 74.2 ± 6.4 74.0 ± 6.6 0.60
Male gender 734 (50.3%) 725 (49.6%) 0.70
Homocysteine level 
(umol/l)
14.5 [13.0 – 16.7] 14.3 [13.0 – 16.5] 0.30
Vitamin B12 level 
(pmol/l)
265.9 [203.9 – 343.4] 267.3 [212.9 – 341.2] 0.27
Folic acid level (nmol/l) 18.8 [14.7 – 21.2] 18.7 [14.7 – 24.4] 0.50
MMA (μmol/l) 0.23 [0.18 – 0.31] 0.22 [0.18 – 0.30] 0.25
Holo TC (pmol/l) 63.0 [45.0 – 84.0] 65.0 [48.0 – 86.0] 0.03
Creatinine (umol/l) 84.1 ± 18.0 83.9 ± 18.6 0.73
eGFR (ml/min per 
1.73m2)
91.3 ± 37.7 90.9 ± 39.2 0.80
Smoking (n, %)
 Former
 Current
821 (56.3%)
142 (9.7%)
828 (56.7%)
139 (9.5%)
0.97
Alcohol use (n, %)
 Light
 Moderate
 Excessive
 Very excessive
972 (66.7%)
422 (28.9%)
57 (3.9%)
5 (0.3%)
994 (68.0%)
417 (28.5%)
43 (2.9%)
7 (0.5%)
0.46
Supplement use daily 
(n, %)
 Vitamin B12
 Folic acid
216 (14.8%)
211 (14.5%)
207 (14.2%)
202 (13.8%)
0.88
0.87
Self-reported CV 
medical history (n, %)
 MI
 Any type CVD
 Cerebrovascular event 
 Hypercholesterolemia
 Diabetes
118 (8.1%)
279 (19,1%)
98 (6.7%)
278 (19.1%)
105 (7.2%)
97 (6.6%)
272 (18,6%)
100 (6.8%)
277 (19.0%)
128 (8.8%)
0.46
0.46
0.94
0.66
0.13
BMI (kg/m2) 27.2 ± 4.0 27.1 ± 4.0 0.70
Peripheral SBP (mmHg) 147.6 ± 20.1 148.4 ± 19.8 0.31
Peripheral DBP (mmHg) 79.0 ± 10.5 79.2 ± 11.3 0.61
Peripheral PP (mmHg) 68.6 ± 17.5 69.2 ± 16.5 0.39
Hypertension measured 
(n, %)
703 (48.2%) 756 (51.7%) 0.06
Values are depicted as means ± SD or as n (%), except for homocysteine, vitamin B12, folate, 
MMA and holoTC level which are provided as median [IQR]. 
Abbreviations: MMA: methylmalomic acid; holo TC: holotranscobalamin; eGFR: estimated 
glomerular filtration rate; MI: myocardial infarction; CVD: cardiovascular disease; BMI: body 
mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; 
Hypertension measured was defined as SBP > 140 mmHg and/or DBP > 90 mmHg.
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Table 2. Population characteristics of the vascular subgroup (n = 569)
Placebo
(n = 274)
Intervention
(n = 295)
p-value
Age (yrs) 72.5 ± 5.3 72.5 ± 5.8 0.99
Male gender 152 (55.5%) 165 (55.9%) 0.91
Homocysteine level (umol/l) 14.3 [13.0 – 16.6] 14.2 [13.0 – 16.3] 0.88
Vitamin B12 level (pmol/l) 271.9 [209.7 – 344.0] 272.9 [217.1 – 356.8] 0.67
Folic acid level (nmol/l) 19.2 [15.0 – 24.5] 20.1 [15.5 – 24.4] 0.21
MMA (μmol/l) 0.21 [0.17 – 0.29] 0.21 [0.17 – 0.26] 0.47
Holo TC (pmol/l) 68.0 [50.0 – 89.8] 72.0 [53.8 – 93.0] 0.23
Creatinine (umol/l) 83.7 ± 17.5 83.0 ± 16.8 0.67
eGFR (ml/min per 1.73m2) 92.1 ± 36.5 90.8 ± 35.1 0.67
Smoking (n, %)
 Former
 Current
92 (33.6%)
156 (56.9%)
26 (9.5%)
107 (36.3%)
161 (54.6%)
27 (9.2%)
0.80
Alcohol use (n, %)
 Light
 Moderate
 Excessive
 Very excessive
175 (63.9%)
83 (30.3%)
15 (5.1%)
2 (0.7%)
184 (62.4%)
96 (32.5%)
11 (3.7%)
4 (1.4%)
0.70
Supplement use daily (n, %)
 Vitamin B12
 Folic acid
42 (15.3%)
37 (13.5%)
37 (12.5%)
36 (12.2%)
0.53
0.63
Self-reported CV medical 
history (n, %)
 MI
 Any type CVD
 Cerebrovascular event 
 Hypercholesterolemia
 Diabetes
28 (10.2%)
60 (21.9%)
23 (8.4%)
77 (28.1%)
33 (12.0%)
18 (6.1%)
62 (21.0%)
22 (7.5%)
74 (25.1%)
32 (10.8%)
0.49
0.43
0.69
0.44
0.67
BMI (kg/m2) 27.0 ± 3.8 27.0 ± 3.6 0.93
Peripheral SBP (mmHg) 136.8 ± 18.1 138.8 ± 18.0 0.17
Peripheral DBP (mmHg) 77.2 ± 9.7 77.5 ± 9.7 0.69
Hypertension measured (n, %) 108 (39.4%) 128 (43.4%) 0.34
PWV (m/s) 14.2 ± 4.1 14.5 ± 4.9 0.44
AIx (%) 26.3 ± 9.9 26.1 ± 10.1 0.85
Aortic SBP (mmHg) 127.9 ± 18.5 129.3 ± 18.6 0.38
Aortic PP (mmHg) 49.7 ± 14.9 50.5 ± 15.4 0.52
Carotid IMT (μm) 727.5 ± 172.9 707.3 ± 153.5 0.22
Values are depicted as means ± SD or as n (%), except for homocysteine, vitamin B12, folate, 
MMA and holoTC level which are provided as median [IQR]. 
Abbreviations: MMA: methylmalomic acid; holo TC: holotranscobalamin; eGFR: estimated 
glomerular filtration rate; MI: myocardial infarction; CVD: cardiovascular disease; BMI: body 
mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; 
PWV: pulse wave velocity; AIx: augmentation index; IMT: intima media thickness. Hyperten-
sion measured was defined as SBP > 140 mmHg and/or DBP > 90 mmHg.
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were lower in the vascular subgroup (p < 0.01), but homocysteine levels did 
not differ. Further, the overall population had less hypertension ( 47.6% vs. 
59.8% in the vascular subgroup; p < 0.01) and DBP levels were lower in the 
total population (78.5 mmHg vs. 81.0 mmHg; p < 0.01). Other cardiovascu-
lar risk factors were similar between the overall population and the vascular 
subgroup. 
Effects on arterial stiffness measurements (vascular subgroup)
Analyzing the effect of the B-vitamin treatment, aortic PP after two years 
of intervention was significantly higher in the B-vitamin treatment group, 
compared to placebo (49.6 mmHg vs. 47.2 mmHg; p = 0.02) (Table 3). 
Also the aortic SBP tended to be higher, although not significant. PWV and all 
other vascular parameters did not differ between the groups. 
In per-protocol analysis, 93% of the participants in the intervention group 
and 90% of the participants in the placebo group remained. The effect on 
aortic PP pertained in this analysis with 49.9 mmHg in the intervention group 
versus 47.4 mmHg in the placebo group (p = 0.02). Also, the effects on the 
other outcomes did not change. 
Table 3. Estimated means of blood pressure and arterial stiffness parameters after 2 
years of intervention with vitamin B12 and folic acid supplementation investigated with 
ANCOVA according to the intention-to-treat principle
Placebo Intervention F p-value
n Estimated mean 
± SD
n Estimated mean 
± SD
Peripheral SBP 
(mmHg)
1284 144.7 ± 0.5 1285 146.0 ± 0.5 3.297 0.07
Peripheral DBP 
(mmHg)
1284 75.7 ± 0.3 1285 76.1 ± 0.3 0.891 0.35
Peripheral PP 
(mmHg)
1284 69.0 ± 0.4 1285 69.9 ± 0.4 2.282 0.13
PWV (m/s) 221 14.3 ± 0.3 243 14.2 ± 0.3 0.036 0.85
AIx (%) 233 28.8 ± 0.6 255 27.5 ± 0.6 2.471 0.12
Aortic SBP (mmHg) 234 123.7 ± 0.9 257 126.2 ± 0.9 3.714 0.06
Aortic PP (mmHg) 234 47.2 ± 0.7 257 49.6 ± 0.7 5.446 0.02
Carotid IMT (μm) 177 710.4 ± 11.1 198 705.8 ± 10.5 0.091 0.76
All estimated means are adjusted for the corresponding baseline measurement, age, gender 
and study center. Peripheral SBP and PP also adjusted for holoTC level, vitamin B12 level and 
the presence of diabetes. Peripheral DBP is also adjusted for holoTC level and MMA level. PWV, 
AIx, Aortic SBP and aortic PP are also adjusted for peripheral SBP.
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Within the vascular subgroup, the homocysteine level changed from 14.3 
μmol/l [IQR 13.0 – 16.6] to 14.9 μmol/l [IQR 12.8 – 17.0] in the placebo 
group (Δ 0.6 μmol/l) and decreased from 14.2 μmol/l [IQR 13.0 – 16.6] 
to 10.6 μmol/l [IQR 9.3 – 12.2] in the intervention group (Δ -3.6 μmol/l). 
Changes in homocyteine levels between female and male participants did 
not differ.
Blood pressure (overall population)
There were no differences in blood pressure indices between the intervention 
group and the placebo group (Table 2). Despite the fact that kidney func-
tion, vitamin B12 level and homocysteine level modified the treatment effect 
(p < 0.01; p = 0.04 and p = 0.02 respectively), stratified analyses did not 
show any effect of the intervention on blood pressure. Per protocol analyses 
did not change these results. 
The incidence of hypertension did not differ between the intervention (287 
cases) and placebo (321 cases) group (data not shown). There were no 
significant interaction-terms with treatment on the outcome of hypertension. 
Incidence of cardiovascular events (overall population)
Within the intervention group, the incidence of cerebrovascular events during 
the intervention period was lower, compared to placebo (46 incidents versus 
60 incidents; incidence proportion ratio: 0.75 [95% CI: 0.51 – 1.10]) (Table 
4). Age was a significant modifier in the treatment effect on cerebrovascular 
events (p < 0.01). However, stratification for participants under and above 
the age of 80 showed no differences in the reduction of cerebrovascular 
events between the age strata. Furthermore, the treatment effect on cere-
brovascular events was different between genders (p = 0.048). In women 
the incidence was lower (OR 0.33 95%CI [0.15 ; 0.71]), with 36 cases in 
the placebo group, compared to 16 cases in the intervention group (Figure 
4.3.2).
There were no differences between the treatment groups in the incidence 
of myocardial infarction or any other type of cardiac disease (Table 4). 
Second, a per-protocol analysis was performed with compliant participants 
only. This comprised 84% of both the placebo and the intervention group. 
Results were similar to those of the intention-to-treat analyses (data not 
shown). 
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Within the total B-PROOF population, the homocysteine level changed from 
14.5 μmol/l [IQR 13.0 – 16.7] to 14.3 μmol/l [IQR 12.4 – 17.0] in the placebo 
group (Δ -0.2 μmol/l) and decreased from 14.3 μmol/l [IQR 13.0 – 16.5] to 
10.3 μmol/l [IQR 8.9 – 12.0] in the intervention group (Δ -4.0 μmol/l). 
Table 4. The effect of vitamin B12 and folic acid supplementation on self-reported 
cardiovascular outcomes investigated with logistic regression analysis according to the 
intention-to-treat principle
Model 1 Model 2
N of cases 
in placebo 
group
N of 
cases in 
intervention 
group
OR ± 95% CI p-value OR ± 95% CI p-value
MI 43 45 1.05 
[0.68 ; 1.60]
0.84 1.19 
[0.66 ; 2.14]
0.56
Any type CVD 170 181 1.07
[0.86 ; 1.35]
0.53 1.08 
[0.86 ; 1.36]
0.50
Cerebrovascular 
event
60 46 0.76 
[0.52 ; 1.13]
0.17 0.72 
[0.45; 1.15]
0.17
Model 1: unadjusted. Model 2: variables were adjusted for age, gender, study center. MI was 
also adjusted for holoTC and diabetes. TIA was also adjusted for diabetes.
Abbreviations as in Table 1.OR: odds ratio; CI: confidence interval.
Figuur 4.3.2.
Values are depicted as OR ± 95%CI demonstrating the effect of the B-vitamin intervention. Analyses 
were performed according to the intention-to-treat principle. Outcomes were only included in the 
figures when the gender*treatment interaction was significant in the logistic regression analysis. 
Abbreviations: as in Table 1.
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4.3.5 dIsCussIon
Within this randomized, double-blind, placebo-controlled trial in elderly, hy-
perhomocysteinemic subjects, we observed that the 2-year intervention with 
vitamin B12 and folic acid did not affect PWV. Moreover, vitamin B12 and folic 
acid supplementation modestly raised aortic pulse pressure, whereas, para-
doxically, the number of cerebrovascular incidents was reduced, although 
only in females. Finally, no effect on any type of cardiac event, including 
myocardial infarction, was observed in females or males after 2-years of 
B-vitamin supplementation. 
Since homocysteine-lowering therapy is thought to have a direct effect on the 
human vasculature, treatment with B-vitamins [22] is assumed to decrease 
cardiovascular risk. However, the arterial stiffening process is also known to 
have a limited reversibility. In concordance with this hypothesis, we did not 
observe a treatment effect on PWV levels, our main outcome. 
Recent meta-analyses have shown contradictory effects of B-vitamin supple-
mentation on cardiovascular disease with a lowering of cerebrovascular 
events but no effect on coronary heart disease [2-4]. Our finding of a reduc-
tion of cerebrovascular events in females after vitamin B12 and folic acid 
supplementation agrees with these findings. However, in the meta-analyses 
no difference between males and females with regard to cerebrovascular 
risk reduction was observed. Differences in age or level of homocysteine 
could not explain the difference we found for gender, since in the model 
adjustment for age and homocysteine levels did not modify the treatment 
effect. However, since this is a sub-group analysis, we need to consider the 
possibility of this being a chance finding. 
Atherosclerosis, thrombo-embolic events and bleedings may all underlie 
cerebrovascular disease, as a consequence cerebrovascular disease is a 
much more heterogeneous condition than coronary artery disease, which 
is due to a local thrombo-embolic process [23]. The difference in etiology 
between cerebrovascular disease and coronary artery diseases may account 
for the difference in effect of vitamin B supplementation between the two 
conditions. Of note, carotid intima-media thickness as a marker of athero-
sclerosis [24], was not influenced by B-vitamin supplementation.
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Regardless of the effect of B-vitamins supplementation on lowering cardio-
vascular risk, increased homocysteine levels are an important cardiovascular 
risk predictor in elderly, that can well predict future cardiovascular events 
in this specific population, in particular compared to the Framingham risk 
score [1]. Furthermore, homocysteine levels tend to decrease more when 
hyperhomocysteinemia is present [22]. Therefore, we hypothesized that if 
homocysteine-lowering therapy indeed lowers cardiovascular risk, this would 
be most clearly demonstrable in older, hyperhomocysteinemic individuals. 
However, besides the beneficial effect on cerebrovascular events in females, 
we did not observe an effect of vitamin B12 and folic acid supplementation 
on myocardial infarction or other cardiac diseases. However, it needs to be 
mentioned that our study was not powered to detect differences in cardio-
vascular events. 
Aortic pulse pressure was higher in the intervention than in the placebo 
group. Remarkably, this rise in aortic pulse pressure occurred despite the 
fact that PWV levels did not change. An increase in central blood pressure 
levels without a change in PWV levels can either reflect a cardiac underlying 
mechanism or a difference in effect between small and large arteries. Cen-
tral arterial pressure also depends on cardiac performance and peripheral 
resistance [25, 26]. Possibly, lowering of elevated homocysteine levels is 
associated with small rise in peripheral resistance resulting in an increase in 
aortic pressure. 
The homocysteine controversy theory needs discussion in light of the para-
doxical perspective described above [27]. It has been described that on the 
one hand there could be a direct harmful effect of B-vitamin supplementation 
on the vascular wall related to an inflammatory response [27], while on the 
other hand a beneficial effect is obtained via homocysteine-lowering per se. 
Although pathophysiological evidence regarding this hypothesis is still lack-
ing, our study adds that arterial stiffness is not involved in this pathophysi-
ological pathway. On the other hand, our finding that central pulse pressure 
levels were higher in the group treated with B-vitamins despite unchanged 
PWV may indicate that B-vitamin supplementation has an adverse effect on 
peripheral resistance. This potential adverse effect on peripheral resistance 
requires further exploration as it is in line with the paradox hypothesis. 
There are several limitations to this study. First, cardiovascular outcomes 
were not the main outcome of this trial. Therefore the cardiovascular in-
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cidents were self-reported with the help of a structured questionnaire and 
not verified by general practitioner or hospital. This may have lead to an 
underestimation of the effect, however there is no reason to assume that 
our structured reporting form of the incidents would differ between the two 
groups. Second, our population consisted of mildly hyperhomocysteinemic 
elderly participants because of the anticipated effect of B-vitamin supple-
mentation in this particular group. Results are therefore not generalizable 
to the general population. However, since almost 50% of the general elderly 
population in the Netherlands [28] has mildly elevated homocysteine levels, 
it is a relevant group to address the effect of lowering of homocysteine levels 
on cardiovascular parameters. Third, we acknowledge that the follow-up 
period of 2 years is relatively short for cardiovascular outcome parameters. 
Our study was designed to study the effect of vitamin B12 and folic acid 
supplementation on PWV and for this parameters a 2 year intervention is 
considered to be sufficient, because PWV is known to respond quickly as 
other trials with PWV as outcome variable have shown. Strengths of the 
study are the multiple cardiovascular outcomes, which makes us able to give 
a full overview of the effects on arterial stiffness, arteriosclerosis and car-
diovascular events. Furthermore, our elderly population is of special interest 
since it has been shown that with age cardiovascular risk profile changes [1]. 
Since there are no trials conducted within an elderly population, our study 
adds knowledge about the homocysteine-lowering effect of this particular 
population. 
Finally, it is important to note that more cancer cases were reported in the 
participants treated with B-vitamin supplementation compared to participants 
who received placebo (unpublished data; van Wijngaarden,J.P. et al. Effect 
of daily vitamin B12 and folic acid supplementation on fracture incidence in 
elderly with an elevated plasma homocysteine level: B-PROOF, a random-
ized controlled trial. Submitted). Therefore caution is warranted for future 
research regarding the effects of vitamin B12 and folic acid supplementation. 
In conclusion, vitamin B12 and folic acid supplementation did not affect PWV 
levels after a treatment duration of two years. Furthermore, despite the 
fact that homocysteine-lowering therapy reduced cerebrovascular incidents 
in females, it also was associated with an increase aortic pulse pressure. All 
in all, our findings indicate that arterial stiffness is unlikely the underlying 
pathway of the effect of vitamin B12 and folic acid supplementation on cere-
brovascular or other cardiovascular events. Further studies are still needed 
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to determine the effects of B-vitamin supplementation on cardiovascular 
outcomes with more certainty as well as the potential underlying pathways. 
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4.4.1 AbstrACt
Introduction
B-vitamin trials failed to demonstrate beneficial effects on cardiovascular 
outcomes, but hyperhomocysteinemia still stands out as an independent 
cardiovascular risk indicator, particularly in elderly. B-vitamins may influence 
early vascular dysfunction, such as endothelial dysfunction, or may have 
adverse effects, for example on inflammation. We investigated the effect of 
B-vitamins on endothelial function and inflammation within an intervention 
study. 
Methods
This study was conducted within the framework of the B-PROOF trial, which 
included 2919 hyperhomocysteinemic elderly, who received daily vitamin B12 
(500 μg) and folic acid (400 μg) or placebo for 2 years. Using an electroche-
miluminescence platform, we measured Intercellular Adhesion Molecule 1 
(ICAM-1), Vascular Adhesion Molecule 1 (VCAM-1), serum amyloid A (SAA), 
vascular endothelial growth factor (VGEF) and C-reactive protein (CRP) both 
at baseline and follow-up in a subsample of 522 subjects (271 intervention 
group; 251 placebo). Treatment effects were analyzed with ANCOVA.
Results
The subjects had a mean age of 72 years and 55% of them was male. With 
2-year follow-up, B-vitamins did not change the ICAM-1 (+36% change in 
the intervention group versus +32% change in the placebo group; p = 0.72), 
VCAM-1 (+27% versus +25%; p = 0.39), VEGF (-1% versus +4%; p = 
0.40), SAA (+34% versus +38%; p = 0.85) or CRP levels (+26% versus 
+36%; p = 0.70) as compared to placebo. 
Conclusion
In elderly patients with hyperhomocysteinemia, vitamin B12 and folic acid 
are unlikely to influence either endothelial function or low-grade systemic 
inflammation.
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4.4.2 IntroduCtIon
Hyperhomocysteinemia is an independent risk indicator for cardiovascular 
disease, in particular among the oldest old [1]. Over the years, several 
homocysteine-lowering trials with B-vitamins have been performed, how-
ever, no beneficial effects on cardiovascular disease or venous thrombosis 
have been observed [2], with the possible exception of stroke [3, 4]. To date, 
this overall lack of benefit of lowering homocysteine remains unexplained. 
One possible explanation is that the association between homocysteine and 
cardiovascular disease is not causal. Alternatively, it has been proposed that 
beneficial cardiovascular effects of homocysteine-lowering therapy could be 
masked by adverse effects of high-dose B-vitamins, such as an increase in 
proliferation or inflammation [5]. 
It is possible that B-vitamins only influence vascular dysfunction at an 
early stage, like endothelial dysfunction, rather than benefit the process of 
advanced atherosclerosis or arterial stiffness. Earlier, we demonstrated no 
effects of B-vitamins on arterial stiffness and intima-media thickness, a sur-
rogate measure of atherosclerosis [6]. An increased homocysteine level has 
previously been related to endothelial dysfunction [7-10]. If homocysteine 
lowering therapy would have a favorable effect on endothelial function, the 
time required to see this translated into clinical endpoint may be considerably 
longer than the 2-5 years follow-up of the current homocysteine lowering 
intervention trials. 
Trials investigating the effect of B-vitamins on endothelial function usu-
ally measured flow-mediated dilatation, for which the results are conflict-
ing [11-16]. There were also several small trials investigating the effects 
of B-vitamins on endothelial biomarkers, again with conflicting results [13, 
17-20]. Most of these trials were performed in selected populations, like 
patients with coronary artery disease or diabetes, and did not select patients 
with high baseline homocysteine. Also, these trials were of relatively short 
duration (longest 40 weeks), and included relative few subjects (max 90 
subjects). Furthermore, only a small variety of biomarkers were used, and 
data regarding the more important and relevant markers of endothelial func-
tion (ICAM, VCAM, VGEF [21-25]) were often lacking. 
As an alternative explanation for the lack of clinical benefit, adverse ef-
fects of high doses of B-vitamins on the cardiovascular system have been 
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postulated. Folate fuels one carbon metabolism, and may stimulate many 
metabolic active cells, including proliferating or inflammatory cells. Since 
the atherosclerotic process is partly inflammatory, involving macrophages 
and T-cells, it is possible that folate enhances inflammation in atheroscle-
rotic lesions, which makes them prone to rupture [5]. Direct assessment 
of inflammation in atherosclerotic lesions is difficult, but the response of 
inflammatory biomarkers to B-vitamins may represent a proof-of-concept for 
pro-inflammatory effects of B-vitamins. 
Based on these considerations, we set out to study the effects of B-vitamins 
on biomarkers of endothelial function and inflammation in a large, population 
of hyperhomocysteinemic elderly subjects.
4.4.3 Methods
Study participants
The B-PROOF trial is a multi-center, randomized, placebo-controlled, double-
blind, intervention study. B-PROOF is an acronym for ‘B-vitamins for the PRe-
vention Of Osteoporotic Fractures’. A detailed description of this randomized 
controlled trial has been reported elsewhere [26]. In short, the B-PROOF trial 
included 2919 participants from three areas in the Netherlands. Inclusion 
criteria were age of 65 years and older, and an elevated homocysteine level 
(12 – 50 μmol/l). Fifty-one percent of the screened population could be 
included based on their homocysteine level. The main outcome was osteo-
porotic fractures. Main exclusion criteria were renal insufficiency (creatinine 
level > 150 μmol/l) and presence of a malignancy in the past five years. All 
participants gave written informed consent before the start of the study. 
The B-PROOF study has been registered with the Netherlands Trial Register 
http://www.trialregister.nl under identifier NTR 1333 since June 1, 2008 and 
with ClinicalTrials.gov under identifier NCT00696514 since June 9, 2008. The 
Wageningen Medical Ethics Committee approved the study protocol. At the 
baseline measurement, participants were invited for vascular measurements 
and dual X-ray absorptiometry. In total, 522 participants underwent both 
additional measurements. Within this group, we measured biomarkers for 
endothelial function and inflammation.
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Intervention
The intervention period comprised 2 years. Participants were randomly al-
located in a 1:1 ratio to the intervention group or to the control group. We 
stratified the randomization for study center, gender, age (65-80 years, ≥ 80 
years), and homocysteine concentration (12-18 μmol/L, ≥ 18 μmol/L). The 
intervention group received a daily tablet with 500 μg vitamin B12 and 400 
μg folic acid, and the control group received a daily placebo. Both tablets 
contained 15 μg (600 IU) vitamin D3 to ensure a normal vitamin D status 
[27]. The intervention and placebo tablets, produced by MCO Health, Al-
mere, the Netherlands, are indistinguishable in taste, smell and appearance. 
The random allocation sequence and randomization were generated and 
performed using SAS 9.2 by an independent research dietician. Recruitment 
took place from August 2008 until March 2011. 
Baseline and follow-up evaluations
All data and measurements were obtained at baseline and at follow-up. Par-
ticipants were scheduled for a follow-up visit at 2 years after the intervention 
period. Adherence was judged by counting tablets, which the participants 
were asked to send back every 6 months. In case of non-reply, the partici-
pants were periodically phoned. Compliance was defined as more than 80% 
adherence over their two-year period, based on the total amounts of tablets 
provided during the study. 
Clinical characteristics
All measurements were performed at the baseline visit and at the end of 
the intervention period after 2 years. Alcohol intake, smoking habits, car-
diovascular history and the presence of diabetes were determined using a 
structured questionnaire [26], which was requested at both baseline and at 
the follow-up measurements. 
Laboratory measurements
Homocysteine and creatinine
Plasma homocysteine, serum creatinine , vitamin B12, folate, methylmalo-
mic acid (MMA) and holo- transcobalamin (holoTC) were measured. Details 
regarding laboratory techniques are described elsewhere [26, 28]. The esti-
mated glomerular filtration rate (eGFR) was calculated with the Modification 
of Diet in Renal Disease (MDRD) formula in ml/min/1.73m2 [29]. 
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ICAM-1, VCAM-1, SAA, VEGF, CRP
A multi-array electrochemiluminescence platform (MesoScale Discovery, 
Gaithersburg, MD, USA, www.mesoscale.com) was used to measure Intercel-
lular Adhesion Molecule 1 (ICAM-1), Vascular Adhesion Molecule 1 (VCAM-1), 
serum amyloid A (SAA), and C-reactive protein (CRP) simultaneously in se-
rum. For vascular endothelial growth factor (VGEF), a single-array platform 
was used. Each serum sample was frozen after the drawn at baseline or 
follow-up and both baseline and follow-up samples were measured simulta-
neously. The samples were measured singular and all measurements were 
done within a period of 30 days. 
Statistical analysis
For comparisons between treatment groups, the student’s t-test was used 
for continuous variables and the chi-square test for categorical variables. 
Mann-Whitney-U was used for variables which were not normally distributed. 
Both intention-to-treat and per-protocol analyses were performed. In the 
intention-to-treat analyses, all participants for whom both a baseline and 
follow-up measurement were available were included. In the per-protocol 
analysis, all non-compliant participants were excluded. 
Associations between homocysteine levels and endothelial markers at base-
line were tested using multivariable linear regression analysis, with standard 
adjustment for age, gender, study center and eGFR. 
Differences between treatment groups were analyzed with analyses of 
covariance (ANCOVA), using the follow-up measurement as the dependent 
factor, the baseline measurement as covariate and treatment allocation as 
the fixed between-subject factor. This analysis was done for all continuous 
outcome measures. Before performing the ANCOVA, the assumption of 
linearity and homogeneity of variance was checked. The ANCOVA was first 
done unadjusted. Secondly, covariates were included in the final model as 
potential confounder, if a variable was different between the two treatment 
groups (p < 0.2) and contributed to a more than 10% change in F. Age, 
gender and study center were all added standard as covariate to the model. 
To investigate the effect of treatment in specific groups, interaction terms 
with treatment were tested for age, gender, cardiovascular disease history, 
homocysteine level, vitamin B12 and folic acid level. If an interaction term 
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was significant (p < 0.05), stratified ANCOVA was performed. For continuous 
variables, strata were created based on tertiles. 
In order to account for biological variability of the biomarkers of interest, 
and to increase statistical power, aggregate scores of endothelial function 
and inflammation were created. First, we calculated the differences between 
baseline and follow-up of all biomarkers. From this, we calculated overall Z-
scores by dividing the difference of the participants individual level minus the 
mean level, through the standard deviation of the total population. Of these 
Z-scores, means were calculated. The inflammation score included CRP, SAA 
and ICAM-1. The endothelial function score included ICAM-1, VCAM-1 and 
VEGF. ICAM-1 is expressed both in monocytes and the endothelium and was 
therefore included in both scores [30].
Statistical analyses were done with use of the statistical software package 
SPSS version 20.0 (SPSS Inc, Chicago, Illinois, USA). Two-sided p-values of 
< 0.05 were considered statistically significant.
4.4.4 results
The study population consisted of 522 participants; a subsample of the 
total B-PROOF study population in whom biomarker data were collected. 
The characteristics of this subsample are shown in Table 1. Of the 522 
participants, 271 had been assigned to the intervention group and 251 to 
the placebo group. Both groups were well-balanced with regard to baseline 
characteristics and covariates (Table 1). Median homocysteine level was 
14.2 [interquartile range 12.9-16.4] µmol/l. As compared to the total B-
PROOF population, the mean age, homocysteine level and the number of 
males were similar. 
At baseline, there was no association between homocysteine level and CRP, 
SAA, ICAM-1 or VCAM-1. There was a significant association between homo-
cysteine level and VEGF level (beta 132.7 pg/ml [95% CI 55.6 ; 209.8]; p = 
0.001) (Figure 4.4.1). 
B-vitamin treatment had no effect on individual plasma biomarkers of en-
dothelial function or on endothelial Z-scores (Table 2). With ICAM-1 levels, 
there was a 36% change in the intervention group and a 32% change in 
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Table 1. Characteristics of the study population at start of the B-PROOF study
Placebo group
(n = 251)
Intervention group
(n = 271)
Age (yrs) 72.3 ± 5.3 72.4 ± 5.7
Male (%) 55.4% 54.6%
Smoking (%)
 Never
 Former
 Current
35%
56%
10%
38%
54%
7%
Alcohol use (%)
 Light
 Moderate
 Excessive
 Very excessive
64%
30%
6%
1%
65%
32%
3%
1%
Pre-study supplement use, 
daily (%)
 Vitamin B12
 Folic acid
16%
14%
13%
13%
Self-reported CVD history (%)
 Coronary heart disease
 TIA / Stroke
 Hypertension
 Hypercholesterolemia
 Diabetes
13%
8%
40%
27%
10%
9%
6%
35%
26%
10%
BMI (kg/m2) 27.0 ± 3.7 27.1 ± 3.8
SBP (mmHg) 132.0 ± 32.7 135.2 ± 32.8
DBP (mmHg) 96.4 ± 30.8 93.8 ± 29.4
Hypertension (%) * 34.3% 38.7%
Homocysteine (µmol/l) 14.4 [12.9-16.7] 14.1 [13.0-16.2]
Vitamin B12 (pmol/l) 287.9 ± 132.2 293.4 ± 109.7
Folate (nmol/l) 21.1 ± 8.9 22.1 ± 9.8
MMA (µmol/l) 0.2 [0.2 – 0.3] 0.2 [0.2-0.3]
Holo TC (pmol/l) 69.0 [48.8-90.0] 72.0 [54.0-93.0]
Creatinine (µmol/l) 83.8 ± 17.4 82.8 ± 16.3
CRP (ng/ml) 3.1 ∙104 ± 6.3 ∙104 3.1 ∙104 ± 5.6 ∙104
SAA (ng/ml) 8.8 ∙104 ± 1.3 ∙105 9.1 ∙104 ± 1.3 ∙105
ICAM-1 (ng/ml) 3.6 ∙103 ± 3.9 ∙103 3.4 ∙103 ± 3.6 ∙103
VCAM-1 (ng/ml) 6.1 ∙103 ± 6.6 ∙103 5.6 ∙103 ± 6.0 ∙103
VEGF (pg/ml) 4.1 ∙10-3 ±3.1 ∙10-3 4.3 ∙10-3 ± 3.6 ∙10-3
Values are depicted as mean ± SD or as %, with the exception of homocysteine, MMA and ho-
loTC which are demonstrated as medians with interquartile ranges. 
Abbreviations: MMA: methylmalomic acid; HoloTC: holotranscobalamin; eGFR: estimated glo-
merular filtration rate; TIA: transient ischemic attack; BMI: body mass index; SBP: systolic 
blood pressure; DBP: diastolic blood pressure; CRP: c-reactive protein; SAA: serum amyloid 
A; ICAM-1: intercellular adhesion molecule 1; VCAM-1: vascular adhesion molecule 1; VEGF: 
vascular endothelial growth factor. 
*Hypertension was defined as a SBP > 140 mmHg and/or DBP > 90 mmHg [42].
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the placebo group between baseline and follow-up (p = 0.72). For VCAM-1 
levels, the intervention group levels changed 27% versus 25% in the placebo 
group (p = 0.39), and according VEGF levels there was no change between 
baseline and follow-up in both groups (-1% versus +4%; p = 0.40). In Table 
3 we demonstrate there was no effect of B-vitamin treatment on individual 
plasma inflammatory markers or on the inflammation Z-score. SAA levels 
changed with 34% during two year follow-up in the intervention group and 
with 38% in the placebo group (p = 0.85). CRP levels increased with 26% in 
the intervention group versus 36% in the placebo group (p = 0.70). 
The presence of cardiovascular disease appeared to be a significant effect 
modifier for the treatment effect on SAA (p = 0.045). Stratified analysis for 
participants with and without cardiovascular disease did not demonstrate a 
treatment effect of B-vitamins in one of these strata. A different effect of 
B-vitamin treatment was seen in the change of SAA levels between follow-up 
and baseline between the strata. In individuals without cardiovascular dis-
ease, B-vitamins caused a 17% increase of SAA levels, whereas in persons 
with a cardiovascular history, SAA levels increased with 77% (Figure 4.4.2). 
In per-protocol analysis, 98 % of the participants remained in the interven-
tion group and 95 % of the participants in the placebo group. Also with this 
analysis we observed no treatment effect of vitamin B12 and folic acid on 
endothelial function or inflammation.
Figuur 4.4.1.
This figure demonstrates the association between homocysteine level and VEGF cross-sec-
tionally at the baseline measurement. Abbreviations as in Table 1.
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4.4.5 dIsCussIon
In our study, no effect of vitamin B12 and folic acid on 2-year changes in 
plasma biomarkers of endothelial function and inflammation was observed in 
hyperhomocysteinemic elderly subjects. 
Other studies on the effect of B-vitamins on endothelial function showed con-
flicting results. Some suggested a beneficial effect, whereas others showed 
no effect at all [11-20, 31-33]. Most of these studies had a short follow-up 
time (maximum of 40 weeks) and were done in specific populations. If a 
treatment effect of homocysteine-lowering therapy with B-vitamins is pres-
ent, it would conceivably be observed most clearly in subjects with increased 
Table 2. Changes in endothelial markers during two-year follow-up for both placebo 
and intervention group.
Placebo group Intervention group p-value
 Baseline Follow-up change Baseline Follow-up change
ICAM-1 (ng/ml) 3620.6 4790.6 +32% 3426.3 4646.9 +36% 0.72
VCAM-1 (ng/ml) 6112.6 7668.4 +25% 5610.3 7116.9 +27% 0.39
VEGF (pg/ml) 0.0041 0.0043 +4% 0.0043 0.0043 -1% 0.40
Aggregated 
endothelial 
function Z-score
+0.01 -0.02 0.58
Analysis was done with ANCOVA and adjusted for age, gender and study center and baseline 
value. The aggregated endothelial function score included ICAM-1, VCAM-1 and VEGF and was 
based on the Z-scores of the change between baseline and follow-up per biomarker. p-values 
show the outcome for ANCOVA analysis. 
Table 3. Changes in inflammation markers during two-year follow-up for both placebo 
and intervention group.
Placebo group Intervention group p-value
Baseline Follow-up change Baseline Follow-up change
CRP (ng/ml) 30950.4 42067.9 +36% 31335.2 39611.9 +26% 0.70
SAA (ng/ml) 88301.9 122046.6 +38% 90710.3 121694.4 +34% 0.85
ICAM-1 (ng/ml) 3620.6 4790.6 +32% 3426.3 4646.9 +36% 0.72
Aggregated 
inflammation 
Z-score
+0.01 -0.02 0.66
Analysis was done with ANCOVA and adjusted for age, gender and study center and baseline 
value. The aggregated inflammation score included CRP, SAA and ICAM-1 and was based on 
the Z-scores of the change between baseline and follow-up per biomarker. p-values show the 
outcome for ANCOVA analysis. 
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levels of homocysteine. We observed no treatment effect in such subjects 
after 2 years and also no significant interactions. We believe this provides 
strong support for a lack of benefit of B-vitamins on endothelial dysfunction.
We selected ICAM-1, VCAM-1 and VEGF as biomarkers for endothelial func-
tion. ICAM-1 and VCAM-1 mediate the adhesion of endothelial cells to leuko-
cytes [34]. Because ICAM-1 is also expressed on monocytes, this biomarker 
is also associated with inflammation [30]. High levels of ICAM-1 and VCAM-1 
may be caused by damaged or activated endothelial cells [35]. VEGF induces 
the migration and proliferation of endothelial cells and is also important for 
vascular permeability and thrombogeneticy [36]. Low-grade inflammation 
was assessed with CRP, SAA and ICAM-1 levels. CRP is a widely accepted 
biomarker for chronic low-grade inflammation and has been consistently 
associated with cardiovascular disease [37-40]. SAA also predicts cardio-
vascular disease, but to a lesser extent than CRP [39]. ICAM-1 is expressed 
both in monocytes and the endothelium and was therefore applied in the 
inflammatory Z-score as well [30]. 
Our findings with respect to inflammation argue against the hypothesis that 
folate could increase systemic inflammation. However, whether a lack of ef-
fect on circulating biomarkers excludes an effect on local inflammation in 
atherosclerotic plaques is unknown. Nevertheless, a small study in stroke 
patients did not observe a B-vitamin treatment effect on arterial wall inflam-
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Figure 4.4.2.
Data represent the percentage of change of SAA levels in the placebo and intervention group 
stratified for participants without cardiovascular history (no CVD history) and with a positive 
cardiovascular disease history (with CVD history). Differences between placebo and interven-
tion were not statistically significant.
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mation, measured with PET scans [41]. Further research is necessary to 
determine the intra-atherosclerotic plaque inflammatory process. 
The possible difference in treatment effect on SAA levels between individuals 
with and without history of cardiovascular disease, implicates we cannot 
completely rule out beneficial effects of B-vitamins in specific subgroups. In 
general, our study supports previous trials [2] concluding that the cardio-
vascular system is generally unresponsive to B-vitamin treatment, as well as 
for cardiovascular disease outcomes, as for arterial stiffness and endothelial 
function. This does not annihilate the strong association between homocys-
teine and cardiovascular disease, but further adds to the notion that we need 
to search for alternative explanations for this association.
This study has its limitations. First, this study was performed in a hyper-
homocysteinemic elderly population and our results can therefore not be 
translated directly to the general population. Nevertheless, when a beneficial 
treatment effect of homocysteine lowering would be expected, this would be 
particularly seen in subjects with high homocysteine levels. Also, the bio-
markers were only measured once which does not ascertain a perfect quality 
of the measurements. Third, the use of an aggregated Z-score of endothelial 
function and inflammation ideally requires that each biomarker has an equal 
weight. Fourth, the outcome parameters of this report were not assigned 
as primary outcome of the B-PROOF study at large. Further, circulating 
biomarkers do not cover the full spectrum of tests for assessing endothelial 
(dys)function and low-grade inflammation. Hence, we cannot exclude that, 
for example, tests of endothelial vasomotor function or of other circulating 
indicators of low-grade inflammation would show different results. However, 
the tests we used have proven relevance in their respective contexts and are 
widely used for study purposes similar to ours. 
In conclusion, in an elderly population with high-normal homocysteine levels, 
the use of vitamin B12 and folic acid did not influence endothelial function 
or inflammation.
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Chapter 5
General discussion
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With advancing age, the predictive value of risk factors for cardiovascular 
disease change [1]. Classical cardiovascular risk factors included in the 
Framingham risk score are less predictive at older age. For older persons, 
an alternative of a risk score is absent. It has been observed that arterial 
stiffness is an important cardiovascular risk factor in older populations [2-6]. 
This thesis underlines the importance of arterial stiffness in older individuals, 
as being an important preclinical marker of cardiovascular disease. Although 
arterial stiffness has already been associated with many conditions, these 
associations may well differ in elderly, in particular because of comorbidity 
and potential modification or mediation. 
For this thesis, we studied the possible associations between arterial stiff-
ness and physical function, osteoporosis and homocysteine, using cross-sec-
tional or longitudinal data of the B-PROOF study population. In addition, we 
researched the effect of 2-year vitamin B12 and folic acid supplementation 
on arterial stiffness and other cardiovascular-related outcomes within the 
B-PROOF study. In this chapter, we will give an overview of the observations 
of this thesis and discuss its implications, and subsequently we will provide 
suggestions for potential further research. 
the b-Proof study
The B-PROOF study (B-vitamins for the PRevention Of Osteoporotic Frac-
tures) is a large, multicenter, double-blind, placebo-controlled randomized 
controlled trial. Individuals with a homocysteine level ≥ 12 – 50 µmol/l 
could be included. Three centers in the Netherlands conducted this trial: 
Wageningen University, VU Medical Center at Amsterdam and the Erasmus 
MC at Rotterdam. We have contacted about 69,000 older individuals aged 
65 years and over, to interest them for our trial. Of them, about 10% gave 
consent and wanted to participate. Blood samples were collected from these 
participants. About half of them, matched our inclusion criteria and could be 
included. In total 2919 individuals started with the trial (Figure 1, flowdia-
gram). These participants all underwent the baseline measurements at of 
close to their home. These baseline measurements included among others: 
weight and length, blood pressure, physical function tests, cognitive tests 
and several questionnaires [7].
At the VU Medical Center and Erasmus MC, participants were invited to 
underwent vascular function tests, all non-invasive. In 567 participants the 
vascular function tests were performed. 
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The intervention of the B-PROOF study was vitamin B12 (500 μg) and folic 
acid (400 μg) once a day. Both the intervention and control group received 
15 μg vitamin D daily. After the two-years of follow-up, the homocysteine 
level decreased with 4.4 μmol/l in the intervention group [8]. Within the 
vascular subgroup, the homocysteine level decreased with 4.3 μmol/l in the 
participants included in the intervention arm [8].
Figuur 5.1.
Flowchart of the inclusion of the B-PROOF study. 
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MeAsurIng ArterIAl stIffness
Because it was not clear whether the applanation tonometry and oscillom-
etry are comparable in terms of arterial stiffness measures, we compared the 
arterial stiffness measurements between applanation tonometry and the os-
cillometric method (Chapter 2). As compared to younger individuals, elderly 
often have increased levels of arterial stiffness being a marker for increased 
cardiovascular disease risk [2-6]. Therefore this age group was of particular 
interest, mainly because an accurate measurement of arterial stiffness can 
be helpful for cardiovascular risk management. We observed that the ap-
planation tonometry and the oscillometric method were not very comparable 
in PWV levels, in particular not in older individuals with elevated levels of 
arterial stiffness. Although we did not investigate whether the oscillometric 
method was capable of predicting cardiovascular risk, we think it might be 
argued whether the oscillometric method can be used for clinical applications 
as cardiovascular risk assessment, especially in elderly who are at risk of 
elevated arterial stiffness levels and therefore higher cardiovascular disease 
risk. More research will be necessary to ascertain whether the oscillometric 
method is able to predict cardiovascular disease and mortality. For example, 
within a longitudinal cohort study as the Rotterdam Study [9], the accuracy 
of this method for cardiovascular risk prediction could be investigated. 
It is also important that researchers are aware that potentially the applana-
tion tonometry and the oscillometric method do not measure similar proper-
ties of the vascular tree. It has been reported the oscillometric is sensitive 
for brachial stiffness [10, 11], because this method measures the PWV in the 
brachial artery and with use of the central pressure, the central PWV is es-
timated [12]. This is especially important when measuring arterial stiffness 
in elderly, since it is thought that the brachial artery is less affected by age-
related arterial stiffness [13]. Nevertheless, the applanation tonometry also 
works with estimations of the central PWV. It therefore remains uncertain 
whether the applanation tonometry and the oscillometric method measure 
similar vascular properties. The advice to other researchers is therefore to 
use the golden standard, applanation tonometry, at least until there are 
clearer data available with regard to the prediction of cardiovascular risk.
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deterMInAnts of ArterIAl stIffness
Arterial stiffness is an abnormality of the vasculature, which co-occurs 
with advancing age. It has been shown to be an important cardiovascular 
risk predictor, especially at older age [2-6]. Therefore, arterial stiffness is 
an interesting phenotype to investigate, mainly to create better insight in 
prevention of cardiovascular disease. Especially in younger populations, 
multiple conditions such as diabetes and renal disease have been linked to 
arterial stiffness [14-20]. Because data are still scarce for older individuals, 
we have investigated several associations with arterial stiffness in elderly. 
Elderly have often been excluded in studies, because of among others the 
presence of co-morbidity, use of medication or cognitive disabilities [21]. 
Therefore, with older subjects it is more difficult to interpret the results and 
to evaluate effectiveness. In this perspective, evidence of the beneficial ef-
fects of drug treatment or other kind of interventions like physical activity is 
scarce. However, especially older individuals have a high prevalence of car-
diovascular disease, with high health care costs as a consequence. Because 
with advancing age, the risk determinants of cardiovascular diseases change 
[1], it is important to get knowledge about other treatable cardiovascular 
risk factors for this age group in order to create better prevention strategies. 
Several associations with arterial stiffness have been described in Chapter 
3. All associations have been investigated within the context of the B-PROOF 
study [8]. Although these participants had mildly elevated homocysteine 
levels (≥12 µmol/l), this condition has a prevalence of 50%, as in the B-
PROOF study half of the elderly could be included. Furthermore, it is worth 
noticing that in our Dutch population we have no fortification with folate in 
our foods [7].
Cross-sectional studies cannot prove causality between the association 
under investigation. Nevertheless, these studies are of importance because 
they provide information about potential mechanisms, leading to new 
hypotheses, which in turn can be tested with, for example, a randomized 
controlled trial, or a genome-wide association study. One of the potential 
mechanisms that is extensively researched in this thesis is the interaction 
of the presence of elevated arterial stiffness with the variable of interest. 
Because arterial stiffness is thought to be an abnormality that is not easily 
or rapidly reversible, it is plausible there is a difference in associations and 
effects of treatment between individuals with low levels of arterial stiffness 
and those with elevated levels. 
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In order to investigate the underlying mechanisms in which way physical 
fitness and exercise reduce cardiovascular disease risk, arterial stiffness has 
already been investigated extensively. Nevertheless, all studies focused on 
exercise with a short-term follow-up and were mostly assessed within young 
or middle-aged populations [16, 22-26]. Therefore, we aimed to investigate 
the associations between physical functioning longitudinally within the B-
PROOF study with elderly subjects (Chapter 3). We observed that physical 
functioning was not related to arterial stiffness in our population and there 
was no difference between participants with and without elevated arterial 
stiffness. Our findings indicate that possibly in elderly, physical functioning is 
not a determinant of arterial stiffness, in contrast to younger individuals [22, 
23]. Nevertheless, further research is warranted in the form of an interven-
tion trial to determine whether long-term physical exercise has beneficial 
effects on arterial stiffness or cardiovascular disease prevention in older 
persons. 
Because both osteoporosis and cardiovascular disease are common among 
elderly, and an association between both diseases appeared to be present 
[27-31], we have also investigated the association of bone parameters and 
fractures with arterial stiffness (Chapter 3). However, we observed no asso-
ciation between these parameters. Recently, other studies became available 
that question causality between osteoporosis and cardiovascular disease 
[32, 33], so our study supports the absence of a causal link between bone 
and vasculature in older individuals. 
It is however still possible that there is a common pathway for these diseases 
that differs between certain populations, explaining a lack of association in 
certain populations as compared to others. One of the hypothesized overlap-
ping etiologies is homocysteine level [34-37]. That is why we researched the 
role of homocysteine in this perspective, but we were not able to confirm 
an overlapping effect of homocysteine. With use of prospective studies in 
older persons, potential associations between bone disease, fractures and 
cardiovascular disease may be further determined. Furthermore, genetic risk 
scores of bone parameters can be used to see whether these genetic mark-
ers will be able to predict cardiovascular disease. This would also provide 
more information regarding causality or overlapping etiology. Potential com-
mon pathways between these conditions might be vitamin D levels, calcium 
levels or maybe even sodium. Sodium is already positively associated with 
cardiovascular disease, via hypertension, but more recently, studies noticed 
an association between sodium levels and bone mineral density [38, 39]. 
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Individuals with higher salt intake, have higher blood pressure levels and 
therefore may have an increased calcium excretion in the urine, which would 
lower the serum calcium levels and as a consequence this could lead to an 
increased risk of osteoporosis. 
Several studies have demonstrated that individuals with low levels of vitamin 
D have a higher incidence and prevalence of cardiovascular disease [40-
45]. On the other hand, also high vitamin D levels have been suggested 
to increase cardiovascular risk, potentially due to calcium depositions [46]. 
Taken these findings together, they point towards a non-linear relation. Our 
study (Chapter 3) confirmed a non-linear association between vitamin D and 
arterial stiffness, as well as for arteriosclerosis. In particular normal-high 
levels of vitamin D were associated with increased arteriosclerosis of the 
carotid artery. This finding suggests that also normal-high levels of vitamin D 
may increase cardiovascular risk via increasing arteriosclerosis. This can be 
of particular interest in the geriatric population, where supplementation with 
vitamin D is world-wide acknowledged for the prevention of osteoporosis. In 
the Netherlands, despite the 25-hydroxy vitamin D level, it is recommended 
for older individuals to use small amounts of vitamin D supplementation 
additional to daily food consumption. However, if indeed vitamin D levels 
in the normal-high range already are associated with an increased cardio-
vascular risk, one might argue about potential negative consequences of 
the supplementation recommendations. To get more certainty about these 
potential disadvantages of vitamin D, and the optimal supplementation dos-
age, a large prospective study, preferably an intervention trial (regardless of 
the possible ethics) with different dosing schemes is warranted. With regard 
to possible ethical problems, it is also possible to do a meta-analysis of all 
trials that have been using vitamin D supplementation as an intervention 
and have adverse events reports, including cardiovascular events. It might 
be more difficult to determine a optimal dosage for supplementation in this 
way, but it will give us more knowledge about the potential harmful effects 
of vitamin D supplementation.
hoMoCysteIne
Homocysteine forms a key element in this thesis. All variables of interest 
also have been shown to be associated with homocysteine: physical function 
[47], measures of osteoporosis [48], and most importantly, its association 
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with cardiovascular disease. In particular regarding the relation with arte-
rial stiffness, we hypothesized that the association would be predominantly 
present in a hyperhomocysteinemic population, since this has been shown to 
form an important cardiovascular risk factor especially in an older age group. 
As mentioned in the introduction, homocysteine level is an independent risk 
factor for cardiovascular disease, which is particularly strong in the very old 
and an even better predictor of cardiovascular disease in comparison to the 
classical risk factors included in the Framingham score [49]. However, up 
to now, data were lacking regarding arterial stiffness at older age. Our first 
cross-sectional analysis, conducted within the framework of the B-PROOF 
study, was the association between homocysteine level and arterial stiffness 
(Chapter 4). We observed a positive association between homocysteine level 
and PWV in elderly, which was strongest in the oldest old. With each point 
increase of homocysteine level, the PWV increased with 8%. It is plausible 
that with advancing age, homocysteine becomes a more important cardio-
vascular risk, as was endorsed by the observed strong association among 
the oldest old. 
However, the question remained whether this observed association between 
homocysteine and arterial stiffness is truly a causal one. In order to explore 
potential causality, we investigated the relation between genetic polymor-
phisms of hyperhomocysteinemia with arterial stiffness and the association 
between serum vitamin B12 and folate with arterial stiffness (Chapter 4). 
The negative findings however undermined this hypothesis. In fact, homo-
cysteine levels were significantly mediating the association, indicating that 
the association with homocysteine and arterial stiffness is not likely to be a 
causal one.
Moreover, one might even speculate about potential protective mechanisms 
individuals with a genetically high risk of hyperhomocysteinemia have on the 
arterial stiffness process. In vitro studies have clearly demonstrated a direct 
effect of homocysteine on the vasculature. It increases thrombogenecity, 
oxidative stress and activates redox-sensitive inflammatory pathways [50]. 
It is possible that individuals with a genetic high risk of having hyperho-
mocysteinemia do have other genetic factors that compensate the effects 
of homocysteine or potentially have an activation of processes protecting 
the vascular wall. Of course this is rather speculative. Because epigenetic 
research is upcoming, we may expect to get more insights in the processes 
of genetic risk factors and their true effects in the human body. A more direct 
way to assess causality are intervention trials, in this case with B-vitamin 
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supplementation. In this thesis the intervention was also reported and will 
be discussed in the next subchapter of this discussion. 
Next to causality, there was also the possibility that the association between 
homocysteine and arterial stiffness is driven by B-vitamins itself. Vitamin B12 
and folate are co-factors in the re-methylation pathway, converting homo-
cysteine into methionine. Methionine is converted to s-adenosylmethionine 
(SAM), which is a universal methyl-group donor, not only for proteins but 
also for DNA and RNA. Over the last years, this process has gained interest, 
including the possible effects on this process with advancing age, since, for 
several reasons, in older persons B-vitamin deficiencies are common. Within 
the B-PROOF study, we observed homocysteine mediated the association 
between B-vitamins and arterial stiffness, making it unlikely that the as-
sociation between homocysteine and arterial stiffness is driven by a direct 
effect of B-vitamin levels. As mentioned before, homocysteine itself has been 
shown to be an independent risk indicator for many disorders, including 
cardiovascular disease. High levels of homocysteine could have a direct 
toxic/negative effect, or negative effects could arise because of less avail-
able SAM, leading to hypomethylation. What underlying mechanism explains 
the association between hyperhomocysteinemia and arterial stiffness and 
cardiovascular disease is not known. It will be interesting to also measure 
SAM and S-adenosylhomocysteine (SAH; the break-down product of SAM) 
within the sera of the individuals of the B-PROOF study, to see whether SAM/
SAH ratio drives the association between homocysteine and arterial stiffness 
in our population. 
effeCt of b-vItAMIns
Despite the fact that homocysteine has been shown to be an independent 
risk factor for cardiovascular events [49], several trials with homocysteine-
lowering therapy with B-vitamins failed to demonstrate beneficial effects 
[51]. Obviously, causality of homocysteine on the incidence cardiovascular 
disease was questioned. However, it has also been brought forward that 
there are potential epidemiological or methodological issues that may have 
influenced the outcomes of these trials [52]. Another possible explanation 
for the lack of benefit of homocysteine-lowering therapy could be arterial 
stiffness. Because arterial stiffness is an abnormality that is not easily or 
rapidly reversible, lack of substantial improvement of arterial stiffness might 
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be the explanation of the non-beneficial effects of B-vitamin supplementation 
on cardiovascular outcomes. Therefore, we aimed to investigate the effect of 
vitamin B12 and folic acid supplementation on arterial stiffness (Chapter 4). 
In concordance with the second hypothesis, we did not observe any treat-
ment effect on arterial stiffness levels; in fact the PWV levels were the same 
in both the intervention and the placebo group. Furthermore, the results did 
not differ between participants with and without elevated levels of arterial 
stiffness at baseline. This last result may imply that homocysteine is not 
causally associated with arterial stiffness, which was endorsed by the fact 
that we also did not find an association between genetic polymorphisms of 
hyperhomocysteinemia and arterial stiffness as we already discussed above.
On the other hand, we did find a beneficial effect on stroke in females. 
Within the intervention group, we have observed a risk reduction of 67% in 
the females treated with B-vitamin supplementation. Although we did not 
power our B-PROOF population size on cardiovascular outcomes, this find-
ing is consistent with literature [53, 54]. Cerebrovascular disease is more 
heterogeneous as compared to coronary artery disease. It is possible that 
not only arterial stiffness does not respond to B-vitamin supplementation, 
but also atherosclerosis does not. We confirmed the latter by showing there 
was no effect of the intervention with vitamin B12 and folic acid on carotid 
intima-media thickness. Furthermore, also age did not appear to influence 
the effects of the intervention. Therefore, we may conclude there is another 
pathway which should explain the potential beneficial effect of B-vitamins 
on stroke. Because we only observed this in females, it might be hormonal. 
However, in literature a gender-specific effect has not yet been described 
[51, 53, 54]. Another, rather unexpected, finding were the higher blood 
pressure levels in the individuals treated with vitamin B12 and folic acid, 
with an approximately 2 mmHg higher level in the intervention group. With 
the potential beneficial effect of B-vitamins on cerebrovascular disease and 
the potential harmful effect of B-vitamins on blood pressure, the suggestion 
arises there are paradoxical effects of B-vitamin supplementation. This has 
also been described previously [52]. In this perspective our results regarding 
blood pressure might be a reflection of a cardiac mechanism or of a differ-
ence in effect of homocysteine-lowering therapy between small and large 
arteries. The homocysteine-lowering effect of B-vitamin supplementation 
would then be partly beneficial, but possibly the treatment as such could lead 
concurrently lead to adverse effects. Because folate is a fuel source for cells 
like macrophages and smooth muscle cells, via the one carbon metabolism, 
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this may lead to increased proliferation of these cells, which are important in 
the atherosclerotic process [52]. However, only one small study have inves-
tigated whether folic acid supplementation does increase the (inflammatory) 
processes in atherosclerotic plaques [55].
Nevertheless, in the context of the paradoxical hypothesis of B-vitamin ef-
fects, we investigated the effect of vitamin B12 and folic acid supplementa-
tion on the inflammation status. The paradox hypothesis comprehends the 
possibility that B-vitamins reduce cardiovascular disease on the one hand, 
but increase the inflammation status on the other. However, we observed no 
effect (Chapter 4). 
We also investigated the effect on endothelial function, but also B-vitamin 
supplementation did not improve endothelial function in our population. 
We therefore conclude that B-vitamin supplementation may have a beneficial 
effect on stroke, but no effect on cardiovascular outcomes. Furthermore, 
regarding potential pathways, B-vitamins did not improve arterial stiffness, 
endothelial function or the inflammatory status. Why homocysteine is still 
such a strong indicator for cardiovascular disease in the elderly is therefore 
remains unknown. Most likely it is not a treatable risk factor, but only a 
biomarker, able to predict cardiovascular events and mortality. Why stroke 
and homocysteine appear to have a different etiology has also not yet been 
elucidated. It is possible that blood pressure may have a role in this perspec-
tive, since we observed higher blood pressure levels in individuals treated 
with B-vitamin supplementation as compared to the individuals with placebo. 
Because of the heterogeneity of cerebrovascular disease, there is the possi-
bility that effects of B-vitamin supplementation is different between the small 
and large arteries. In order to elucidate the mechanisms of homocysteine 
and B-vitamin supplementation further, we may need to focus on the smaller 
arteries. A potential study with cerebral perfusion scans would be of interest 
to demonstrate the effects of B-vitamins on the small arteries in the brain. 
The lack of beneficial effects of B-vitamin supplementation on cardiovascular 
disease, also in other trials, also has been explained by the fact that most 
studies were done in folic-acid fortified populations [52]. The B-PROOF study 
was conducted in the Netherlands, were we do not have folate-fortification. 
Another limitation that has been mentioned many times is the relatively 
short time-period (3-5 years) in which the studies were conducted [52]. It 
is true that the B-PROOF study had a duration of only 2 years. As cardiovas-
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cular disease was a secondary outcome, and the study was designed for the 
prevention of fractures, it was hypothesized that a period of 2 years would 
be enough to detect differences in fracture incidence. However, with respect 
to cardiovascular pathophysiology, it would be expected that differences in 
the vasculature for the prevention of disease will take longer than 3-5 years. 
In particular if arterial stiffness is indeed a condition which may be non-
rapidly reversible. With other drug treatments, for example statins [56], we 
were lucky to demonstrate their beneficial effects on a shorter term, but this 
may not be true for other drug targets as homocysteine-lowering therapy. A 
larger trial of more than 5 years would therefore be necessary to ascertain 
effects of B-vitamin supplementation on cardiovascular outcomes. However, 
more and more discussion arises about the potential harmful effects of folate 
supplementation; since higher cancer incidences are described. Although a 
large meta-analyses could not confirm this [51], we may question whether 
a new trial is ethical. 
IMPlICAtIons
This thesis helped us to get more insight into the determinants of arte-
rial stiffness in older individuals. Although arterial stiffness is an important 
cardiovascular risk predictor, there are some conditions that according to 
literature seemed to be associated with arterial stiffness, but of which data 
were scarce, especially in elderly. Therefore we have studied those associa-
tions within our elderly, B-PROOF population. We observed that arterial stiff-
ness was not associated with physical functioning and bone parameters in 
our older population. Furthermore, vitamin D levels appears to associate in 
a U-shaped curve with carotid intima-media thickness, an important marker 
for atherosclerosis. Therefore, we must conclude that research is still needed 
to find other (treatable) cardiovascular risk factors for older individuals in 
order to decrease mortality and morbidity rates. 
Whether our B-PROOF population can be seen as a general elderly popula-
tion, might be questioned. We have included (based on homocysteine level) 
approximately 50% of a general elderly population. Therefore, one might 
say this is a quite well representation of the general population. However, 
our inclusion is based on mildly elevated homocysteine levels. This can be an 
indication of certain underlying conditions, as increased cardiovascular risk, 
but maybe also other, not yet identified conditions which are associated with 
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hyperhomocysteinemia. Therefore, it is important to interpret the results 
with caution. We cannot be sure the results are present in the total general 
population of older individuals.
Furthermore, our studies have improved the understanding in the patho-
physiological mechanisms of homocysteine and B-vitamin supplementation 
regarding cardiovascular outcomes. Although we observed a clear association 
between homocysteine and arterial stiffness, in particular in the oldest old, 
we did not find any effects of B-vitamin supplementation on cardiovascular 
disease, arterial stiffness, endothelial function or inflammation. This lack of 
benefit in all outcome variables may indicate that homocysteine is indeed 
not causally associated to cardiovascular outcomes. This hypothesis was 
also confirmed by a lack of an association with genetic polymorphisms of 
hyperhomocysteinemia, making this hypothesis even more likely. Why we 
did see an effect of B-vitamin supplementation on stroke remains unknown. 
As described before, it is still possible there is a difference in B-vitamin effect 
between small and large arteries. Nevertheless, considering the sometimes 
equivocal results of meta-analysis on stroke and the fact that homocysteine-
lowering therapy did also not have a large influence on other health outcomes 
[8], and it might increase the risk of cancer [8], B-vitamin supplementation 
cannot be seen as a true treatment option for the prevention of stroke. 
And in the end, as we observed no large treatment effects in any of the 
outcomes, we can also not suggest to use B-vitamin supplementation for the 
total elderly population in the Netherlands. 
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In Chapter 1, we describe two cardiovascular risk factors important for an 
elderly population. Because classical cardiovascular risk factors are less 
predictive with advancing age, other risk factors become more important. 
One of the cardiovascular risk factors is pulse wave velocity as measurement 
of arterial stiffness. Arterial stiffness is a condition, characterized by less 
elasticity of the arteries and considered a pre-clinical state of cardiovascular 
disease. In Chapter 1 we explain the etiology of arterial stiffness and its 
measurements. Also, we introduce another risk factor of cardiovascular 
disease, homocysteine. However, several trials with homocysteine lowering 
B-vitamin supplementation as intervention did not observe beneficial effects 
on the prevention of cardiovascular disease. Numerous hypotheses have 
been formed to explain the lack of a beneficial effect. One of them is arterial 
stiffness. Arterial stiffness is a condition that is not easily or rapidly revers-
ible. If an increased homocysteine level would lead to arterial stiffness, this 
process would be largely irreversible. 
In Chapter 1, we also describe the population we have used for this thesis. 
All subjects are participants of the B-PROOF (B-vitamins for the PRevention 
Of Osteoporotic Fractures) study, an RCT with 2919 participants, aged 65 
years and over, based on their homocysteine level (≥ 12-50 μmol/l). 
 In Chapter 2 we compared two different methods of assessing PWV within the 
B-PROOF population. We observed that with oscillometry, the PWV levels in 
individuals with increased arterial stiffness are not comparable with those of 
the applanation tonometry. Because applanation tonometry is well validated 
and has been shown to be associated with cardiovascular risk prediction, we 
have chosen to use the applanation tonometry based PWV levels to use for 
the rest of this thesis. 
In Chapter 3, we studied potential associations of arterial stiffness with 
physical function, osteoporosis and vitamin D. Despite the fact that it has 
been shown that physical function has an influence on arterial stiffness levels 
in young adults, no effect of physical function or activity was seen in our 
elderly population (Chapter 3.1). However, many participants in our study 
population had increased arterial stiffness and it is probable that arterial 
stiffness is indeed irreversible. However, stratified analysis in individuals 
without arterial stiffness did also not demonstrate an association between 
physical function and activity and arterial stiffness. 
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In Chapter 3.2, we describe the association between arterial stiffness and 
bone parameters: bone mineral density, bone quality and fractures. Lit-
erature demonstrated that osteoporosis and fractures predict cardiovascular 
events. Homocysteine is a possible underlying common mechanism, since 
homocysteine is associated with both osteoporosis as well as cardiovascular 
disease. Within the B-PROOF study however, we did not observe an associa-
tion between bone parameters and arterial stiffness. Furthermore, homocys-
teine did not modify or mediate this association and is therefore not plausible 
to be interacting with this association. 
The association between arterial stiffness and vitamin D is described in 
Chapter 3.3. This relation appears not to be linear but U-shaped. Both a 
low as well as a high level of 25-OH vitamin D is associated with increased 
arterial stiffness and in particular with increased intima media thickness, a 
measure of atherosclerosis. In individuals with a 25-OH vitamin D level ≥ 
50 nmol/l, there was a significant increase of the intima-media thickness of 
1.24 μm per point of 25-OH vitamin D increase. This finding implies that also 
normal-high levels of vitamin D may also lead to an increased cardiovascular 
disease risk. 
In Chapter 4 we investigate the relation between homocysteine, arterial 
stiffness and cardiovascular disease. Firstly in Chapter 4.1, we describe the 
association between homocysteine and arterial stiffness. This relation is 
strongest in the oldest old. Nevertheless, such an association study cannot 
ascertain causality. The relation between homocysteine and arterial stiff-
ness could be driven by B-vitamin levels itself for example. In Chapter 4.2 
we therefore tested the association between B-vitamin levels and arterial 
stiffness, but found no association. With the use of a genetic risk score 
for hyperhomocysteinemia, we investigated potential causality between 
homocysteine and arterial stiffness. However, the genetic risk score of hy-
perhomocysteinemia was not associated with arterial stiffness and was even 
modified by homocysteine level itself, thus making a causal relationship less 
likely. 
In Chapter 4.3 we assessed effects of B-vitamin supplementation on cardio-
vascular outcome measures. B-vitamin supplementation did indeed lower 
levels of homocysteine, but did not decrease arterial stiffness. Furthermore, 
a stratified analysis of individuals with and without increased arterial stiffness 
did not show an effect of the B-vitamin supplementation within the individu-
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als without arterial stiffness. Therefore we may conclude that homocysteine 
is not causally associated with arterial stiffness. However, we also observed 
in Chapter 4.3 that within females receiving the intervention with B-vitamins, 
less strokes occurred during the two year follow-up. It is not known why we 
only observed this in females, although, in the entire population there was 
also a trend towards lower incidence of stroke in the intervention group with 
B-vitamins. It can be speculated there is a difference between small and 
large arteries, but further research is warranted. 
In order to get more insight in potential underlying pathways in the associa-
tion between homocysteine and cardiovascular disease, we also investigated 
the effect of B-vitamin supplementation on endothelial function and inflam-
mation in Chapter 4.4. It has already been described that folic acid is as-
sociated with an increased inflammatory status, which might neutralize the 
potential protective effects of homocysteine-lowering therapy. However, we 
did not observe any treatment effect on endothelial function or inflammation. 
In Chapter 5, we elaborate on the implications of our findings. In conclu-
sion, physical function and osteoporosis were not related to arterial stiffness. 
Secondly, normal-high levels of vitamin D are potentially associated with 
increased cardiovascular risk. Thirdly, the association between homocysteine 
and arterial stiffness is present in elderly, but is most likely not causal. Fur-
thermore, homocysteine can be seen as a biomarker, but not as a treatable 
risk factor. 

6.2
Nederlandse samenvatting
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Hart- en vaatziekten zijn veelvoorkomende aandoeningen, met name in 
ouderen. Dit brengt veel comorbiditeit en gezondheidskosten met zich mee. 
Omdat traditionele risicofactoren een mindere voorspellende waarde hebben 
met het toenemen van de leeftijd, is het belangrijk dat er nieuwe risicofacto-
ren worden geïdentificeerd. In hoofdstuk 1 geven we een inleiding over twee 
factoren die het onderwerp van dit proefschrift zijn. 
Een van die factoren is vaatstijfheid. In hoofdstuk 1 vertellen we dat dit 
een goede voorspeller blijkt te zijn voor hart- en vaatziekten in ouderen. 
Vaatstijfheid houdt een mindere elasticiteit van de bloedvaten in, wat een 
voorloper van hart- en vaatziekten blijkt te zijn. Dit wordt vaak gemeten met 
de zogenaamde: ‘pulse-wave-velocity’, oftewel de snelheid waarmee een 
polsgolf van de arteria carotis naar de arteria femoralis beweegt. Aangezien 
vaatstijfheid een preklinische fase is van hart- en vaatziekten, is het goed 
om te onderzoeken of dit ook geassocieerd is met diverse aandoeningen of 
biomarkers, zodat vaatstijfheid mogelijk al vroeg kan worden voorkomen.
De andere risicofactor, die in hoofdstuk 1 wordt besproken, is het homocys-
teine gehalte. Homocysteine wordt in het lichaam omgezet in methionine 
en is een aminozuur dat van belang is bij diverse metabole processen in 
het lichaam. Voor deze omzetting is vitamine B12 en foliumzuur nodig. Een 
tekort aan deze vitamines kan dus leiden tot een verhoogd homocysteine 
gehalte. Er zijn vele aandoeningen die geassocieerd lijken te zijn met een 
verhoogd homocysteine, waaronder dus hart- en vaatziekten. 
In hoofdstuk 1 bespreken we ook de reden van dit proefschrift. Het is ge-
bleken dat diverse studies met suppletie van vitamine B12 en foliumzuur, 
welke het homocysteine dus verlagen, niet konden aantonen dat er hierdoor 
hart- en vaatziekten voorkomen konden worden. Er zijn diverse hypotheses 
in omloop over de reden hiervoor. Een ervan is vaatstijfheid. Van vaatstijf-
heid wordt gedacht dat dit niet snel, of zelfs niet, reversibel is. Wanneer een 
verhoogd homocysteine zou leiden tot vaatstijfheid, zou dit dus niet meer 
omkeerbaar kunnen zijn. Aangezien de B-PROOF studie (B-vitamins for the 
PRevention Of Osteoporotic Fractures) werd opgezet, om te onderzoeken of 
suppletie van vitamine B12 en foliumzuur osteoporotische fracturen konden 
voorkomen, was dit een mooie gelegenheid om ook naar de effecten op 
vaatstijfheid en hart- en vaatziekten te kijken. Deze dubbel-blinde, geran-
domiseerde en placebo gecontroleerde trial heeft van 2008 tot 2012, 2919 
65+-ers geincludeerd, op basis van hun homocysteine gehalte. Dit moest 
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≥ 12 - 50 μmol/L zijn. Door personen te selecteren met een iets verhoogd 
homocysteine gehalte, konden we een verlaging van homocysteine bewerk-
stelligen middels suppletie van vitamine B12 (500μg) en foliumzuur (400μg). 
De proefpersonen werden gerandomiseerd in de interventie groep (suppletie 
B-vitamines) of in de placebo groep en werden 2 jaar behandeld. 
In hoofdstuk 2 onderzochten we twee manieren om de pulse-wave-velocity te 
meten in ouderen. Dit kan met een tonometer: deze methode maakt gebruik 
van de drukverschillen van de polsgolf, te voelen bij de arterieen van het 
lichaam: de carotis- en femoralis arterie. De andere methode maakt gebruik 
van een oscillometer: een bloeddrukband, welke de druk in de radialis arterie 
meet en daarmee een inschatting maakt van de carotis-femoralis pulse wave 
velocity. In hoofdstuk 2 vergelijken we deze metingen in onze B-PROOF 
onderzoekspopulatie. We vonden dat de oscillometer minder goed hogere 
PWV-waardes kon bepalen ten opzichte van de tonometer. Mede aangezien 
de tonometer beter gevalideerd is en tevens is gebleken dat deze waarden 
hart- en vaatziekten kunnen voorspellen, hebben wij bij de B-PROOF geko-
zen om onze PWV metingen uit te voeren met de tonometer. 
In hoofdstuk 3 onderzoeken we diverse associaties van vaatstijfheid met: 
fysiek functioneren, osteoporose en vitamine D. Ondanks dat in jong volwas-
senen is beschreven dat fysieke functie van invloed is op de vaatstijfheid, 
lijkt dit bij ouderen niet het geval (hoofdstuk 3.1). We hebben bekeken of de 
fysieke functie en de dagelijkse activiteiten van invloed waren op vaatstijfheid 
en op vaatstijfheid na 2 jaar, echter dit bleek niet het geval. Aangezien veel 
van onze populatie reeds vaatstijfheid heeft, zou het mogelijk zijn dat vaat-
stijfheid inderdaad irreversibel is. Echter, wanneer we onderscheid maakten 
tussen proefpersonen met en zonder vaatstijfheid, vonden we ook in de 
proefpersonen die nog geen vaatstijfheid hadden, geen associatie met fysiek 
functioneren en dagelijkse activiteit. Het is mogelijk dat alleen intensievere 
activiteit van invloed is op vaatstijfheid bij ouderen, echter dit konden we 
binnen de B-PROOF niet onderzoeken. 
In hoofdstuk 3.2 beschrijven we het onderzoek naar de associatie tussen 
vaatstijfheid en bot parameters: botdichtheid en fracturen. Er zijn diverse 
onderzoeken die beschrijven dat osteoporose en fracturen van voorspellende 
waarde zijn voor het ontstaan van hart- en vaatziekten. Homocysteine is 
een van de mogelijk onderliggende mechanismen aangezien het zowel geas-
socieerd is met hart- en vaatziekten en vaatstijfheid, als met osteoporose en 
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fracturen. Er bleek binnen de B-PROOF studie echter geen relatie te zijn tus-
sen vaatstijfheid en bot parameters, ook niet met fracturen. Homocysteine 
bleek ook geen invloed te hebben op deze associatie en is dus waarschijnlijk 
geen onderdeel van een mogelijk onderliggend mechanisme. 
De associatie tussen vaatstijfheid en vitamine D wordt beschreven in hoofd-
stuk 3.3. Deze relatie blijkt een soort U-shape te hebben en is niet lineair. 
Zowel een laag als een hoog vitamine D gehalte blijkt dus gerelateerd met een 
verhoogde vaatstijfheid, maar met name met een verhoogde intima-media 
dikte van de arteria carotis (IMT), een maat voor atherosclerose. Vanaf een 
25-OH vitamine D gehalte van ≥ 50 nmol/l bleek er een significante toename 
van de IMT te zijn (beta 1.24 μm) per punt stijging van 25-OH vitamine D. 
Dit zou kunnen impliceren dat ook normaal-hoge waarden van vitamine D 
een verhoogd risico kunnen geven op hart- en vaatziekten. 
Vanaf hoofdstuk 4 onderzoeken we de relatie homocysteine, B-vitamines 
en vaatstijfheid. Allereerst hebben we in hoofdstuk 4.1 de associatie tus-
sen homocysteine gehalte en vaatstijfheid beschreven. Deze relatie blijkt 
het sterkst te zijn in de oudste ouderen. Zoals al eerder werd beschreven 
in de literatuur, dat homocysteine met name in oudste ouderen een goede 
voorspeller is voor hart- en vaatziekten, ondersteunen we dit met onze stu-
die door de associatie met vaatstijfheid aan te tonen. Echter een associatie 
studie zegt nog niets over causaliteit. De gevonden relatie homocysteine 
– vaatstijfheid zou bijvoorbeeld ook gedreven kunnen worden door vitamine 
B12 en foliumzuur gehaltes. Hierom hebben we in het volgende hoofdstuk 4.2 
beschreven of er een relatie is tussen deze vitamines en vaatstijfheid, welke 
er niet bleek te zijn. Middels een genetische risicoscore voor een verhoogd 
homocysteine konden we onderzoeken of er aanwijzingen waren voor een 
causaal verband tussen homocysteine en vaatstijfheid. Echter, er bleek geen 
verband te zijn tussen de genetische variaties die homocysteine verklaarden 
en vaatstijfheid. Mogelijk heeft het lichaam een soort protectiemechanisme 
ontwikkeld, waardoor de schadelijke effecten van een genetisch verhoogd 
homocysteine teniet worden gedaan. Temeer omdat we vonden dat het ho-
mocysteine gehalte zelf de onderzochte associatie modificeerde. 
Uiteraard is de uitkomst van het B-PROOF onderzoek een nog betere manier 
om te zien of homocysteine causaal gerelateerd is aan vaatstijfheid (hoofd-
stuk 4.3). De suppletie van vitamine B12 en foliumzuur leidde inderdaad tot 
lagere homocysteine waarden, maar niet tot een vermindering van de vaat-
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stijfheid. Dit was in lijn met onze hypothese vooraf: wanneer vaatstijfheid 
inderdaad een onomkeerbaar proces is, verwacht je geen effect meer van 
een interventie. Echter, er bleek ook geen effect van de B-vitamine suppletie 
te zijn in de proefpersonen die vooraf geen vaatstijfheid hadden. Dit maakt 
dan toch aannemelijk dat het homocysteine gehalte geen causaal verband 
heeft met vaatstijfheid en hart- en vaatziekten. 
Wel hebben we in hoofdstuk 4.3 ook gevonden dat er in vrouwen die B-
vitamine suppletie kregen een lagere incidentie was van beroertes. Waarom 
we dit alleen in vrouwen vonden is niet bekend, al was er gedurende de 2 
jaar follow-up in de gehele groep ook een trend naar een lagere incidentie 
van beroertes in de groep die behandeld werd met B-vitamines. We kunnen 
speculeren over verschillen in effect van B-vitamine suppletie op kleine en 
grote arteriën, wat uiteraard nog verder onderzoek nodig heeft. 
Om nog meer inzicht te krijgen in het verband tussen homocysteine en hart- 
en vaatziekten, hebben we in hoofdstuk 4.4 onderzocht wat het effect van 
de B-vitamine supplementen is op de endotheelfunctie en inflammatie. Er 
is eerder beschreven dat het zou kunnen dat B-vitamines al werken op het 
endotheel en dat B-vitamines mogelijk een verhoogde inflammatoire status 
kunnen induceren, wat de mogelijke positieve effecten van B-vitamines op 
het voorkomen van hart- en vaatziekten zou kunnen neutraliseren. We heb-
ben echter geen effect van de B-vitamines gevonden op zowel de endotheel-
functie als op inflammatie, gemeten met biomarkers. 
In hoofdstuk 5 bediscussiëren we onze resultaten. We kunnen uit dit 
proefschrift concluderen dat vaatstijfheid inderdaad veelvoorkomend is bij 
ouderen, maar dat de verbanden beschreven in jongere populaties niet altijd 
overeenkomen met die in ouderen. Zo hebben fysieke functie en osteoporose 
geen relatie met vaatstijfheid. Van vitamine D echter, lijken normaal-hoge 
waardes ook een verhoogd risico te geven op hart- en vaatziekten. Wat 
betreft de relatie homocysteine en vaatstijfheid, hebben we sterke aanwij-
zingen dat dit verband niet causaal is. Homocysteine kan gezien worden als 
een goede voorspellende biomarker, maar is geen behandelbare risicofactor. 
Chapter 7
Dankwoord
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Na al die jaren B-PROOF is het resultaat dan eindelijk daar: mijn proefschrift! 
En dan te bedenken dat ik nooit wilde promoveren, omdat dat zoveel werk 
zou zijn.. Nu, veel werk was het zeker, maar ik heb het met veel plezier 
gedaan en kan terugkijken op een aantal bijzondere jaren. Ik heb ontzettend 
veel geleerd, op zowel werk als persoonlijk vlak en ben flink wat ervaringen 
rijker! Uiteraard had ik het niet kunnen doen zonder alle mensen die op een 
of andere manier betrokken waren met het B-PROOF onderzoek of met mij 
en zij verdienen dan ook allen mijn hartelijke dank!
Allereerst verdienen de deelnemers aan het B-PROOF onderzoek natuurlijk 
alle lof, want zonder hen was dit boekje überhaupt niet mogelijk geweest!
Beste proffessor Uitterlinden, beste André, heel erg bedankt voor de we-
tenschappelijke ruimte en de nodige zetjes voor mijn wetenschappelijke 
ontwikkeling. Al ligt mijn onderwerp wellicht wat ver af van het dagelijkse 
werk op jouw afdeling, het lukte je toch altijd om weer te zorgen voor een 
nieuwe kijk op mijn onderzoek en manuscripten. Dit zorgde dan ook voor de 
nodige verbeteringen in kwaliteit! 
Beste Nathalie, als mijn dagelijkse begeleider en co-promotor hebben we 
heel wat uurtjes samen doorgebracht. Heel erg bedankt voor de mogelijk-
heid die jij en Tischa mij in 2009 hebben gegund, om het cardiovasculaire 
deel van B-PROOF op me te mogen nemen. Ondanks mijn minimale onder-
zoekservaring heb je me de ruimte gegeven om te groeien in de wereld van 
onderzoek, waarvoor ik je erg dankbaar ben! Naast het beoordelen van mijn 
analyses en manuscripten was er ook tijd voor brainstormen, waardoor we 
op nog meer leuke onderzoeksideeën zijn gekomen en ik hoop dan ook dat 
we B-PROOF hierna nog kunnen doorzetten! 
Francesco, als mijn opleider en tweede co-promotor kan ik je natuurlijk niet 
vergeten. Grazie mille! Ondanks dat je zelf een zware periode hebt moeten 
doormaken, stond je toch voor me klaar, waar ik alleen maar bewondering 
voor kan hebben. Bedankt voor je kritische blik op mijn analyses en ma-
nuscripten en de kennismaking met je netwerk, met name in de wereld van 
arterial stiffness. Gelukkig voor jou ben je nog niet van me af, want nu gaan 
we door met de opleiding tot klinisch geriater! Ik verheug me nu al op de 
komende jaren. 
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Beste Ton, wat gaf jouw bijdrage altijd een enorme verbetering aan mijn on-
derzoeken! Ik wil je heel erg bedanken voor de kritische noot en je vermogen 
om alles in een helder licht te zetten en de dingen vooral niet moeilijker te 
maken dan ze zijn. Waar ik met name wel eens geremd moest worden in het 
speculeren, kon je me weer met beide benen op de grond zetten waar ik je 
erg dankbaar voor ben!
Uiteraard had mijn hele onderzoek niet mogelijk geweest zonder het be-
staan van het B-PROOF onderzoek en daarvoor wil ik de grondleggers dan 
ook enorm bedanken. Waar met name Lisette en Rosalie in Wageningen de 
leidende rol hadden, gaven jullie andere centra toch ook de ruimte voor 
eigen inbreng en hebben we een prachtig onderzoek neergezet met onze 
drie centra! Paul en Natasja natuurlijk ook heel erg bedankt voor de fijne 
samenwerking in de afgelopen jaren! Janneke, als eerste B-PROOF-er had 
jij de eer je boekje af te hebben. Al duurde het misschien wat langer dan 
je had gehoopt, het is toch een mooi resultaat van het harde werken aan 
B-PROOF! Bedankt voor de gezellige vergaderingen en overleggen. Karin, 
heel erg bedankt voor de leuke jaren, je gezelligheid en altijd nuttige en 
nuchtere inbreng! Voor jou is ook het einde bijna in zicht! Nikita en Elske, 
onze samenwerking was altijd erg prettig en fijn te zien dat jullie inmiddels 
ook jullie verdediging goed hebben afgerond!
Uiteraard heb ik ook veel gehad aan de vasculaire commissie binnen B-
PROOF. Yvo, Henk, Edith, Marianne en Renate heel erg bedankt voor jullie 
tijd en input waarmee we toch een aantal mooie manuscripten hebben kun-
nen schrijven! Yvo, jij verdient ook een persoonlijke noot aangezien je veel 
hebt bijgedragen aan de inhoud van mijn stukken en vaak veel tijd nam 
om te brainstormen over hoe het beter kon. Erg fijn dat je ook zitting hebt 
willen nemen in mijn promotie commissie. Ik heb veel van je kunnen leren, 
waarvoor heel erg bedankt! 
Ja, en dan zijn daar de vrouwen met wie ik de eer heb gehad dagelijks 
te mogen werken! Sandra, die ik natuurlijk niet ons B-PROOF moedertje 
mag noemen, maar dat stiekem toch doe.. Ik heb superfijn met je samen 
mogen werken de afgelopen jaren en ik denk dat we allemaal, mede door 
jou, persoonlijk heel erg zijn gegroeid. Je hebt altijd een luisterend oor en 
als het even minder ging, was jij er om even mee te klagen, om vervolgens 
weer opbeurend te zijn. Met je praktische kijk en inlevingsvermogen hebben 
we B-PROOF Rotterdam enorm kunnen laten groeien. Als ik ooit nog een 
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research nurse nodig heb, dan weet ik je te vinden! We hebben uiteraard ook 
veel gezelligheid gehad, zoals op de Italiaanse congressen en tijdens onze 
dinertjes en ik zal me deze tijd nog lang heugen! 
Anke, wat heeft het eigenlijk goed uitgepakt we beiden zijn aangenomen 
op het B-PROOF project Rotterdam! Jouw nuchterheid en doordachtzaam-
heid maken het prettig samenwerken en daaraan hebben we waarschijnlijk 
ook veel deelnemers te danken! Al gingen de afgelopen jaren ook wel eens 
minder makkelijk, uiteindelijk hebben we het toch maar mooi voor elkaar 
gekregen. Nu kunnen we het na zoveel jaar bijna tegelijk afsluiten en ik hoop 
dat je in je volgende baan de uitdaging kunt vinden die je zoekt en natuurlijk 
heel veel geluk met je gezin! 
Annelies, in je eerste jaar zag je mij af en toe in witte jas voorbij vliegen, 
maar toen ik eenmaal weer terug was konden we het gelijk goed vinden! Al 
moest je je mindfullness soms even terugvinden, was je open karakter ook 
erg fijn want iedereen weet meteen wat ze aan je hebben. Bedankt voor de 
gezelligheid en al onze uurtjes waarin we konden ‘sparren’. Ik wens je nog 
veel succes met de afronding van je eigen onderzoek en weet zeker dat het 
je gaat lukken! 
Sadaf, eigenlijk hebben we maar een relatief korte tijd mogen samenwer-
ken. Het was erg leuk om je snel te zien groeien in het onderzoek en hoe 
meer plezier je eraan beleefde. Ik kan soms met verbazing aanzien hoe jij 
alles weer voor elkaar krijgt, en bewonder je om je doorzettingsvermogen. 
Heel veel succes in je verdere carriere, en wie weet kan ik daar ook nog een 
bijdrage aan leveren! 
Een ander die ik wel moet noemen in mijn boekje is natuurlijk Mirjam, want 
zonder haar stond ik hier nu niet. In de bus naar Zierikzee wees jij mij op 
een advertentie in het Medisch Contact, wat ‘helemaal iets voor mij was’. En 
zo kwam het dat ik ineens in een AGIKO-constructie zat! Vanaf het eerste 
jaar geneeskunde mag ik genieten van je gezelligheid, heel erg bedankt 
daarvoor! Evelyne en Linda, in de huidige drukte zien we elkaar gelukkig nog 
steeds af en toe. Dus Evelyne, Linda en Mirjam: tot snel! 
Ook wil ik mijn andere vrienden en familie bedanken voor hun vriendschap 
en hun steun. Ik zal mijn best doen genoeg tijd voor jullie te maken nu ik 
weer in de kliniek zit! Een aantal van hen wil ik speciaal bedanken. Marjolein, 
zussie, wat fijn eigenlijk dat ik jou gevonden heb en hopelijk volgen er nog 
vele jaren met uitjes, sporten en feestjes! Ik bewonder je om hoe je in 
het leven staat en wens je alle geluk en voorspoed! Loek, ik ben er trots 
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op dat jij mijn paranimf wil zijn en ik hoop dat dit je met name inspireert, 
want je kunt veel meer dan je denkt! Als het goed is kunnen we samen een 
belangrijke periode afsluiten en ik ben zeker trots op ons! 
Natuurlijk mogen de belangrijkste mensen in mijn leven niet vergeten wor-
den. Pap en mam bedankt wat jullie altijd voor mij hebben gedaan en het 
mogelijk gemaakt hebben dat ik kon studeren wat ik wilde. Wie had dat toch 
gedacht dat dat kleinzerige meisje een dokter zou worden?! Ik zal het toch 
van iemand moeten hebben.. George, bedankt dat je er altijd voor me bent 
en in me gelooft. Ik verheug me op onze toekomst samen om uiteindelijk te 
eindigen als grijze geriatrische oudjes! Zoals George Sand ooit al opschreef: 
“Er is maar één geluk in het leven: iemand liefhebben en die liefde beant-
woord zien.” 
Suzanne
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